

AD 5858-BC-02

DTIC FILE COPY

DATA45-87-M-0322

INTERNATIONAL WORKSHOP  
ON  
STRUCTURAL AND FUNCTIONAL  
ASPECTS OF THE  
CHOLINERGIC SYNAPSE

Neve-Ilan Guest House, near Jerusalem, ISRAEL

August 30 - Sept. 4, 1987

DTIC  
ELECTE  
SEP 13 1989  
S D D

Scientific Committee

G. Amitai (Ness-Ziona)  
E. Kosower (Tel-Aviv)  
D. Michaelson (Tel-Aviv)  
R. Rahamimoff (Jerusalem)  
I. Silman (Rehovoth)  
H. Soreq (Jerusalem)

DISTRIBUTION STATEMENT A

Approved for public release  
Distribution Unlimited

89 9 11 093

AD-A212 825

INTERNATIONAL WORKSHOP  
ON  
STRUCTURAL AND FUNCTIONAL  
ASPECTS OF THE  
CHOLINERGIC SYNAPSE

Neve-Ilan Guest House, near Jerusalem, ISRAEL

August 30 - Sept. 4, 1987

Scientific Committee

G. Amitai (*Ness-Ziona*)  
E. Kosower (*Tel-Aviv*)  
D. Michaelson (*Tel-Aviv*)  
R. Rahamimoff (*Jerusalem*)  
I. Silman (*Rehovoth*)  
H. Soreq (*Jerusalem*)



Accession For	
NTIS CRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By <i>per lti</i>	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

The organizers wish to express their gratitude to the following sponsors:

- The Israel Institute for Psychobiology (Charles E. Smith Family Foundation).
- Maurice & Gabriella Goldschleger Conference Foundation at the Weizmann Institute of Science.
- Committee for Cell Biology and Biophysics of IUPAB.
- Israel Academy of Sciences and Humanities.
- Center for Neurosciences and Behavior of the Weizmann Institute of Science.
- International Union of Biochemistry.
- International Brain Research Organization.
- Conference Committee of the Hebrew University of Jerusalem.
- U.S. Army Medical Research and Development Command, Fort Detrick, MD, USA.
- U.S. Air Force European Office of Aerospace Research and Development, London, U.K.
- U.S. Navy, Office of Naval Research at London, U.K. and Arlington, U.S.A.
- U.S. Army Research Office, N.C., U.S.A., via USARDCG, U.K.

Acknowledgement:

The Scientific Committee gratefully acknowledges the kind help of Mrs. R. Goldstein, Mrs. H. Bohak and Dr. A.H. Futerman

## GENERAL INFORMATION

### **Lectures:**

Projection equipment will be provided for 2"x 2" slides, for 16mm film and for overhead projector transparencies (25 x 25 cm). All speakers are requested to give their slides to the projectionist before their session.

### **Posters:**

Poster authors are requested to put up their posters on Monday Aug 31, 7.30-8.30 a.m., and be present by their posters on Monday evening between 20.00 and 21.00. Posters will be displayed throughout the whole meeting.

### **Meal Times:**

Breakfast	.....from	07.30
Lunch	Monday, Tuesday	13.00
	Wednesday, Thursday	12.30
Dinner	.....from	18.45

### **Name Badges:**

Participants are requested to wear their name badges at all times whilst at Neve ilan.

### **Secretariat and travel desk:**

Will be open daily from 8.30. Please contact "Kenes" representative.

### **Social activities:**

Several special events are planned:

Sunday	20.30	- Mixer Buffet
Monday	21.15	- Lecture on the Dead Sea Scrolls
Wednesday	13.30	- Excursion to Jerusalem
Thursday	18.00	- Closing dinner at the National Palace Hotel Roof Top Gardens Restaurant Jerusalem.

Participants are advised to bring  
a sweater or jacket as it can be  
cool in the evening in Jerusalem

Participation in all the social events is covered by the registration fee.

### **Check out Time:**

All participants are kindly requested to check out on Friday Sept, 4 by 9.00 a.m.

# PROGRAM

Sunday, August 30th

18:00 Registration

20:30 Mixer

Monday, August 31st

SYNAPTOGENESIS <sup>and</sup> REGULATION (I)

CHAIRMAN: S. FUCHS (Rehovot)

08:30

J.-P. CHANGEUX (Paris)

*A molecular approach to the development of the rat neuromuscular junction*

09:00

S. ROTSHENKER (Jerusalem)

*Multiple modes and sites for the regulation of motor axonal growth*

09:30

R. WERMAN (Jerusalem)

*Intracellular accumulation of acetylcholine can lead to neuronal death*

10:00

M. BRZIN (Ljubljana)

*The appearance of two distinct types of subsynaptic specialization bearing AChE activity in regenerating rat muscle*

10:30

Coffee

11:00

U.J. McMAHAN (Stanford)

*Agrin: identification and characterization*

11:20

B.G. WALLACE (Stanford)

*Agrin: mechanism of action*

11:40

L. ANGLISTER (Jerusalem)

*Acetylcholinesterase in regenerating neuromuscular junctions*

12:00

Z. VOGEL (Rehovot)

*Role of neurotrophic factor(s) and calcium channels in the regulation of acetylcholinesterase in cultured muscle*

12:30

End of Session

13:00

Lunch

SYNAPTOGENESIS AND REGULATION (II)

CHAIRMAN: U.J. McMAHAN (Stanford)

16:00

M-m. POO (New Haven)

*Early minutes of synaptogenesis: a physicochemical view*

16:30

A. SHAINBERG (Ramat Gan)

*Changes in the levels of acetylcholine receptors are mediated by the calcium concentration in the sarcoplasmic reticulum*

17:00

Coffee

- 17:30 H. MEIRI (Jerusalem)  
*Short and long term effects of aluminum on synaptic transmission and on the activity of cultured nerve cells*
- 18:00 D. MICHAELSON (Tel-Aviv)  
*Antibodies to cholinergic neurons in Alzheimer's Disease*
- 18:20 End of session
- 18:45 Dinner
- 20:00 Poster session
- 21:15 Lecture on the Dead Sea Scrolls, M. Broshi.

Tuesday, September 1st

Cont'd ACETYLCHOLINESTERASE - on till >

CHAIRMAN: M. BRZIN (Ljubljana)

- 08:30 J. MASSOULIE (Paris)  
*Molecular diversity of cholinesterases*
- 09:00 P. TAYLOR (La Jolla)  
*Molecular structures and gene organization of the acetylcholinesterases*
- 09:30 R.L. ROTUNDO (Miami)  
*Biogenesis of acetylcholinesterase in nerves and muscle*
- 10:00 W.R. RANDALL (Miami)  
*Avian acetylcholinesterase: molecular studies on the structure and regulation of the asymmetric forms in muscle*
- 10:20 Coffee
- 10:50 B.P. DOCTOR (Washington, DC)  
*Structural and immunochemical properties of fetal bovine serum acetylcholinesterase*
- 11:20 H. SOREQ (Jerusalem)  
*Biogenesis of human cholinesterase: from gene to protein*
- 11:50 P. DREYFUS (Jerusalem)  
*Structure-function relationships in cholinesterase approached by microinjection of Xenopus oocytes with clone-produced SP<sub>6</sub>mRNA*
- 12:10 E. SCHMELL (Arlington)  
*Inhibition of human erythrocyte AChE by monoclonal antibodies: evidence for novel allosteric sites*
- 12:30 A. FUTERMAN (Rehovot)  
*Covalently attached phosphatidylinositol as a membrane anchor for acetylcholinesterase and other membrane proteins*
- 12:50 End of session

13:00

Lunch

**PRESYNAPTIC MECHANISMS (I)**

CHAIRMAN: R. RAHAMIMOFF (Jerusalem)

15:30

I. PARNAS (Jerusalem)

*The calcium-voltage hypothesis for neurotransmitter release*

16:00

R.S. ZUCKER (Berkeley)

*Presynaptic calcium domains and voltage control of transmitter release*

16:30

R. RAHAMIMOFF (Jerusalem)

*Short term and long term modulation of neurotransmitter release*

17:00

Coffee

17:30

E. NEHER (Gottingen)

*Calcium buffering and calcium measurement in single secretory cells under patch clamp*

18:00

P. GAGE (Canberra)

*Neuromuscular transmission in muscles paralysed by butanedione monoxime*

18:30

End of session

18:45

Dinner

**PRESYNAPTIC MECHANISMS (II)**

CHAIRMAN: E. NEHER (Gottingen)

20:00

S.M. PARSONS (Santa Barbara)

*Regulatory, molecular and pharmacological aspects of acetylcholine storage*

20:30

M. ISRAEL (Gif-sur-Yvette)

*Purification of a nerve terminal protein which mediates a calcium-dependent acetylcholine release*

21:00

H. RAHAMIMOFF (Jerusalem)

*Molecular properties of the sodium-calcium exchanger*

21:30

M.P. BLAUSTEIN (Baltimore)

*Presynaptic potassium channels as the target sites of certain snake toxins and other drugs*

22:00

Y. YAARI (Jerusalem)

*Presynaptic currents in vertebrate motor nerve terminals*

22:20

S.C. FROEHNER (Hanover)

*Monoclonal antibodies to the voltage-activated calcium channel*

22:40

End of session



Wednesday, September 2nd

## SIGNAL TRANSDUCTION AND MODULATION

CHAIRMAN: P. TAYLOR (La Jolla)

- 08:30 M.E. ELDEFRAWI (Baltimore)  
*Action of anticholinesterases on acetylcholine receptors*
- 09:00 G. AMITAI (Ness-Ziona)  
*Certain muscarinic antagonists are non-competitive inhibitors of the nicotinic acetylcholine receptor*
- 09:20 E. HELDMAN (Ness-Ziona)  
*Binding properties and transmembrane signalling in muscarinic acetylcholine receptor subtypes*
- 09:40 K. SHERMAN (Springfield)  
*Biochemical and behavioral effects of acetylcholinesterase inhibition in brain*
- 10:00 Coffee
- 10:30 E.X. ALBUQUERQUE (Baltimore)  
*Molecular basis of anticholinesterase actions on nicotinic and glutamatergic synapses: peripheral and central effects*
- 11:00 T.S. REESE (Woods Hole)
- 11:30 Y. HENIS (Tel-Aviv)  
*Role of lipids in the regulation of rat heart muscarinic receptors and their interaction with G-proteins*
- 11:50 Y. LASS (Tel-Aviv)  
*Neurotransmission and second messengers in *Xenopus* oocytes*
- 12:20 End of session
- 12:30 Lunch
- 13:30 Excursion to Jerusalem
- 19:00 Dinner

## ACETYLCHOLINE RECEPTOR (I)

CHAIRMAN: E. KOSOWER (Tel-Aviv)

- 20:00 A. KARLIN (New York)  
*Functional sites of the nicotinic acetylcholine receptor*
- 20:30 J. EARNEST (San Francisco)  
*What do the structure of the acetylcholine receptor and of ion channels tell us about their function?*
- 21:00 A. MAELICKE (Dortmund)  
*Antibodies as specific ligands of the nicotinic acetylcholine receptor*

- 21:20 F. HUCHO (Berlin)  
*The helix-II model of the ion channel of the nicotinic acetylcholine receptor*
- 21:40 J.M. GERSHONI (Rehovot)  
*Correlating structure with function in the nicotinic acetylcholine receptor*
- 22:00 G. NAVON (Tel-Aviv)  
*NMR studies of the binding of agonists to the acetylcholine receptor*
- 22:20 End of session

Thursday, September 3rd

### ACETYLCHOLINE RECEPTOR (II)

CHAIRMAN: F. BARRANTES (Bahia Blanca)

- 08:30 J. PATRICK (La Jolla)  
*Expression of functional neuronal acetylcholine receptors from cDNA clones*
- 09:00 H.A. LESTER (Pasadena)  
*Expression of acetylcholine receptors in *Xenopus* oocytes*
- 09:30 C. METHFESSEL (Gottingen)  
*Ion conductance of genetically modified acetylcholine receptor channels*
- 10:00 Coffee
- 10:30 H. BREER (Osnabruck)  
*Receptors for acetylcholine in the nervous system of insects*
- 10.50 G.P. HESS (Ithaca)  
*Chemical kinetic measurements of the acetylcholine receptor with 8mu.s to ms time resolution*
- 11.20 End of session
- 12:30 Lunch

### ACETYLCHOLINE RECEPTOR (III)

CHAIRMAN: A. KARLIN (New York)

- 14.00 F.J. BARRANTES (Bahia Blanca)  
*The membrane environment for the nicotinic acetylcholine receptor*
- 14:30 M. McNAMEE (Davis)  
*Biophysical studies of acetylcholine receptor in reconstituted membranes: role of lipids in regulating function*

- 15.00 S. FUCHS (*Rehovot*)  
*The cholinergic binding site and phosphorylation sites of the  
nicotinic acetylcholine receptor*
- 15.30 Coffee
- 16.00 R.L. HUGANIR (*New York*)  
*Regulation of the nicotinic acetylcholine receptor by protein  
phosphorylation*
- 16:30 E.M. KOSOWER (*Tel-Aviv*)  
*A structural and dynamic model for the nicotinic acetylcholine  
receptor*
- 17:00 End of session
- 17.45 Departure for closing dinner

*Friday, September 4*

Departure

## POSTER PRESENTATIONS

- 01 M. ARPAGAU (Gif-sur-Yvette)  
*Transition in molecular forms of acetylcholinesterase during the development of *Drosophila melanogaster*.*
- 02 F. BACOU (Montpellier)  
*Acetylcholinesterase of newborn denervated fast and slow rabbit muscles: polymorphic and immunological characteristics.*
- 03 E. BANIN (Jerusalem)  
*Acute administration of aluminium alters synaptic transmission.*
- 04 M. BENNETT (Gif-sur Yvette)  
*Acetylcholine release from rat brain synaptosomes as measured by the chemiluminescence method.*
- 05 C. BON (Paris)  
*Negatively charged phospholipids, a possible target for the presynaptic phospholipase neurotoxin from snake venoms.*
- 06 W. FINGER (Munich)  
*High-frequency asynchronous release of excitatory and inhibitory transmitter quanta triggered by veratridine in nerve-muscle synapses of crayfish.*
- 07 A. GNATT (Jerusalem)  
*Molecular cloning and structural characterisation of human cholinesterase genes.*
- 08 M. JACKSON (Gottingen)  
*Mechanism and energetics of activation of the nicotinic receptor.*
- 09 K. KAUFMANN (Essen)  
*On the role of the lipid bilayer in synaptic transmission.*
- 10 R. LICHT (Tel Aviv)  
*Basal acetylcholine release from Torpedo nerve terminals*
- 11 P. MASSON (Toulon-Naval)  
*Pressure effects on the carbamylation of butyrylcholinesterase.*
- 12 J.L. MIDDLEBROOK (Frederick)  
*A neutralizing monoclonal antibody to crotoxin.*
- 13 P.C. MOLENAAR (Leiden)  
*The effect of AH5183 on the release and storage of newly synthesized ACh in frog muscle.*
- 14 N. MOREL (Gif-sur-Yvette)  
*An antiserum specific for the mediatophore, an ACh-releasing protein, exhibits presynaptic binding in Torpedo and rat neuromuscular junctions.*
- 15 Y. MOROT-GAUDRY (Gif-surYvette)  
*Cetiedil, a drug which inhibits acetylcholine release in Torpedo marmorata electric organ.*
- 16 S.J. MOSS (Cambridge)  
*Regulation of chicken muscle nicotinic acetylcholine receptor gene expression.*

- 17 S.J. MRCHEV (Sofia)  
*Human memory modelling: Synapse level.*
- 18 D. NEUMANN (Rehovot)  
*Cloning of the snake acetylcholine receptor  $\beta$ alpha-subunit.*
- 19 C. PRODY (Jerusalem)  
*Alternate termination sites in human cholinesterase genes.*
- 20 R. ROSENBLUM (Tel-Aviv)  
*Coexistence of endorphins and acetylcholine in Torpedo electromotor neurons*
- 21 A. SAFRAN (Rehovot)  
*Phosphorylation of the acetylcholine receptor.*
- 22 TH. SCHURHOLZ (Bielefeld)  
*Reconstitution of isolated acetylcholine receptors: A critique*
- 23 J. SKETELJ (Ljubljana)  
*Acetylcholinesterase in regenerating myotubes in vivo.*
- 24 N. STEINBERG (Rehovot)  
*Spectroscopic characterisation of differences in the active-site conformation of aged and non-aged organophosphoryl conjugates of serine hydrolases*
- 25 S.N. TIWARAI (Gorakhpur)  
*Physical parameters of the transformation and distribution of information*
- 26 J.-P. TOUTANT (Montpellier)  
*Molecular forms of acetylcholinesterase in adult Drosophila: Structure and hydrophobic interactions.*
- 27 K.W.K. TSIM (Cambridge)  
*Monoclonal antibodies to chicken acetylcholinesterase and butyrylcholinesterase.*
- 28 M. VERDIERE-SAHUQUE (Paris)  
*Developmental aspects, cellular localization and mode of attachment of AChE in neuronal ganglionic cells.*
- 29 H. ZAKUT (Tel-Aviv)  
*Cholinesterase synthesis in developing human oocytes examined by in situ hybridization in frozen ovarian sections.*
- 30 R. ZAMIR (Jerusalem)  
*Chromosomal mapping of human cholinesterase genes by in situ hybridization.*
- 31 R. ZISLING (Rehovot)  
*Antibodies to clone-produced human cholinesterase: Interaction with denatured and native cholinesterases and cross-species homologies.*

# ABSTRACTS

LONG-TERM EVOLUTION OF THE ACETYLCHOLINE RECEPTOR  
DURING SYNAPSE FORMATION

by

Jean-Pierre CHANGÈUX, André KLARSFELD, Bertrand FONTAINE  
and Ralph LAUFER

Neurobiologie Moléculaire et UA CNRS 1149, Institut Pasteur,  
25 rue du Dr Roux, 75725 Paris Cedex 15, France.

The acetylcholine nicotinic receptor protein (AChR) from vertebrate neuromuscular junction is subject to a long-term regulation of its distribution and properties by muscle innervation (1). In the adult synapse, the AChR is integrated into a supramacromolecular edifice which persists for weeks after denervation and involves privileged interactions with the basal lamina and/or the cytoskeleton. Its surface density (10 - 20 000 molecules per  $\mu\text{m}^2$ ) is 100-1000 times higher than outside the synapse, it is strongly immobilized, with a long metabolic life-time ( $>10$  days in mammals) and a short (msec) mean channel open time (not in birds). By contrast, in the non-innervated embryonic myotube, the AChR is evenly distributed at a low surface density, it is mobile, labile (half life  $<1$  day) and its mean channel open time is long (several msec) (1).

The genesis of the adult postsynaptic domain results from a complex sequence of molecular interactions which include regulations at the transcriptional and post-transcriptional level. The evolution of the total content of AChR of a fast skeletal muscle (such as PLD, in chick) comprises three main steps : 1) a rapid increase which coincides with the fusion of myoblasts into myotubes, 2) a sharp decline which corresponds to the elimination of the extra junctional AChR and, 3) a late increase, mostly postnatal, associated with the enlargement of the endplate. In the chick, the metabolic life-time of the AChR does not change throughout this evolution (except at the end of the third period) which, therefore, primarily involves regulation of AChR biosynthesis (2).

Chronic paralysis of the embryo by flaxedil interferes with step 2 which, thus, represents an electrical activity-dependent repression of AChR genes (2). This process has been analysed by the methods of molecular genetics using a chicken  $\alpha$ -subunit genomic probe (3) in a model system consisting of chick myotubes in primary culture. Blocking their spontaneous electrical activity by tetrodotoxin (TTX) causes,

after 2 days, a 13-fold increase of  $\alpha$ -subunit mRNA level (against an only 2-fold increase of surface AChR) while  $\alpha$ -actin mRNA levels do not change. Denervation of chick leg muscle gives similar results. Southern blot data are consistent with the presence in the chicken of a unique chromosomal gene encoding the  $\alpha$ -subunit, whose expression would be differentially regulated during development. The 3' end and part of the upstream flanking region of this gene was isolated and sequenced (4). Transcription initiates at the same position in innervated and denervated muscles (see also 5). TATA and CAAT boxes and a potential Spl binding site are found upstream. This  $\alpha$ -subunit promoter, including 850 bp of the 5' flanking sequence, was inserted into a plasmid vector in front of a chloramphenicol acetyltransferase (CAT) gene (4). This construct directed high CAT expression in transfected mouse C2.7 myotubes but not in unfused C2.7 myoblasts or non myogenic mouse 3T6 cells. It thus contains DNA sequences important for tissue specificity and developmental regulation (step 1). Yet, it is not known whether these sequences contain the target for the electrical activity-dependent regulation of  $\alpha$ -subunit gene expression.

The maintenance and late increase in number (step 3) of AChR at the level of the endplate while extrajunctional AChR disappears requires the intervention of an anterograde signal from neural origin. Calcitonin-gene-related peptide (CGRP), a peptide shown to coexist with acetylcholine in chick spinal cord motoneurons, increases surface and total AChR by about 50 % in cultured chick myotubes without affecting AChR turnover or total protein synthesis (6). This increase was additive with that elicited by TTX, but not by cholera toxin which activates adenylate cyclase. Parallel results were obtained when AChR  $\alpha$ -subunit mRNA was quantitated by Northern blots (7). CGRP increases the cAMP content of myotubes and stimulates membrane-bound adenylate cyclase in the range of concentration where it enhances AChR  $\alpha$ -subunit gene expression (8). The phorbol ester TPA abolishes the increase of  $\alpha$ -subunit mRNA caused by TTX but not by CGRP suggesting that distinct second messengers are involved in the regulation of AChR biosynthesis by electrical activity and by CGRP.

The data are interpreted in terms of a model (9) which assumes that :  
1) in the adult muscle fiber, nuclei may exist in different stages of gene expression in subneural and extra junctional areas (see also 10),  
2) different second messengers elicited by neural factors or electrical activity regulate the state of transcription of these nuclei via trans-acting allosteric proteins. Distinct families of genes involved in the functional organisation and maintenance of the endplate



(including the several AChR subunits (11)), may be concerned by this regulation. In the case of the AChR  $\alpha\beta\gamma$  and  $\delta$  subunits the relevant genes are distributed, in the mouse, on three different chromosomes ( $\alpha$  Chr 17,  $\beta$  Chr 11 and  $\gamma$  and  $\delta$  Chr 1) (12) and are thus regulated by trans-activating factors.

The subneural post-transcriptional clustering and metabolic stabilisation of the AChR which takes place at the level of the developing endplate involves, in addition, a complex sequence of molecular interactions with, in particular, the basal lamina and/or cytoskeletal proteins. The role of the 43 000  $v_1$  protein (13), which specifically binds to the cytoplasmic face of the AChR, is discussed in this framework and its interaction with the cytoskeleton demonstrated (14). Speculations about the plausible extension of some of these views to the selective stabilisation of neuronal synapses are presented (15).

REFERENCES :

- (1) Changeux, J. P. (1981) The acetylcholine receptor : An "allosteric" membrane protein. In "Harvey Lectures". Acad. Press Inc. 75, 85-254.  
  
Salpeter, M. and Loring, R.H. (1986) Nicotinic acetylcholine receptors in vertebrate muscle : properties, distribution and neural control. Progr. Neurobiol. 25, 297-325.  
  
Merlie, J.P. and Smith, M.M. (1986) Synthesis and assembly of acetylcholine receptor, a multisubunit membrane glycoprotein. J. Memb. Biol. 91, 1-10.
- (2) Betz, H., Bourgeois, J.P. and Changeux, J.P. (1980) Evolution of cholinergic proteins in developing slow and fast skeletal muscles from chick embryo. J. Physiol. 302, 197-218.  
  
Burden, S. (1977a) Development of the neuromuscular junction in the chick embryo. The number, distribution and stability of the acetylcholine receptor. Dev. Biol. 57, 317-329.  
  
Burden, S. (1977b) Acetylcholine receptors at the neuromuscular junction : Developmental change in receptor turnover. Dev. Biol. 61, 79-85.
- (3) Klarsfeld, A. and Changeux, J.P. (1985) Activity regulates the level of acetylcholine receptor alpha-subunit mRNA in cultured chick myotubes. Proc. Natl. Acad. Sci. USA, 82, 4558-4562.
- (4) Klarsfeld, A., Daubas, P., Bourachot, B. and Changeux, J.P. (1987) A 5' flanking region of the chicken acetylcholine receptor alpha-subunit gene confers tissue-specificity and developmental control of expression in transfected cells. Mol. Cell Biol. (in press).
- (5) Buonanno, A. and Merlie, J.P. (1986) Transcriptional regulations of nicotinic acetylcholine receptor genes during muscle development. J. Biol. Chem. 261, 11452-11455.

- (6) Fontaine, B., Klarsfeld, A., Hükfelt, T. and Changeux, J.P. (1986) Calcitonin gene-related peptide, a peptide present in spinal cord motoneurons, increases in number of acetylcholine receptors in primary cultures of chick embryo myotubes. *Neuroscience Letters* 71, 59-65.
- (7) Fontaine, B., Klarsfeld, A. and Changeux, J.P. (1987) Calcitonin-gene related peptide and muscle activity regulate acetylcholine receptor  $\alpha$ -subunit mRNA levels by distinct intracellular pathways. *J. Cell Biol.* (in press).
- (8) Laufer, R. and Changeux, J.P. (1987) Calcitonin gene-related peptide elevates cyclic AMP levels in chick skeletal muscle : possible neurotrophic role for a coexisting neuronal messenger. *EMBO J.* (in press).
- (9) Changeux, J.P., Klarsfeld, A. and Heidmann, T. (1986b) The acetylcholine receptor and molecular models for short and long term learning. *Dahlem Konferenzen*. In "The cellular and molecular bases of learning". J.P. Changeux and M. Konishi, ed. Wiley London p. 31-83.
- (10) Merlie, J. and Sanes, J.R. (1985) Concentration of acetylcholine receptor mRNA in synaptic regions of adult muscle fibers. *Nature* 317, 66-68.
- (11) Takai, T., Noda, M., Mischina, M., Shimizu, S., Furutani, Y., Kayano, T.T., Ikeda, T., Kubo, T., Takahashi, H., Takahashi, T., Juno, M. and Numa, S. (1985) Cloning, sequencing and expression of cDNA for a novel subunit of acetylcholine receptor from calf muscle. *Nature* 315, 761-764.  
  
Mishina, M., Takai, T., Imoto, K., Noda, M., Takahashi, T., Numa, S., Methfessel, C. and Sakmann, B. (1986) Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. *Nature* 321, 406-411.
- (12) Heidmann, O., Buonanno, A., Geoffroy, B., Robert, B., Guénet, J.L., Merlie, J.P. and Changeux, J.P. (1986) Chromosomal localization of muscle nicotinic acetylcholine receptor genes in the mouse. *Science* 234, 866-868.
- (13) Sobel, A., Weber, M. and Changeux, J.P. (1977) Large scale purification of the acetylcholine receptor protein in its membrane-bound and detergent extracted forms from Torpedo marmorata electric organ. *Eur. J. Biochem.* 80, 215-224.

- Cartaud, J., Sobel, A., Rousselet, A., Devaux, P. F. and Changeux, J. P. (1981) Consequences of alkaline treatment for the ultrastructure of the acetylcholine-receptor-rich membranes from Torpedo marmorata electric organ. *J. Cell. Biol.* 90, 418-426.
- Nghiêm, H. O., Cartaud, J., Dubreuil, C., Kordeli, C., Buttin, G. and Changeux, J. P. (1983) Production and characterization of a monoclonal antibody directed against the 43,000 M.W.  $\mu$ l polypeptide from Torpedo marmorata electric organ. *Proc. Natl. Acad. Sci. USA* 80, 6403-6407.
- Burden, S.J. (1985) The subsynaptic 43KD protein is concentrated at developing nerve-muscle synapses in vitro. *Proc. Natl. Acad. Sci. U.S.A.* 82, 7805-7809.
- Froehner, S. C., Gulbrandsen, V., Hyman, C., Jeng, A. Y., Neubig, R.R. and Cohen, J. B. (1981) Immunofluorescence localization at the mammalian neuromuscular junction of the  $M_r$  43,000 protein of Torpedo postsynaptic Membranes. *Proc. Natl. Acad. Sci. USA* 78, 5230-5234.
- (14) Kordeli, E., Cartaud, J., Nghiê, H.O., Pradel, L.A., Dubreuil, C., Paulin, C. and Changeux, J.P. (1986) Evidence for a polarity in the distribution of proteins from the cytoskeleton in Torpedo marmorata electrocytes. *J. Cell Biol.* 102, 748-761.
- (15) Changeux, J.P. (1986) Coexistence of neuronal messengers and molecular selection. *Progr. Brain Res.* 68, 373-403.

MULTIPLE SITES AND MODES FOR THE REGULATION  
OF GROWTH OF CHOLINERGIC AXONS.

Shlomo Rotshenker  
Department of Anatomy and Embryology  
Hebrew University-Hadassah Medical School, Jerusalem, Israel

Synapses can be modified by remodelling their structure. One major way of doing so is by inducing the innervating neuron to sprout and form additional synaptic connections with its target. Our experimental findings in the motor system of *amphibia* and *mammals* suggest that mechanisms regulating sprouting and synapse formation can be divided into three major categories: peripheral, central and transneuronal. We define: (1) peripheral mechanisms, those that involve a direct growth promoting effect of factor(s) on the peripheral extensions of the motoneuron that responds with sprouting, (2) central mechanisms, those that involve the regulation of axonal growth at the level of the motoneurons' cell body, and (3) transneuronal mechanisms, those involving the transfer of a signal for growth from one neuron to another within the spinal cord.

We examined the pattern of innervation to individual muscle fibers of cutaneous-pectoris (CP) and sartorius (S) muscles of the frog, and of peroneal (P) and extensor digitorum longus (EDL) muscles of the mouse. The morphology of neuromuscular junctions was studied by light microscopy in silver-cholinesterase (CP, S, P, EDL) and zinc iodide stained muscles (CP), and by electron microscopy (CP). Silver-cholinesterase preparations revealed some degree of sprouting and synapse formation in all intact muscles of normal animals. Sprouting and synapse formation were enhanced in intact muscles by severing nerves innervating contralateral homologous muscles.

We hypothesize a transneuronal mechanism to underlie the induction of sprouting following contralateral axotomy. The mechanism formulates that axotomy initiates a signal for growth in the cell bodies of severed motoneurons. The signal is then transferred transneuronally across the spinal cord to intact contralateral motoneurons that respond with sprouting. The experimental results that led to the formulation of the transneuronal mechanism for the induction of sprouting and synapse formation (SSF) did so by ruling out alternative mechanisms, and by being in accord with predictions of the suggested mechanism. Alternatives to the transneuronal mechanism are that sprouting was induced by products of degeneration and denervation or by inactivity of denervated muscles. This was ruled out by experiments demonstrating: (1) contralateral axotomy was followed by SSF only when the severed and sprouting motoneurons were located in the same segments of the spinal cord (CP, S, P, EDL), thus ruling out the role of systemic distribution of degeneration and denervation products; (2) SSF developed in CP muscles after removing contralateral muscles, thus ruling out the necessity for the presence of degeneration and denervation products; (3) contralateral axotomies that were placed in too close proximity to the spinal cord failed to induce sprouting (CP), thus ruling out the role of inactivity of denervated muscles and the role of degeneration and denervation products. Predictions of the transneuronal mechanism that were met are: (1) the time to onset of SSF is shortened when the contralateral axotomy is placed closer to the spinal cord (CP, P, EDL). (2) Axotomized regenerating and intact contralateral

sprouting motoneurons demonstrate an increase in the incorporation of uridine into RNA following unilateral axotomy (CP).

We further suggest a central mechanism for the induction of sprouting. We hypothesize a role for a muscle derived trophic substance as a regulator of axonal growth; the site of regulation being the motoneurons' cell body. This proposition is based on the following experimental data: (1) SSF followed the blockade of retrograde axonal transport in contralateral nerves (CP); (2) SSF was induced in both ipsilateral and contralateral motoneurons after depriving the ipsilateral neurons of their target muscle fibers (CP). The common denominator of axotomy, the blockade of the retrograde axonal transport, and the removal of muscle fibers is the prevention of the retrograde supply of a muscle derived trophic substance.

Direct evidence for the existence of peripheral mechanisms for the induction of SSF is provided in a series of experiments in which motor axons that were isolated from their cell bodies responded with SSF after exposing them to minimal doses of colchicine (CP).

#### DEATH OF NEURONS AS A CONSEQUENCE OF EXCESS INTRACELLULAR TRANSMITTER?

R. Werman & Y. Yarom, Department of Neurobiology, Institute of Life Sciences, Hebrew University, Jerusalem

Motoneurons of the dorsal motor vagal nucleus (DMVN) of the adult guinea pig disappear slowly following cervical vagotomy, with a time constant of 8.6 months (Laiwand, Werman & Yarom, *J. Comp. Neurol.* 256: 527-37, 1987). Following vagotomy, the motoneurons become more excitable, apparently as a result of marked decreases in  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  conductance and in the voltage dependent transient current  $\text{I}_{\text{K,A}}$ .

Acetylcholinesterase activity in these neurons decreases markedly following vagotomy, suggesting that ACh may reach higher than normal concentrations. In fact, ACh injected into normal vagal motoneurons acutely blocks various  $\text{K}^{+}$  conductances, particularly the  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  conductance (Yarom, Bracha & Werman, *Neuroscience* 16: 739-52, 1985). These actions of ACh are not produced by extracellular application but are reproduced and enhanced by intracellular injection of blockers of acetylcholinesterase activity.

Thus it is possible that a major part of the physiological changes produced by axotomy are reproduced by excess intracellular ACh in a cholinergic neuron.

In fact, the vagal motoneuron only appears to be more vulnerable following vagotomy. An acute process, lasting about 25 days and leading to cell disintegration, appears to be superimposed on the chronic vulnerability. Reduction of  $\text{K}^{+}$  conductances which serve to inhibit firing leads to increased neuronal firing and probably to increases in internal  $\text{Ca}^{2+}$  concentrations, which may be the acute factor in cell death.

It is of interest that non-cholinergic neurons such as the Purkinje cell revert to a primitive state following axotomy and express latent enzymes related to ACh metabolism.

THE APPEARANCE OF TWO DISTINCT TYPES OF SUBSYNAPTIC SPECIALIZATIONS WITH  
AChE ACTIVITY IN REGENERATING RAT MUSCLE

Brzin, M., Sketelj, J., Institute of Pathophysiology, Ljubljana 61105,  
Yugoslavia

One of the basic postulated requirements of the humoral theory of cholinergic transmission is the presence of AChE activity at the postsynaptic membrane, (in the vicinity of the cholinergic receptor). Nevertheless, the activity and the distribution of AChE at different peripheral and central cholinergic synapses varies considerably, ranging from the extremely high activity in the synaptic clefts of motor endplates, to the neuronal synapses of caudate nucleus and sympathetic ganglia, where the accumulation of AChE is much less dense and its distribution appears predominantly extrajunctional. Various tissues with cholinergic synapses differ also in regard to the regulating effect of nerve on the level and distribution of AChE activity and the pattern of its molecular forms.

In skeletal muscle the main target susceptible to various regulatory influences on AChE seems to be the muscle cell itself. During ontogenesis AChE appears in early myoblasts and attains a high activity before innervation. Following the formation of neuromuscular junctions, AChE, previously distributed along the muscle cell begins to accumulate at the junction. Concomitantly the sarcolemmal specialization is being formed and a gradual change of AChE molecular forms is taking place until maturation is reached.

The ability of muscle cells to focally accumulate AChE and to maintain junctional specialization of sarcolemma remains after denervation. Furthermore, under in vivo aneural conditions, muscle fibers regenerating from myoblasts within degeneration-resistant basal laminae accumulate newly synthesized AChE at the sites of previous motor endplates. In addition, along regenerating myotubes, extrajunctional AChE accumulations and postjunctional specializations are being formed. Pretreatment of muscles with papain before reimplantation prevents the formation of both types of accumulations, without affecting muscle regeneration.

It is suggested that basal junctional lamina stores a protein or a protein-bound substances which triggers in aneurally developing myotubes the sarcolemmal alteration and focalization of AChE.



AGRIN: AN EXTRACELLULAR SYNAPTIC ORGANIZING MOLECULE. Uel J. McMahan.  
Department of Neurobiology, Stanford University School of Medicine, Stanford,  
California 94305, U.S.A.

Studies conducted in this laboratory have demonstrated that the portion of a muscle fiber's basal lamina sheath that occupies the synaptic cleft at the neuromuscular junction has stably bound to it molecules that direct the formation of postsynaptic apparatus on regenerating muscle fibers. Accordingly, if muscles are damaged in ways that spare the basal lamina sheaths of the muscle fibers, the new muscle fibers that develop within the sheaths form aggregates of acetylcholine receptors (AChR) and acetylcholinesterase (AChE) where they contact the synaptic sites on the sheaths despite the absence of axon terminals. The extracellular synaptic organizing molecules in the synaptic basal lamina may be identical to those molecules that mediate the nerve-induced formation of AChR and AChE aggregates in developing myofibers during synaptogenesis in the embryo and they may also be involved in the maintenance of the postsynaptic apparatus in the adult.

Our studies have also led to the identification of agrin, a protein that is extracted from the synapse-rich electric organ of Torpedo californica and that may be similar to the AChR- and AChE-aggregating molecules in the basal lamina at the neuromuscular junction. For example, agrin is found in basal lamina containing fractions of the electric organ, it induces the formation of patches in cultured myotubes that contain a high concentration of AChRs, AChE and other components of the postsynaptic apparatus, low levels of a similar factor are found in extracts of muscle, and monoclonal antibodies directed against agrin recognize molecules highly concentrated in the synaptic basal lamina at the neuromuscular junction in vivo. We have now purified agrin to homogeneity, determined its n-terminal amino acid sequence, and prepared oligonucleotide probes with the aim of using molecular genetic techniques to characterize agrin and study how the expression of agrin is regulated during development and regeneration.

I will document the above findings, discuss our progress in characterizing agrin and present results showing that the cell bodies of motor neurons contain agrin-like molecules, consistent with the hypothesis that the agrin-like molecules in the synaptic basal lamina are produced by motor neurons and released by their axon terminals.

AGRIN: MECHANISM OF ACTION. Bruce G. Wallace. Dept. of Neurobiology, Stanford University School of Medicine, Stanford, CA. 94305.

Agrin induces patches on chick myotubes in culture at which at least six components of the postsynaptic apparatus are concentrated: two extracellular matrix molecules (a heparin sulfate proteoglycan and the A<sub>2</sub> asymmetric form of acetylcholinesterase [AChE]), three membrane proteins (acetylcholine receptors [AChRs] and globular forms of AChE and butyrylcholinesterase), and a cytoplasmic protein (a 43 kD receptor-associated protein). All of the aggregating activities are immunoprecipitated by each of 5 different anti-agrin monoclonal antibodies and all activities copurify and comigrate on gel filtration columns. The studies reported here were aimed at characterizing agrin's effects on AChR distribution and metabolism as a step toward determining agrin's mechanism of action and comparing it to the mechanism of nerve-induced receptor aggregation at developing neuromuscular junctions.

The accumulation of AChRs at developing neuromuscular junctions begins with the formation of a loose aggregate of small clusters of AChRs that subsequently coalesce into a large, relatively uniform patch. When agrin was added to the medium bathing chick myotubes small (<4 $\mu$ m<sup>2</sup>) aggregates of AChRs began to appear within 2 hrs and increased rapidly in number until 4 hrs. Over the next 12-20 hrs the number of aggregates per myotube decreased as the mean size of each aggregate increased to ~15  $\mu$ m<sup>2</sup>. If newly formed junctions *in vivo* are denervated there is a marked dispersal of junctional AChRs. Similarly, in agrin-treated myotubes in culture, aggregates of AChRs remained as long as agrin was present in the medium; if agrin was removed the number of aggregates declined slowly. Most AChRs accumulated into agrin-induced aggregates by lateral migration, as do many of the AChRs that aggregate at developing neuromuscular junctions. Agrin did not alter the rate of appearance of new AChRs.

AChRs on embryonic myofibers are degraded with a  $t_{1/2}$ =1 day. Days to weeks after AChRs accumulate at neuromuscular junctions their rate of degradation slows such that AChRs aggregated at adult neuromuscular junctions are degraded with a  $t_{1/2}$ =10 days. In our chick myotube cultures, ~85% of the AChRs were degraded at a rapid rate ( $t_{1/2}$ =1d), ~15% turned over more slowly ( $t_{1/2}$ =10d). Agrin-containing extracts increased the proportion of slowly turning over receptors to ~20%.

The formation and maintenance of AChR aggregates at developing neuromuscular junctions requires Ca<sup>++</sup>. Agrin-induced AChR aggregation also required Ca<sup>++</sup>; a half-maximal response occurred at 0.2 mM Ca<sup>++</sup>. Typical inorganic Ca<sup>++</sup> antagonists, such as Co<sup>++</sup>, Mn<sup>++</sup>, and Ni<sup>++</sup>, inhibited agrin-induced AChR aggregation. Two other divalent cations, Mg<sup>++</sup> and Sr<sup>++</sup>, did not inhibit receptor aggregation in the presence of Ca<sup>++</sup>, but could not substitute for Ca<sup>++</sup>. Agrin-induced receptor aggregation also was inhibited by the phorbol ester TPA, an activator of protein kinase C; 20 nM TPA completely prevented AChR aggregation. Two dimensional SDS-PAGE of extracts of cultures identified several polypeptides that were phosphorylated in response to TPA treatment. Agrin itself did not change the pattern of phosphoproteins.

Thus agrin induces AChRs in the myotube plasma membrane to accumulate into aggregates by a rapid, Ca<sup>++</sup> dependent process that is inhibited by protein kinase C-mediated protein phosphorylation and is accompanied by a decrease in the rate of degradation of a fraction of AChRs. In many ways agrin's effects on cultured myotubes mimic events that occur during formation of the neuromuscular junction *in vivo*.

#### ACETYLCHOLINESTERASE IN REGENERATING NEUROMUSCULAR JUNCTIONS.

Lili Anglister, Department of Anatomy and Embryology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.

Acetylcholinesterase (AChE) in skeletal muscle is concentrated at the neuromuscular junctions. If muscles are damaged in ways that spare the myofiber basal lamina sheaths, new myofibers develop within the sheaths and the damaged axons regrow to form new neuromuscular junctions on the regenerating myofibers at the original synaptic sites. AChE accumulates at the regenerating neuromuscular junctions, and as at normal ones, a substantial fraction of the enzyme is found in the synaptic cleft where it is associated with the synaptic portion of the basal lamina, passing between nerve terminal and myofiber. The studies we describe were aimed at learning whether synaptic AChE is produced by muscle, nerve or both and whether basal lamina directs its accumulation at the synaptic sites.

Frog muscles were damaged in a way that caused disintegration of the myofibers while sparing basal lamina sheaths. Myofibers were allowed to regenerate but reinnervation was deliberately prevented. The regenerating myofibers produced new AChE which preferentially accumulated at points where the plasma membrane of the new muscle fibers was apposed to the region of the basal lamina that had occupied the synaptic sites at the original neuromuscular junctions. The newly formed enzyme became incorporated into the synaptic basal lamina. These results demonstrate that regenerating myofibers produce synaptic AChE and that its accumulation is directed by synaptic basal lamina.

A complementary study was carried out on operated frog muscles in which myofibers had been removed from the basal lamina sheaths, while leaving intact motor axons, nerve terminals and synaptic basal lamina sheaths. The nerve terminals persisted at the synaptic sites on the sheaths in the absence of myofibers and had all the structural features of normal terminals. We found out that these terminals produced surface AChE and a substantial amount of the newly formed enzyme became associated with the extracellular matrix at the synaptic site, primarily with the synaptic basal lamina adjacent to the terminal. Nerve terminals that reinnervated synaptic basal lamina behaved similarly. This finding shows that some of the AChE that is made and transported by the motor nerve contributes directly to the synaptic cleft enzyme.

We conclude that myofibers and nerve terminals can produce synaptic cleft AChE and that its appearance in the regenerating neuromuscular junction is directed by synaptic basal lamina. Other factors such as nerve and muscle activity may play a role in regulating the production and maintenance of the synaptic enzyme.

ROLE OF A NEUROTROPHIC FACTOR AND CALCIUM CHANNELS IN THE  
REGULATION OF ACETYLCHOLINESTERASE IN CULTURED MUSCLE

N. Rosenberg and Z. Vogel

Dept. of Neurobiology , Weizmann Institute of Science,  
Rehovot, 76100, Israel.

The accumulation of AChE in C<sub>2</sub> cultured mouse muscle cells was found to be stimulated by incubation of the cultures with extracts prepared from rat brains. We have purified the stimulatory activity by various HPLC procedures. The neurotrophic factor (NTF) preparation increased the accumulation of true AChE (EC 3.1.1.7) in a dose dependent manner. Incubation with NTF increased all AChE molecular forms in the muscle cultured cells. However, the increase of the 16S form was relatively more pronounced. In addition, treatment with NTF changed the cellular distribution of AChE and increased the number of membrane patches containing high concentrations of enzyme. Increasing Ca<sup>2+</sup> concentration in the culture medium synergistically increased the effect of NTF on AChE accumulation, while Ca<sup>2+</sup> by itself had only a marginal effect. The voltage dependent Ca<sup>2+</sup> channel blocker, nitrendipine, inhibited the effects of NTF on the accumulation of AChE. It also reduced the amount of AChE in the untreated cells although to a lesser extent. Nitrendipine also inhibited the clustering of AChE seen in NTF-treated cells. Moreover, preincubation of C<sub>2</sub> muscle with NTF increased the <sup>45</sup>Ca<sup>2+</sup> rate of influx into the cells compared with control.

The results, thus, suggest that NTF increases the uptake of Ca<sup>2+</sup> into the cells, possibly through nitrendipine sensitive sites. This uptake of Ca<sup>2+</sup> plays a role in the regulation of AChE in the cells.

Supported by grants to Z.V. from the Muscular Dystrophy Association, the U.S.-Israel Binational Science Foundation and the Minerva Foundation, Munich, Germany, and by a short term EMBO fellowship to N.R.

CHANGES IN THE LEVEL OF ACETYLCHOLINE RECEPTORS ARE MEDIATED BY CALCIUM CONCENTRATION IN THE SARCOPLASMIC RETICULUM

by Shainberg, A., Freud-Silverberg M. and Brik, H.  
Bar-Ilan University, Ramat-Gan 52100, Israel.

Regulation of the AChR level, assayed by  $^{125}\text{I}$ - $\alpha$ -bungarotoxin ( $^{125}\text{I}$ - $\alpha$ -Bgt) binding sites was studied in chick skeletal muscles differentiated in vitro. A large variety of agents known to affect muscle contractions and calcium movement were investigated. The level of AChR is increased by various treatments which have a similar effect on cytoplasmic  $\text{Ca}^{2+}$ , presumably its accumulation in the sarcoplasmic reticulum (SR). Thus, tetrodotoxin (TTX) sodium dantrolene, or Ca channel blockers like D600, which inhibit the spontaneous contractions and therefore probably cause accumulation of  $\text{Ca}^{2+}$  in the SR, enhanced receptors synthesis. Muscle inactivity *per se* is not enough to cause receptor elevation. When TTX was given with low  $\text{Ca}^{2+}$  (50  $\mu\text{M}$ ), there was no increase in receptor's level. In contrast, there was receptor elevation when immobilization was achieved with D600 in low  $\text{Ca}^{2+}$ . These results indicate that  $\text{Ca}^{2+}$  is required for the induction process of the receptors synthesis. However, it does not have to be from an external source. The apparent contradiction between the effects of low  $\text{Ca}^{2+}$  in TTX and those of D600 on AChR, could be explained by the possibility that in the TTX group Ca is not accumulated in the SR. According to this model, redistribution of  $\text{Ca}^{2+}$  in the opposite direction - from the SR to the myoplasm - is expected to bring about a decrease in the level of AChR. Caffeine, which causes  $\text{Ca}^{2+}$  release from the SR, indeed decreased the  $^{125}\text{I}$ - $\alpha$ -Bgt binding. Comparable effects on Ca distribution and the level of AChR were observed using electrical stimulation (ES), carbamylcholine or ryanodine. Electrical stimulation of the muscle cultures in a frequency of 100 Hz for 1s was more efficient in reducing the level of the receptors than chronic 1 Hz or 10 Hz for 10 s each 100 s. Exposure of the myotubes to ES in high K, which paralyzed the muscle, also reduced the level of the receptors. Furthermore, ES in low voltage, insufficient to elicit muscle contraction, was also effective in reducing the level of the receptors. We conclude that intracellular  $\text{Ca}^{2+}$  release from the SR is a necessary mediator for the decline in AChR synthesis. Since even media taken from electrically stimulated muscle cultures are capable of inhibiting receptor synthesis a property lost by heating, we assume that electrically stimulated myotubes probably release to the medium a protein(s) responsible for reducing AChR synthesis. The level of this protein is probably regulated by Ca content in the SR. Calcium in high concentration binds this protein and the synthesis of AChR ensues. In conditions of low Ca in the SR this protein remains free, and synthesis of receptors is reduced.

THE EARLY MOMENTS OF SYNAPTOGENESIS: A PHYSICO-CHEMICAL VIEW.

Mu-ming Poo. Section of Molecular Neurobiology, Yale University School of Medicine, New Haven, Connecticut, U.S.A.

Synaptogenesis depends upon the interactions between specific molecules. Molecular specificity, however, operates only when the interacting molecules are brought within molecular ranges. Nonspecific physical forces are probably responsible for the spatial arrangement of molecules that sets the stage for specific molecular interactions. Experimental and theoretical evidence suggest that an intricate combination of specific chemical interactions and nonspecific physical processes may occur during the early moments of synaptogenesis between nerve and muscle cells. Two cases will be considered:

1. DIFFUSION-MEDIATED TRAPPING of specific membrane-bound molecules at the site of nerve-muscle contact may be an integral part of the process of cell-cell recognition, the development of selective cell adhesion, and the selective synaptic localization of transmitter receptors and ion channels. The absence of basal lamina during the early phase of synaptogenesis allows for the close apposition of pre- and post-synaptic plasma membranes. Thus, direct binding of membrane components of two contacting surfaces is feasible. This binding provides the mechanism for the diffusion-mediated trapping of specific molecules.

2. ELEKTROKINETIC MIGRATION of membrane and cytoplasmic components induced by local synaptic currents may impose a bias in their distribution, and facilitate localized molecular interactions at the synaptic site. Contact with the muscle cell triggers a pulsatile release of acetylcholine from the nerve terminal, leading to local synaptic current within seconds after nerve-muscle contact. Such current generates substantial electric field (0.1 to 1.0 V/cm) in the cytoplasm and along the membrane of the muscle cell. Studies on model systems indicate that such a field is capable of inducing electrokinetic (electrophoretic or electro-osmotic) migration of both cytoplasmic and membrane components. The direct electrokinetic action of the synaptic current may help to localize or concentrate the cytoplasmic second messengers, the cellular organelles, and the substrates for local molecular interactions. It also provides a cellular mechanism for an activity-dependent stabilization of the synapse, and a basis for competition among multiple synaptic contacts on the same postsynaptic cell.

SHORT AND LONG TERM EFFECTS OF ALUMINUM ON SYNAPTIC TRANSMISSION AND ON THE ACTIVITY OF CULTURED NERVE CELLS. Halina Meiri, Eyal Benin and Michal Roll, Dept. of Physiology, Hebrew University-Hadassah Medical School, Jerusalem, ISRAEL.

Elevated brain concentrations of aluminum which are toxic to many biochemical processes are found in a few neurological conditions in humans. In the senile and presenile dementia of Alzheimer type and in the Guam parkinsonian-dementia complex, aluminum is localized at sites bearing typical neurofibrillary degenerations. In dialysis encephalopathy extremely high levels of aluminum in the brain tissue occur in the absence of characteristic neuropathology. The etiological importance of aluminum to these diseases is still questionable and its contribution to the neurological symptoms in human patients is difficult to evaluate. However, in experimental animals neurological disorders associated with neurofibrillary degeneration have been induced by intracerebral injection with aluminum.

In this study, we attempted to relate to functional rather than pathological aspects of aluminum neurotoxicity at the level of a single nerve cell and an individual synapse. Electrical activity of two isolated preparations exposed to aluminum was examined: the frog cutaneous pectoris motor synapse and the tumor cells of the mouse neuroblastoma line N1E-115. Conventional electrophysiological techniques and computer assisted analysis were utilized to monitor synaptic potentials and neuronal action potentials at aluminum exposed cells.

The following results were observed:

A. Isolated frog neuromuscular junction:

Aluminum (6-200 $\mu$ g/ml) has a dual effect on synaptic transmission:

1. Within two hours of aluminum administration to the experimental bath both the quantal content of evoked acetylcholine release and the frequency of spontaneous transmitter secretion are simultaneously augmented by (15-100%) in a dose dependent manner. This effect is independent of the concentration of calcium ions in the extracellular solution.

2. Deterioration of activity at nerve terminals detached from their motor nerve cells is accelerated in the presence of aluminum. An isolated control neuromuscular preparation constantly stimulated at a frequency of 0.1-0.3 Hz, stops releasing transmitter after  $18.0 \pm 2.4$  hours. In the presence of aluminum evoked acetylcholine release stops earlier, after  $11.2 \pm 3.2$  hours. Spontaneous secretion of individual quanta from an unstimulated nerve persists for more than 36 hours independently of aluminum.

B. Neuroblastoma cells in culture:

Differentiated neuroblastoma cells in culture deteriorate when exposed to aluminum. Following addition of  $AlCl_3$  to the culture dish containing the cells, progressive changes in the shape of their action potential are observed. Within 4-6 days, the cells fail to respond to electrical stimulation. The vulnerability to aluminum toxicity is higher in differentiated cells than during the other phases of the cell cycle.

Proliferating neuroblastoma cells maintained in aluminum containing solution differentiate normally when exposed to DMSO; they develop neurites and respond to electrical stimulation with characteristic polyphasic action potentials. However, once differentiated they deteriorate within 4-6 days whereas control cells, kept without aluminum, function properly for at least 14 days.

In conclusion, aluminum at concentrations found in the brain tissue of some demented patients affects the activity of isolated nerve cells and synapses: it interferes with the control of synaptic transmission and accelerates the deterioration of mature nerve cells.



# ANTIBODIES TO CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

Daniel M. Michaelson, Joab Chapman, Orit Bachar, Amos D. Korczyn, Eliyanu Wertman<sup>†</sup> and Yoram Feldon<sup>†</sup>.

Departments of Biochemistry and Psychology<sup>†</sup>, Tel Aviv University; Department of Neurology, Ichilov Medical Center<sup>‡</sup>, and Department of Neurogeriatrics, Ezrat Nashim Hospital<sup>§</sup>.

Alzheimer's disease (AD) is associated with a reduction in presynaptic cholinergic parameters in the cortex and hippocampus. Although the etiology and pathogenesis of AD are not known, several reports indicate the involvement of immunological mechanisms. In the present work we examined the existence of antibodies in AD sera which bind specifically to cholinergic neurons and investigated their role in the disease. As antigens we employed the purely cholinergic electromotor neurons of the electric fish Torpedo. These neurons are chemically homogeneous and cross react antigenically with human and mammalian cholinergic neurons.

Our findings, based on immunoblot assays, show that AD immunoglobulins bind to a specific polypeptide (PK120) in the cholinergic cell bodies of Torpedo electromotor neurons, and that immunoglobulins of patients with other dementias and neurological disorders do not bind to this antigen.

The possibility that the anti-PK120 antibodies play a role in the development of cholinergic dysfunction in AD was examined by immunizing rats with Torpedo cholinergic cell bodies and assessing the resulting effects on their brain cholinergic neurons and on their behaviour. Prolonged immunization with this antigen (>1 year) resulted in impaired spatial learning (T-test and Morris water maze) and in specific changes in the level of cholineacetyltransferase and acetylcholinesterase activities in the rat brain. The extent to which this system may be used as a model for the study of immunological mechanisms in AD will be discussed.

**Alternative splicing generates different mRNAs for the catalytic subunits of globular and asymmetric forms of Torpedo acetylcholinesterase**

Jean Massoulié, Jean-Louis Sikorav, Eric Krejci and Bernard Reimund  
Laboratoire de Neurobiologie, Ecole Normale Supérieure, 75005 Paris, France

The electric organs of Torpedo contain asymmetric and globular forms of AChE. In the asymmetric forms, the catalytic subunits (type A) are associated through disulfide bonds to a collagen-like tail, which inserts the enzyme in the basal lamina. In the globular, dimeric form, the catalytic subunits (type G) possess a C-terminal-linked glycolipid which anchors them in the cellular membranes.

We have used cDNA probes corresponding to the C-terminal portion of the A subunit to demonstrate the existence of distinct mRNAs by S1 mapping analysis, and thus determined the position of a divergence. We have isolated a cDNA clone, the sequence of which differs from that of the A form (Schumacher *et al.*, 1986; Sikorav *et al.*, 1987), downstream from that divergence. The divergent sequence codes for a 30 aminoacid extension possessing the following characteristics. 1) It starts with Ala-Cys (at positions 538-539 of the mature protein); i.e. the sequence of the C-terminal peptide which is amide-linked to the glycolipid, as determined by P. Taylor (personal communication). 2) The extension showed a clear homology to the corresponding sequence of Drosophila AChE, which is indeed known to consist of glycolipid-anchored dimers. 3) The end of the 30 aminoacid extension is hydrophobic.

We conclude that this cDNA corresponds to the catalytic subunit of the amphiphilic G<sub>2</sub> form. Like other glycolipid anchored proteins, this type of AChE subunit is therefore synthesized as a precursor possessing a C-terminal extension which is exchanged for the glycolipid after completion of its synthesis.

Further analyses of cDNA and genomic sequences will clarify the mechanisms of alternative splicing in the generation of AChE molecular forms.

Schumacher, M., Camp, S., Maulet, Y., Newton, M., McPhee-Quigley, K., Taylor, S.S., Friedmann, T. and Taylor, P. (1986) *Nature*, 319, 407-409.  
Sikorav, J.-L., Krejci, E. and Massoulié, J. (1987) *EMBO J.*, 6, 1865-1873.

**Molecular Structures and Gene Organization of the Cholinesterase Species.** Palmer Taylor, Mark Schumacher, Yves Maulet, Michael Newton, Katherine Quigley, Shelley Camp, Gretchen Gibney and Susan Taylor, University of California, San Diego, La Jolla, California 92093

The determination of the primary structure of the cholinesterases obtained either from the c-DNA sequence or from direct amino acid sequencing has yielded essential information on structures of the various cholinesterases and their relationship to other proteins. Analysis of disulfide-linked peptides has shown three internal loops in the molecule and that the most C-terminal cysteine forms the intersubunit disulfide linkage. Torpedo acetylcholinesterase and human butyrylcholinesterase show 53% residue identity. Less homology is seen with the *Drosophila* enzyme but the cysteine positions show similar disulfide arrangements in the enzyme. The overall sequence homology between acetylcholinesterase, the C-terminal portion of thyroglobulin, an inducible protein in *Dictyostelium* and other esterases suggests a larger gene family for acetylcholinesterase. The availability of several c-DNA clones for acetylcholinesterase also permits an analysis of messenger RNA species. Genomic cloning and RNAase digestion experiments reveal a point of divergence in the acetylcholinesterase messages and have permitted the analysis of the molecular basis of the polymorphism of acetylcholinesterase. This information has been correlated with differences in amino acid sequence between the asymmetric and hydrophobic species of acetylcholinesterase.

# THE BIOGENESIS OF ACETYLCHOLINESTERASE IN NERVES AND MUSCLE

Richard L. Rotundo, Anna M. Gomez, Cristina Fernandez-Valle,  
Karin Fendl, and William R. Randall

Department of Anatomy and Cell Biology  
University of Miami School of Medicine  
Miami, Florida 33101

Acetylcholinesterase (AChE) is expressed in numerous vertebrate cells including neurons, muscle, endocrine, and hematopoietic. Each tissue in turn expresses a complex yet characteristic pattern of AChE forms which differ in oligomeric structure, hydrophobicity, and subcellular localization. We have studied the biogenesis of these multiple AChE forms to determine the molecular basis for this diversity and to understand how electrically excitable cells regulate and target identified synaptic components to highly specialized functional domains on their plasma membranes. We now present evidence that all AChE forms in electrically excitable cells are encoded by a single gene and therefore the diversity of molecular forms most likely arises by post-transcriptional and/or post-translational events including assembly and post-translational modifications.

Chicken and quail express two allelic forms of the AChE catalytic subunit polypeptide which differ by an apparent 5-10K daltons on SDS polyacrylamide gels. Individual quails express either the alpha (110 KDa) or beta (100 KDa) AChE subunits, or both. Our studies in quails show that the alpha and beta AChE alleles occur with a frequency of 0.7 and 0.3 respectively in our sample population and in mating experiments segregate as co-dominant autosomal loci in classic Mendelian-fashion. Within individuals, neurons and muscle cells always express the same AChE alleles. Furthermore, the same alleles are expressed in all oligomeric AChE forms, whether globular or asymmetric. These studies indicate that all AChE forms in nerves and muscle are encoded by a single gene.

Newly synthesized AChE polypeptide chains in neurons and muscle appear identical by SDS gel electrophoresis. Unlike the mature AChE in chicken neurons, or the membrane-bound human erythrocyte AChE, the newly synthesized neuronal AChE molecules do not aggregate in the absence of detergents nor exhibit altered mobility by charge-shift gel electrophoresis indicating that they are not initially hydrophobic. It appears that the hydrophobic property of a subset of the neuronal AChE polypeptides is acquired during a subsequent maturational step. Muscle cells, on the other hand, do not appear to synthesize and assemble detectable quantities of the hydrophobic AChE polypeptide chains. The biogenesis of the various AChE forms will be discussed in relation to targeting these molecules to specialized regions of the plasma membrane in electrically excitable cells.

AVIAN ACETYLCHOLINESTERASE: MOLECULAR STUDIES ON THE STRUCTURE AND REGULATION OF THE ASYMMETRIC FORM IN MUSCLE.

W. R. Randall\*, K.W.K. Tsim and E.A. Barnard

MRC Molecular Neurobiology Unit, University of Cambridge Medical School, Hills Road, Cambridge, Great Britain

\* Current address: Dept. of Anatomy and Cell Biology (R-124), University of Miami Medical School, Miami, Florida 33101 USA

Acetylcholinesterase (AChE) in cholinergic tissues occurs as a series of oligomeric forms. The largest of these forms contains a dimensionally asymmetric (collagen-like) subunit in addition to the globular catalytic subunits. These asymmetric forms are the predominant species at the neuromuscular junction where their localization and appearance are directly dependent upon functional innervation. In birds or mammals these forms disappear following denervation or blockage of neurotransmission. During embryonic development, these forms become specifically localized at high density on the synaptic basal lamina at the earliest stages of skeletal muscle innervation.

To study the mechanisms underlying regulation of appearance and localization of the asymmetric AChE forms we have purified this enzyme from newly hatched chicken pectoral muscle using immunoaffinity methods. The purified asymmetric AChE exhibits inhibition properties of both AChE and butyrylcholinesterase (ChE) and contains three subunits with apparent molecular weights of 110 kDa, 72 kDa and 58 kDa. Inhibitor binding and specificity to mAbs directed against AChE and ChE indicate that the 110-kDa subunit contains the AChE catalytic site whereas the 72-kDa subunit is a ChE catalytic subunit. All these types of subunits (of this hybrid form) are linked together by disulfide bonds. A model for this new "hybrid" asymmetric form found in developing chicken muscle will be presented.

We have examined the expression of the AChE catalytic subunit mRNA transcripts during muscle development by Northern hybridization using a cDNA encoding the AChE catalytic subunit from chicken muscle. cDNAs were isolated from a gt 10 cDNA library derived from 13-day embryonic chicken muscle poly A+ RNA by cross hybridization using an oligonucleotide probe synthesized from selected nucleic acid sequences of the analogous enzyme from *Torpedo californica*. The isolated cDNAs showed high regional homology with the deduced sequence from *Torpedo* AChE, showed divergence in several of these homologous regions from the deduced sequence for human brain ChE, and showed specificity to transcripts for AChE but not ChE by Northern blot analysis. This cDNA hybridizes with the highest intensity to three transcripts within 14-day-embryonic poly A+ RNA in Northern blots from muscles of 10-day-embryonic to newly-hatched chickens. Further analyses and quantitation of the transcripts encoding these AChE subunits during muscle development and synaptogenesis will be presented.

STRUCTURAL AND IMMUNOCHEMICAL PROPERTIES OF  
FETAL BOVINE SERUM ACETYLCHOLINESTERASE

B P DOCTOR

Division of Biochemistry  
Walter Reed Army Institute of Research  
Washington D.C. 20307-5100 U.S.A.

We have recently shown that there are structural and conformational differences in the vicinity of the active center domains of fetal bovine serum acetylcholinesterase (FBS-AChE) and Torpedo AChE (Kopeck et al. (1987) Fed. Proc. 46, 285). This conclusion was reached on the basis of determination of the sequence of the first 105 amino acid residues at the amino terminus of FBS-AChE and of the differential inhibition of catalytic activity of these two enzymes by the monoclonal antibody AE-2. The epitope for MAb AE-2 is located between amino acids 52 and 82 of FBS-AChE.

We have elucidated approximately 90% of the amino acid sequence of FBS-AChE and compared it with those of Torpedo AChE (Schumacher et al. (1986) Nature 319, 407) and human serum BuChE (Lockridge et al. (1987) JBC 262, 549). FBS AChE shows approximately 60% and 50% amino acid sequence homology with Torpedo AChE and with human serum BuChE, respectively. There are long stretches in the amino acid sequences of FBS-AChE and of Torpedo AChE in which very high sequence homology is observed, whereas other regions display little or no sequence homology. There are seven cysteine residues in FBS-AChE as against eight in Torpedo, Cys 231 being replaced by glycine. We have so far located five of the remaining six cysteine residues in FBS-AChE, all of which are located at the same positions as in the Torpedo enzyme, as is the active site serine. Comparison of the amino acid sequences of the three cholinesterases permits the proposal of candidate aspartic acid and histidine residues which may be involved in the charge relay systems of these serine esterases.

## BIOGENESIS OF HUMAN CHOLINESTERASES: FROM GENE TO PROTEIN

Hermona Soreq

Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem 91904, Israel

Cholinesterases (ChEs) are highly polymorphic serine hydrolases involved in the termination of neurotransmission in cholinergic synapses and neuromuscular junctions [1]. Both the levels and the molecular forms of ChEs were shown to be modulated during development, denervation and regeneration processes in various species [2]. In order to examine the molecular mechanisms underlying these phenomena in humans, we have used oligodeoxynucleotide probes to isolate full-length cDNA clones coding for human ChE [3,4]. These clones are currently employed in our laboratory to study the biogenesis of human ChE at various levels of gene expression.

Several genes encode for human cholinesterases. In situ hybridization of [<sup>35</sup>S]-labeled ChEcDNA to spread human chromosomes revealed sites for ChE genes on two different chromosomes, No. 3 and 16 [5,6]. Screening of several genomic DNA libraries, using [<sup>32</sup>P]-ChEcDNA as a probe, enabled the isolation of genomic DNA fragments derived from at least 3 different genes, one of which (on chromosome 3) appears to contain multiple introns, whereas 2 others (on chromosomes 3 and 16) appear to be processed genes, originated by post-transcriptional events from the latter [7,8]. When combined with published genetic linkage evidence [9], these findings imply that at least 2 genes (the original one and a processed one) may direct the synthesis of active ChE in humans.

Active transcription of ChE genes in human oocytes. Oocytes from different species display cholinceptive properties [10] and ChE activities [11]. Using *in situ* hybridization to frozen ovarian sections, we detected high amounts of ChEmRNA transcripts in developing human oocytes [12,13]. The enhanced transcription of ChE genes in oocytes suggests that ChEs are involved in oogenesis and/or sperm-egg interaction processes. It also implies that if processed ChEDNA sequences are re-inserted into the genome by post-transcriptional mechanisms, they would be inheritable, which may explain the origin of the processed ChE genes in humans.

Alternate transcription of ChE genes in nervous system tumors. Previous studies have shown distinct patterns of ChE molecular forms in various brain tumors [14] as compared with normal brain [15]. To examine whether these arise from alternative transcription of the ChE genes, cDNA libraries from various tissue origins were screened using labeled ChEcDNA and synthetic oligonucleotides. Evidence for both alternative splicing and multiple termination sites was found in ChEcDNA clones from glioblastoma and neuroblastoma tumors, but not in normal tissues [16].

Synthetic ChEmRNA is sufficient to produce active ChE in microinjected oocytes, while additional mRNAs contribute to the tissue-specific properties of ChEs. Synthetic ChEmRNA, transcribed off the human ChEcDNA clone, was microinjected into *Xenopus* oocytes, where tissue ChEmRNA was shown to be translated into active ChE [17,18]. The clone-produced ChEmRNA was highly efficient in inducing the synthesis, assembly into dimers and membrane association of active ChE molecules with high affinity towards specific substrates and inhibitors. Co-injection with brain poly(A) RNA further enabled the assembly of ChE into tetramers, whereas with muscle poly(A) RNA heavier membrane-associated forms appeared [19]. Thus the tissue-specific expression patterns of ChE genes depend first on the mRNA coding for the catalytic ChE subunit but also on other mRNAs, probably coding for non-catalytic "tail" subunits and/or for proteins performing post-translational processes.

Antibodies to clone-produced human ChE interact with multiple ChE forms and with thyroglobulin. Bacterial expression of ChEcDNA enabled the production of ChE peptides and the elicitation of antibodies against those. These antibodies interact with various denatured and native forms of ChEs as well as with purified human thyroglobulin (Tg), which bears sequence homology with ChE [7,20]. Reciprocal experiments have shown that autoantibodies to Tg in hyperthyroid patients interact with the blotted ChE peptides as well as with ChE in endplates of fetal muscle fibers, which may explain the cholinergic-related symptoms implicated with hyperthyroidism [21].

Current research in our laboratory continues along these lines, aiming to relate the expression of particular ChE genes and their mRNA transcripts to defined tissue-specific molecular forms of ChE in humans.

#### References

1. Silver (1974) *The Biology of Cholinesterases*. North-Holland Publishers.
2. Massoulie, J. and Bon, S. (1982) *Ann. Rev. Neurosci.* 5, 57-106.
3. Prody, C., Gnat, A., Zevin-Sonkin, D., Koch, R., Goldberg, O. and Soreq, H. (1986) *J. Neurosci. Res.* 16, 25-36.
4. Prody, C., Zevin-Sonkin, D., Gnat, A., Goldberg, O. and Soreq, H. (1987), *PNAS*, 84, 3555-3559.
5. Soreq, H., Zamir, R., Zevin-Sonkin, D. and Zakut, H. (1987) *Human Genetics*, in press.
6. Zamir et al., this conference.
7. Soreq, H. and Gnat, A. (1987) *Molecular Neurobiology*, in press.
8. Gnat and Soreq, this conference.
9. Lovrien, E. W., Magenis, R. E., Rivas, M. L., Lamvik, N., Rowe, S., Wood, J. and Hemmerling, S. (1978) *Cytogenet. Cell Genet.* 22, 324-326.
10. Kusano, K., Miledi, R. and Stinnakre, J. (1977) *Nature* 270, 739-741.
11. Soreq, H., Parvari, R. and Silman, I. (1982).
12. Malinger, G., Zakut, H. and Soreq, H., submitted.
13. Zakut et al., this conference.
14. Razon, N., Soreq, H., Roth, E., Bartal, A. and Silman, I. (1984) *Exp. Neurol.* 84, 681-695.
15. Zakut, H., Matzkel, A., Schejter, E., Avni, A. and Soreq, H. (1985) *J. Neurochem.* 45, 382-389.
16. Prody et al., this conference.
17. Soreq, H., Zevin-Sonkin, D. and Razon, N. (1984) *EMBO J.* 3, 1371-1375.
18. Soreq, H. (1985) *CRC Crit. Rev. Biochem.* 18, 199-238.
19. Dreyfus et al., this conference.
20. Schumacher, M., Camp, S., Maulet, Y., Newton, M., McPhee-Quigley, K., Taylor, S. S., Friedman, T. and Taylor, P. (1986) *Nature* 319, 407-409.
21. Zisling et al., this conference.

Supported by the U.S. Army Medical Research and Development Command.



STRUCTURE-FUNCTION RELATIONSHIPS IN HUMAN CHOLINESTERASE APPROACHED BY MICROINJECTING XENOPUS OOCYTES WITH CLONE-PRODUCED SP<sub>6</sub> mRNA

Patrick Dreyfus\*, Dina Zevin-Sonkin\*, Shlomo Seidman\*, Haim Zakut\* and Hermona Soreq\*

\*Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem, 91904.

+Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel Aviv University, Israel.

Cholinesterases (ChE) are ubiquitous, highly polymorphic serine hydrolases degrading acetylcholine. The various forms of ChE in different tissues may be distinguished by their substrate specificities and sensitivity to selective inhibitors, as well as by their subcellular and cell type localization and by the different nature and number of catalytic and non-catalytic ("tail") subunits composing each form [1]. For example, the major ChE form in the human serum is globular soluble tetramers of butyrylcholinesterase (BuChE), highly sensitive to the organophosphorous compound iso-OMPA [2]. In contrast, membrane-associated dimers of acetylcholinesterase (AChE) appear on red blood cells and are sensitive to the quaternary compound BW284C51 [3]. Heavy "tailed" forms of membrane-associated AChE are characteristic of muscle [4], whereas AChE tetramers are the major ChE form in the human brain [5]. In order to approach the molecular mechanisms underlying the biogenesis of the polymorphic human ChEs, a full length cDNA clone coding for human serum BuChE [6] was subcloned into the SP<sub>6</sub> transcription vector [7]. Synthetic polyadenylated ChEmRNA was transcribed *in vitro* of these constructs and microinjected into *Xenopus* oocytes, where the translation of ChEmRNA [8], as well as the post-translational processing and subcellular compartmentalization of the catalytically active enzyme product take place [9,10].

When injected alone, the synthetic clone-produced ChEmRNA induced in the oocytes the synthesis of ChE capable of degrading acetylthiocholine (AcThCh) and butyrylthiocholine (BuThCh) in the range of micromoles/hr/ng of injected SP<sub>6</sub> ChEmRNA, several orders of magnitude higher than the activities produced in oocytes injected with non-enriched poly(A) RNA [8-10]. The nascent cytoplasmic enzyme displayed  $K_m$  values of  $6.3 \times 10^{-4}$  M and  $1.7 \times 10^{-5}$  M towards BuThCh and AcThCh, respectively, as expected from human BuChE [11]. Also, the BuChE-specific organophosphorous inhibitor iso-OMPA (but not the AChE-specific inhibitor BW284C51) blocked this ChE activity in the micromolar range, similar to their action on serum BuChE [12]. In contrast, the membrane-associated fraction of the enzyme displayed  $K_m$  values of ca.  $2 \times 10^{-5}$  M towards both substrates, and was sensitive to the AChE-specific inhibitor BW284C51 as well, at the same concentration ( $1.10^{-5}$  M) as the red blood cell AChE.

Subcellular fractionation of the SP<sub>6</sub> ChEmRNA injected oocytes, followed by sucrose gradient centrifugation and activity measurements, revealed that the clone-produced enzyme appears as assembled dimers in the oocyte's cytoplasm, membrane-associated fraction and incubation medium. Co-injection of SP<sub>6</sub> ChEmRNA with unfractionated total poly(A)+ brain RNA induced the formation of ChE tetramers, sedimenting as 12 S, in the membrane-associated fraction. When liver poly(A)+ RNA was co-injected, the activity was mainly constituted of light forms (mostly monomers and dimers). Finally, co-injection with muscle poly(A)+RNA resulted in the appearance of heavy, perhaps tailed forms, associated with the membrane of the injected oocytes. Altogether, these findings demonstrate that:

- a) SP<sub>6</sub> ChEmRNA by itself is sufficient for the biosynthesis, assembly into dimers and association with the membrane of active ChE;
- b) The affinity of BuChE towards specific substrates and its sensitivity to organophosphates are most probably inherent properties of the primary amino acid sequence, whereas the sensitivity to the reversible AChE inhibitor BW284C51 may be acquired through post-translational processing; and
- c) The correct formation of multi-subunit molecular forms of ChE in particular tissues requires both ChEmRNA and other, tissue-specific proteins, that are absent from Xenopus oocytes.

#### References

1. Massoulie, J. and Bon, S. (1982) *Ann. Rev. Neurosci.* 5, 57-106.
2. Lockridge, O. and LaDu, B. N. (1986) *Biochem. Genetics* 24, 485-498.
3. Dutta-Choudhury, T. A. and Rosenberry, T. (1984) *J. Biol. Chem.* 259, 5653-5660.
4. Dreyfus, P. A., Rieger, F. and Pincon-Raymond, M. (1983) *PNAS* 80, 6698-6702.
5. Zakut, H., Matzkel, A., Schejter, E., Avni, A. and Soreq, H. (1985) *J. Neurochem.* 45, 382-389.
6. Prody, C., Zevin-Sonkin, D., Gnatt, A., Goldberg, O. and Soreq, H. (1987) *PNAS* 84, 3555-3559.
7. Krieg, P. A. and Melton, D. A. (1984) *Nuc. Ac. Res.* 12, 7057-7070.
8. Soreq, H., Parvari, R. and Silman, I. (1982) *PNAS* 79, 830-835.
9. Soreq, H., Zevin-Sonkin, D. and Razon, N. (1984) *The EMBO J.* 3, 1371-1375.
10. Soreq, H. (1985) *CRC Crit. Rev. Biochem.* 18, 199-238.
11. Aldridge, W. N. and Reiner, E. (1972) *Enzyme Inhibitors as substrates*. North-Holland Publishing Co., Amsterdam.
12. Razon, N., Soreq, H., Roth, E., Bartal, A. and Silman, I. (1984) *Exp. Neurol.* 84, 681-695.

Supported by the U.S. Army Medical Research and Development Command. P. Dreyfus is an INSERM fellow.

COVALENTLY ATTACHED PHOSPHATIDYLINOSITOL AS THE MEMBRANE-ANCHORING  
DOMAIN OF TORPEDO ACETYLCHOLINESTERASE

Anthony H. Futerman and Israel Silman

Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel

Acetylcholinesterase (AChE) is one of the growing group of proteins which are attached to the plasma-membrane via covalently bound PI. Evidence for this role of PI comes from two experimental approaches: 1) Selective release of these proteins by a phosphatidylinositol-specific phospholipase C (PIPLC) from *Staphylococcus aureus*; 2) Chemical analysis of their membrane-anchoring domain. AChE from *Torpedo* electric organ was one of the first such proteins to be described. Hydrophobic forms of *Torpedo* AChE can be selectively released from membranes on addition of PIPLC; in addition, chemical analysis of the membrane-anchoring domain of AChE reveals stoichiometric amounts of inositol phosphate covalently attached, by a glycosidic linkage, to a non-acetylated sugar residue, which is itself attached to the protein polypeptide backbone, probably via an intervening oligoglycan. Further, approximately 3 moles of phosphate are found in this domain and GC/MS analysis reveals that the PI consists of a mixture of fatty acids, of which stearate and palmitate are major components. Evidence will be presented for homology between AChE and a number of other proteins anchored via PI.

In order to examine the localization, distribution, sites of biosynthesis and ontogeny of the post-translational addition of the PI-glycolipid to the polypeptide backbone of the AChE catalytic subunit, the susceptibility of AChE to PIPLC during the embryonic development of *Torpedo* electric organ and in the electromotor system and other excitable tissues of the adult *Torpedo ocellata* was tested. PIPLC solubilizes significant amounts of the membrane-bound form of AChE throughout embryonic development of the electric organ, as it does in the adult electric organ. In the electromotor system of the mature fish, PIPLC solubilizes almost quantitatively the AChE dimer in the electromotor axon as in the electric organ itself, but the corresponding fraction in the electric lobe is almost totally resistant to the phospholipase. This finding implies that the covalently bound phosphatidylinositol is added concomitantly with axonal transport. A substantial part of the membrane-bound AChE in back muscle is sensitive to PIPLC, whereas the membrane-bound form in *Torpedo* brain is completely resistant.

The possible functional significance of using PI as a membrane anchor for AChE will be discussed.

## THE VOLTAGE-DEPENDENCE OF TRANSMITTER RELEASE

Robert S. Zucker  
Physiology-Anatomy Dept.  
University of California  
Berkeley, CA 94720 U.S.A.

In 1981, Llinás et al. (Biophys. J. 33:323) reported that transmitter release at the squid giant synapse appeared to be voltage-dependent. Large depolarizations approaching the calcium equilibrium potential admit the same calcium influx presynaptically during the pulse as small ones, but the larger pulses released more transmitter. Subsequently, Augustine et al. (J. Physiol., Lond. 367:163, 1985) showed that this was partly due to the large calcium tail current following large pulses, and reduced the effect by restricting attention only to release during the pulse. They further found that by considering synaptic delay and plotting release at a short time after presynaptic current, this voltage-dependence sometimes vanished.

Meanwhile, Simon and Llinás (Biophys. J. 48:485, 1985) and Fogelson and I (Biophys. J. 48:1003, 1985) developed ways of predicting the local presynaptic calcium concentration at release sites near calcium channels. We considered the diffusion of calcium after influx through channels into cytoplasm, with binding to cytoplasmic buffer. Calcium was removed by uptake into organelles, or extrusion by surface pumps. All parameters had been measured independently. Calcium channels and release sites were located according to microscopic evidence.

Simulations using these models showed that large depolarizations lead to different distributions of presynaptic calcium than do small ones. Large depolarizations open more channels, with less influx per channel, leading to a more uniform distribution of submembrane calcium. Simon and Llinás considered that the power-law dependence of transmitter release might indicate activation of vesicles at multiple points, leading to more effective release when many channels open near a vesicle. I and Fogelson (Proc. Natl. Acad. Sci. USA 83:3032, 1986) considered that the nonlinear dependence of release on external calcium concentration might reflect cooperativity of calcium action at single sites, and that higher voltages opening more channels cause the calcium domains, or clouds of calcium ions surrounding channel mouths, to overlap and result in higher calcium concentrations at release sites. Both models predict a larger transmitter release at higher voltages admitting the same overall amount of calcium presynaptically as lower voltages, without implicating any voltage-sensitive step in transmitter release.

Parnas and Parnas have performed a very different series of experiments on neuromuscular junctions (Parnas and Parnas, J. Physiol., Paris 81:289, 1986), suggesting that in addition to the effect of calcium on release, voltage directly controls the release process, too. They propose that presynaptic calcium enables release, but that in addition presynaptic depolarization is required for exocytosis. We tested this hypothesis (Zucker and Landò, Science 231:574, 1986) by using hyperosmotic treatment or mitochondrial uncouplers to elevate presynaptic calcium sufficiently to trigger substantial spontaneous release. Calcium influx was prevented by chelating external calcium. Depolarization then leads to calcium efflux through open calcium channels, and this effect can be blocked with calcium antagonists (Landò et al., J. Neurobiol. 17:707, 1986). However, depolarization failed to evoke release, even when presynaptic calcium was high. Controls showed that the treatments used did not block the phasic

release process.

We re-evaluated the evidence that had been presented in support of a direct effect of voltage. Macro-patch electrodes were used to excite nerve terminals twice. As the first pulse increased, release increased while facilitation measured by the second pulse decreased. Although this could indicate an increase in release while calcium influx decreased in the first pulse, we found evidence that pulses of different amplitudes preferentially activate different terminals. Increasing the first pulse recruited distant terminals, which were not tested by a small second pulse. A large second pulse testing these terminals showed facilitation to increase as the first pulse increased. When the first pulse is given intracellularly and the test pulse still uses a macro-patch electrode, the same interpretation of the results is possible (Zucker et al., J. Physiol., Paris 81:237, 1986).

Another experiment indicated that a small pulse alone released almost no transmitter, while after a spike train it triggered massive release. We found this result to reflect changes in terminal excitability following the train, such that a subthreshold pulse triggered an action potential after a train. Similar, but less dramatic results, could be obtained in tetrodotoxin, where calcium spikes at nerve terminals can still occur.

The time course of transmitter release remains remarkably invariant with changes of calcium influx and resting calcium. Although some formulations of the calcium hypothesis of release contradict this, our simulations of presynaptic calcium transients indicate that this result is expected, especially if the rise in active calcium is not the rate-limiting step in exocytosis.

Small hyperpolarizing pulses just before or after a depolarizing pulse can have large effects on release by the pulse, but little effect on subsequent release by a second test pulse. This was taken to indicate that the small hyperpolarizations affected release directly without affecting calcium influx and subsequent facilitation. However, it is easily shown (Zucker, Biophys. J., in press, 1987) that small changes in calcium influx will have large effects on release but very small and probably undetectable effects on subsequent facilitation.

In conclusion, there is no evidence that presynaptic potential during a spike has any effect on transmitter release beyond its effect on calcium entry.

Short Term and long term regulation of transmitter release. By R. Rahamimoff<sup>\*,</sup> S.A. DeRiemer<sup>+</sup>, S. Ginsburg<sup>++</sup>, B. Sakmann<sup>\*</sup>, R. Shapira<sup>\*</sup>, S. Silberberg<sup>\*</sup> and H. Stadler<sup>\*</sup>.

Department of Physiology<sup>+</sup>, Hebrew University-Hadassah Medical School, Jerusalem.

Department of Biological Sciences<sup>+</sup>, Columbia University, New York, USA.

Everyman's University<sup>++</sup>, Tel Aviv, ISRAEL

Max Planck Institute for Biophysical Chemistry<sup>\*</sup>, Göttingen, FRG.

The synapse is the site of many short term and long term changes in transmission efficiency. In this communication we concentrate on four recent findings regarding the presynaptic nerve terminal and transmitter liberation.

1. Extracellular calcium inhomogeneity. Clamping the extracellular free calcium concentration ( $[Ca]_o$ ) to values found in the bulk solution by calcium buffers, produces a reduction in quantal transmitter liberation. This indicates that  $[Ca]_o$  is higher near the release sites (presumably the synaptic cleft), than in the bulk extracellular medium. We do not know whether this inhomogeneity is due to localized extrusion processes directed towards the synaptic cleft generating a standing concentration gradient or due to local calcium binding molecules. Whatever the cause for this inhomogeneity will turn out to be, it can produce long term changes in the amount of transmitter liberated and thus can regulate the synaptic efficiency.

2. Slow depression in transmitter release. Prolonged stimulation of the presynaptic nerve terminal at low rates (0.067 to 0.5 Hz) produces a slow decrease in the end plate potential amplitude at the frog neuromuscular junction blocked by d-tubocurarine or  $\alpha$ -bungarotoxin. This slow depression which can reach 50% of the initial response, develops over many minutes and is of presynaptic origin. Fluctuation analysis by the group regression method shows that it is due to a reduction in the number of quanta released by the nerve impulse. Furthermore, ionophoretic application of acetylcholine does not reveal any substantial change in the post synaptic sensitivity. This slow depression seems to be an additional frequency modulator of synaptic transmission.

3. The phosphoinositide pathway. In recent years there is a great renewed interest in the phosphoinositide second messenger system, which employs two intracellular signals: inositol 1,4,5 triphosphate (IP<sub>3</sub>) and 1,2 diacylglycerol (DG). The action of DG in the activation of a calcium-phospholipid dependent protein kinase C (PKC) can be mimicked by the phorbol ester TPA (12-O-tetradecanoyl phorbol-13 acetate). We show that application of TPA causes an increase in the end plate potential amplitude at the frog neuromuscular junction. This increase in amplitude is due to an increase in the number of acetylcholine quanta liberated by the nerve impulse, without any appreciable change in post synaptic sensitivity. Spontaneous transmitter release is also augmented in parallel with evoked release. Synaptic depression is deepened by TPA. These results indicate that the DG branch of the phosphoinositide system can be used in regulation of synaptic transmission; its natural activator is not yet known.

4. Channels in synaptic vesicles. Synaptic vesicles are considered to be the subcellular structures responsible for quantal transmitter liberation; but their small size and intracellular localization made them difficult for a direct electrophysiological study. We used a fused vesicle preparation to obtain large structures suitable for patch recording. Three types of electrical activity were observed, indicating that the vesicle membrane possesses conductances to K<sup>+</sup>, Na<sup>+</sup> and Cl<sup>-</sup> ions. We envisage that the observed channels may participate in vesicle function and thus in the regulation of transmitter liberation.

Supported by MDA, EMBO, SFB236, LSRF, CTR, Israeli Academy of Sciences and US-Israel BSF.

CALCIUM BUFFERING AND CALCIUM MEASUREMENTS IN SINGLE SECRETORY  
CELLS UNDER PATCH CLAMP.

E. Neher

Max-Planck-Institut für biophysikalische Chemie  
D-3400 Göttingen, West Germany

Various ways of stimulating mast cells lead to a stereotyped calcium signal (1,2) as measured by the fluorescent indicator dye fura-2 (3). A prominent transient increase in free intracellular calcium concentration, lasting two to five seconds, is followed by a prolonged phase of elevated calcium. The transient is most probably due to calcium released from intracellular stores because i) it can also be elicited by intracellularly administered Inositoltrisphosphate ( $IP_3$ ), ii) it is independent of extracellular calcium, and iii) no ionic currents can be observed which could mediate calcium entry. If the rising phase of the transient were due to electrogenic calcium entry through the plasma membrane, currents in the order of magnitude 10-100 pA would be expected in a given cell. Intracellularly administered Ca/EGTA buffers have to be in the concentration range 1 to 10 mM in order to reliably suppress the calcium transients (4). The transients also allow an order of magnitude estimate of the cell's high-affinity calcium buffer concentration, which turns out to be in the range 200  $\mu$ M to 1 mM.

The origin of the prolonged phase of calcium elevation is not clear. It is found, however, that  $[Ca]_i$  following a transient can be quite markedly influenced by membrane voltage (4), which points towards an involvement of ionic channels or other membrane transport mechanisms during that phase. Estimates of membrane currents which would be required to maintain such elevated calcium levels (if they were due to calcium entering through channels) are in the range 1 pA per cell. Whole-cell currents of such small amplitude are hard to detect above the background of unspecific conductances.

- (1) Neher, E. & Almers, W. (1986). *EMBO J.* 5, 51-53.
- (2) Penner, R., Pusch, M. & Neher, E. (1987). *Bioscience Reports*, (in press).
- (3) Grynkiewicz, G., Poenie, M. & Tsien, R.Y. (1985). *J. Biol. Chem.* 260, 3440-3450.
- (4) Neher, E. (1987). *J. Physiol.* (in press).



NEUROMUSCULAR TRANSMISSION IN MUSCLES PARALYSED BY  
BUTANE DIONE MONOXIME

P.W. Gage, J. McArdle and A.F. Dulhunty  
Department of Physiology, John Curtin School of Medical Research,  
The Australian National University, Canberra, Australia 2601.

The chemical phosphatase, butane dione monoxime (BDM) depresses surface membrane calcium currents and contraction in cardiac muscle and the two effects are thought to be related (Wiggins et al., 1980). We have found that BDM also depresses contraction in mammalian skeletal muscle, whether elicited by indirect stimulation, direct stimulation or by raising the extracellular potassium concentration: twitches, tetanic contractions and potassium contractures are all depressed and the effects are reversible. As the resting membrane potential and action potentials are essentially normal in the presence of BDM, it was concluded that BDM depresses contraction by affecting intracellular steps in excitation-contraction coupling. Neuromuscular transmission persisted in muscles paralysed by BDM (2-20 mM). There was little change in the time course, amplitude or frequency of spontaneous miniature endplate currents or potentials but the amplitude of endplate currents and potentials increased, indicating an increase in acetylcholine secretion. It is intriguing that a drug that blocks calcium currents should increase transmitter secretion: presumably, it does not block calcium currents in nerve terminals. BDM should be an invaluable tool for paralysing muscles in investigations of neuromuscular transmission.

Wiggins, J.R., Reiser, J., Fitzpatrick, D.F. and Bergey, J.L. (1980)  
Inotropic actions of diacetyl monoxime in cat ventricular  
muscle. *J. Pharmacol and Exp. Ther.* 212: 217-224.

COMPLEXITY AND REGULATION IN THE ACETYLCHOLINE STORAGE SYSTEM OF  
SYNAPTIC VESICLES

Stanley M. Parsons, Krystyna Norenberg, Laurence M. Gracz,  
Wayne D. Kornreich, Ben A. Bahr, and Rose Kaufman.

Department of Chemistry, University of California, Santa Barbara,  
Santa Barbara, CA, USA, 93106.

The acetylcholine(ACh) storage system of Torpedo electric organ synaptic vesicles is composed of an ATPase, an ACh transporter and a receptor for the inhibitory compound 2-(4-phenylpiperidino)cyclohexanol (vesamicol; formerly AH5183). The vesamicol receptor is a very stable protein containing a critical SH group and a carboxyl group of  $pK_a\ 6.26 \pm 0.03$  which probably ion pairs in a hydrophobic environment with the bound drug. Chemical modification, proteolysis and pH titration approaches were used to demonstrate this. The drug binding site was shown to be on the cytoplasmic surface of the vesicle membrane by use of a membrane-impermeant analogue of vesamicol. Rate processes for association and dissociation of vesamicol were studied and found to be heterogeneous in some cases, suggesting that multiple forms of the receptor can exist.

When crude vesicles were banded in an isosmotic sucrose density gradient both classical fully loaded  $VP_1$  and recycling  $VP_2$  vesicles could be observed to actively transport [ $^3H$ ]ACh. The properties of the vesamicol receptor (measured with [ $^3H$ ]vesamicol binding) and the amount of the SV2 antigen characteristic of many neurosecretory vesicles were studied in both vesicle types. Relative to  $VP_1$  vesicles, the  $VP_2$  vesicles had a ratio of ACh transport activity to apparent vesamicol receptor concentration which typically was 4 to 7-fold higher, whereas the ratio of SV2 antigen concentration to apparent vesamicol receptor concentration was about 2-fold higher. The Hill coefficients and equilibrium dissociation constants for vesamicol binding to  $VP_1$  and  $VP_2$  vesicles were essentially the same at 2.0 and 19 nM, respectively. This study demonstrated that the vesamicol receptor ACh storage system appears to be regulated in a manner which survives homogenization of the tissue.

A transmembrane signal has been found to regulate the vesamicol receptor. Typical intact  $VP_1$  vesicle preparations express about 200 pmol receptor/mg protein, whereas hyposmotically lysed, resealed vesicle ghosts express up to 600 pmol/mg or 12 receptors/vesicle. [ $^3H$ ]vesamicol binds to intact  $VP_1$  vesicles in a manner essentially unaffected by exogenous ACh, but binding to lysed vesicles is blocked by 5 to 50 mM ACh in a positively cooperative noncompetitive manner. Previously bound [ $^3H$ ]vesamicol is dissociated by added ACh with a several minute lag period, which suggests that a significant reorganization in the ACh binding site occurs before it can cause vesamicol dissociation. Since vesicle ghosts are sealed (demonstrated with [ $^{14}C$ ]ribitol) this might appear to suggest that the linked ACh site is on the outside of the membrane. However, in ghosts the vesicle membrane was rapidly (<3 sec) and fully permeable to as much as 0.3 M exogenous ACh. The results demonstrate that much of the vesamicol receptor in intact  $VP_1$  vesicles often is cryptic because of the presence of a factor inside of the vesicles which can be released by hyposmotic lysis and that the factor might be internal ACh.

Finally, it has been demonstrated that the vesamicol receptor is linked indirectly to ACh transport inhibition. Binding of [ $^3\text{H}$ ]vesamicol and inhibition of [ $^{14}\text{C}$ ]ACh transport are coincident at high  $\text{VP}_1$  vesicle concentration, but at low vesicle concentration, ACh transport inhibition occurs when only a small fraction of the receptor sites have been occupied. This behavior is apparently time independent. Also, at very low vesicle concentration some very high affinity ( $K_d$  less than  $1\text{nM}$ ) vesamicol receptor clearly is expressed. This suggests that a dissociable factor which weakens the vesamicol receptor affinity copurifies with the vesicles, or that the vesicles interact with each other through the vesamicol receptor. Using trace [ $^3\text{H}$ ]vesamicol (not enough to inhibit ACh transport) and [ $^{14}\text{C}$ ]ACh, it was shown that a biotinylated vesamicol analogue occupied the receptor and inhibited [ $^{14}\text{C}$ ]ACh transport. Addition of excess avidin "neutralized" the biotinylated vesamicol and freed the receptor, yet [ $^{14}\text{C}$ ]ACh transport did not reactivate for at least the next 50 min. It does reactivate after much longer time periods or *in vivo*. Thus, although drug binds with equilibrium behavior, the transport inhibition is irreversible over the relevant time scale. Using trace levels of [ $^3\text{H}$ ]vesamicol, [ $^{14}\text{C}$ ]ACh and nonlabeled drug analogues as competitors (varied from zero to high concentrations), it was shown that at low vesicle concentration the shift in the midpoint of the [ $^3\text{H}$ ]vesamicol displacement curve from the [ $^{14}\text{C}$ ]ACh transport inhibition curve depends on the analogue studied. For example, it is 3-fold for L-vesamicol (the active enantiomer), 6-fold for D-vesamicol and 10-fold for deoxyvesamicol. This relationship held for 16 vesamicol analogues and 9 other compounds of widely varying structures. Only for a weakly binding dimer of vesamicol, hexamethonium and chloroquine did the two curves fall in reverse order, and in no case was there a potent compound able to block [ $^{14}\text{C}$ ]ACh uptake without displacing [ $^3\text{H}$ ]vesamicol within a factor of 10-fold higher concentration of the ligand. Thus, there is no evidence that another ligand binding site critical to ACh storage exists. The result also suggests that an induced conformational change in the receptor dependent on the drug structure links the vesamicol receptor and ACh transport inhibition. Lastly, in lysed vesicles where ACh inhibits [ $^3\text{H}$ ]vesamicol binding, the inhibition was shown to not occur at very low vesicle concentration. This suggests that an external dissociable factor which copurified with the vesicles mediates linkage between the ACh and vesamicol binding sites.

In summary, these results strongly suggest that the ACh vesicular storage system is physiologically regulated and complex. At least one osmotically active internal factor which might be ACh controls the conformation of the vesamicol receptor on the outside of the vesicle. An external dissociable factor mediates this signal and the affinity of the receptor for vesamicol. A possible physiological role for such a signaling device will be discussed.

THE MECHANISM OF ACETYLCHOLINE RELEASE : ITS ESSENTIAL COMPONENT  
THE MEDIATOPHORE

M. ISRAEL, N. MOREL, B. LESBATS, S. BIRMAN and R. MANARANCHE

Département de Neurochimie, Laboratoire de Neurobiologie  
cellulaire et moléculaire, C.N.R.S., 91190 Gif sur Yvette, FRANCE

Torpedo electric organ synaptosomes have proven to be very convenient for studying the mechanism of acetylcholine release. Ultrastructural changes taking place in the nerve terminal membrane while it releases transmitter suggest that a category of large intramembrane particles which become more numerous support the translocation of acetylcholine upon calcium action. The involvement of integral membrane proteins in the release process was also demonstrated by incorporating them into artificial membranes which inherited from the native membrane the property of releasing acetylcholine in response to a calcium influx. This observation led us to purify from synaptosomal membranes the protein called mediatophore which is involved in the release process. A doughnut shaped molecule of about 200 000 d made of subunits at 15-17 000 d could be characterized. It has several essential physiological and pharmacological properties attributed to the mechanism of acetylcholine release.

MOLECULAR PROPERTIES OF THE SODIUM-CALCIUM EXCHANGER.

Hannah Rahamimoff, Ari Barzilai, Nurit Sharabani and Rivka Spanier.

Department of Biochemistry, Hebrew University - Hadassah Medical School,  
P.O.Box 1172, Jerusalem, Israel.

The  $\text{Na}^+-\text{Ca}^{2+}$  exchanger is one of the major  $\text{Ca}^{2+}$  transporting molecules in excitable cells. To date, no inhibitor, toxin or affinity probe is known that could label the protein moiety associated with the  $\text{Na}^+-\text{Ca}^{2+}$  antiport activity and identify it. Therefore enriched appearance of a protein band on SDS-polyacrylamide gels in conjunction with increased specific transport activity served as a sole criterion for its purification and identification. Recently we have identified the protein moiety responsible for  $\text{Na}^+-\text{Ca}^{2+}$  exchange activity in synaptic plasma membranes (SPM). This was done by raising polyclonal antibodies in rabbits against each one of the detectable proteins present in the purified preparation containing the enriched specific transport activity. Two of the antibody preparations bound specifically to native SPM: antibodies which were raised against the 70,000 Da protein (the most prominent species consistently present in the purified preparation), and antibodies raised against a 33,000 Da protein (inconsistently present in variable amounts in the purified preparation). Both antibodies bound exclusively to a protein of 70,000 Da in native SPM. When, however, the purified 33,000 and 70,000 Da proteins were used as antigens, each one of the antibody preparations bound to both proteins.

In addition, both antibody preparations immunoprecipitated  $\text{Na}^+$  gradient-dependent  $\text{Ca}^{2+}$  transport activity from solubilized SPM. This was obtained by incubation of solubilized SPM with a complex containing antibodies bound to Protein A-Sepharose beads, reconstitution of the material excluded from the beads and determination of the residual transport activity. The decrease in  $\text{Na}^+$  gradient-dependent  $\text{Ca}^{2+}$  transport activity paralleled the amount of antibody bound to Protein A-Sepharose beads and could reach 82% as compared to the activity remaining in control experiments using preimmune sera. In comparison, ATP-dependent  $\text{Ca}^{2+}$  transport activity was unpaired.

These results indicate that the 70,000 Da protein in SPM contains the catalytic  $\text{Na}^+-\text{Ca}^{2+}$  antiport activity. The presence of the 33,000 Da protein in some preparations and its properties may be explained by its being either a degradation product or a subunit of the 70,000 Da protein.

---

Supported by the Muscular Dystrophy Association, New York, N.Y.  
and the Israel Academy of Sciences, Basic Research Division.

The purified 70,000 Da protein is a glycoprotein as revealed by treatment of the purified 70,000 Da species with endoglycosidase F. The deglycosylated protein migrates on SDS-polyacrylamide gels as an approximately 50,000 Da protein. Limited proteolysis by V8 protease or trypsin reveals that the polyclonal antibody preparation binds also to some of the larger peptide fragments obtained.

The stoichiometry of the  $\text{Na}^+ - \text{Ca}^{2+}$  exchanger from the synaptic plasma membranes was studied in both native and reconstituted preparations. In kinetic experiments performed with the native preparation, initial rates of  $\text{Na}^+$  gradient-dependent  $\text{Ca}^{2+}$  influx were compared to  $\text{Ca}^{2+}$  dependent  $\text{Na}^+$  efflux. These experiments showed that 4.82  $\text{Na}^+$  ions are exchanged for each  $\text{Ca}^{2+}$  ion. Thermodynamic approach in which equilibrium measurements were done with the reconstituted preparation resulted in similar (4.76) stoichiometry. The effects of membrane potential, employing valinomycin induced  $\text{K}^+$  fluxes could be demonstrated in the reconstituted preparation. The stoichiometry of the  $\text{Na}^+ - \text{Ca}^{2+}$  exchanger remained the same both under conditions of positive inside or negative inside polarization of the vesicles membrane. The direct contribution of the  $\text{Na}^+ - \text{Ca}^{2+}$  exchanger to the membrane potential across the reconstituted vesicle membrane could be demonstrated by using the lipophilic cation tetraphenylphosphonium.

Positive inside membrane polarization did not change the  $K_m$  to  $\text{Ca}^{2+}$  when  $\text{Na}^+$  gradient dependent  $\text{Ca}^{2+}$  influx was measured. It led however to a 4-fold increase in the  $V_{\text{max}}$  of the process. When the ratio of internal to external  $\text{Na}^+$  concentration was varied, positive inside membrane polarization led to a reduction by a factor of approximately 20 in the extent of  $\text{Na}^+$  gradient required for half apparent maximal reaction velocity to be reached.

POTASSIUM CHANNELS IN SYNAPTOSOMES: PHARMACOLOGY AND TOXICOLOGY.

Blaustein, M.P., Bartschat, D.K., Benishin, C.G., Colby, K.A., Krueger, B.K., Schneider, K.J. and Sorensen, R.G.

Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, 21201 USA.

Tracer  $^{42}\text{K}$  and  $^{86}\text{Rb}$  efflux methods have been developed to study the properties of K channels in isolated rat brain presynaptic nerve terminals (synaptosomes). On the basis of blocking pharmacology and characteristic tracer kinetic profiles, we have identified six different types of K channels: 1) Resting K channels represented by the efflux into media containing 5 mM K. This conductance is relatively insensitive to K channel blockers. 2) A depolarization-gated, rapidly inactivating (1 sec) K conductance that corresponds to the A current. This is selectively blocked by 4-aminopyridine (< 1 mM) and by  $\beta$ - and  $\delta$ -Tx, two polypeptide components of *Dendroaspis angusticeps* venom (dendrotoxins). 3) A depolarization-gated, non-inactivating K conductance that corresponds to the delayed rectifier. This is selectively blocked by phencyclidine (PCP) and dexoxadrol, by  $\beta$ - and  $\delta$ -Tx, and by venoms from several scorpions including *T. serrulatus*, *C. sculpturatus*, and *L. quinquestratus*. 4 and 5) Two Ca-activated K channels that are selectively blocked by low concentrations of quinine (1  $\mu\text{M}$ ), and the neuroleptics, haloperidol and the phenothiazines. There are two components, with different sensitivities to the phenothiazines ( $\text{IC}_{50}$  = 20-30 nM and 1-3  $\mu\text{M}$ ). A component of *L. quinquestratus* venom blocks some of this conductance. 6) A K conductance that is selectively activated by certain sigma opioids and by levoxadrol (but not by its enantiomer, dexoxadrol). The ability of these agents to open this K channel can be blocked by naloxone.

The two voltage-gated K channels in hippocampus and corpus striatum nerve endings apparently can be modulated by protein kinase C, since diacyl glycerol causes a time-dependent inhibition of these channels. The data suggests that phosphorylation may be involved in regulating these channels.

We have begun to determine the chemical nature of some of these K channels by labelling them covalently with  $^3\text{H}$ -azido PCP and with  $^{125}\text{I}$ -labelled dendrotoxins.

## PRESYNAPTIC CURRENTS IN FROG MOTOR NERVE TERMINALS

A. Arnon, G. David, E. Hevron and Y. Yaari  
Department of Physiology,  
Hebrew University School of Medicine, Jerusalem, Israel

Transmitter release from presynaptic nerve terminals is strongly influenced by the waveform of nerve terminal polarization following the arrival of an action potential. This, in turn, is largely determined by the properties of ionic conductances present in the nerve terminal membrane.

The small caliber of vertebrate motor nerve terminals precludes direct analysis of membrane currents by standard current- and voltage-clamp techniques. A more indirect approach is provided by the perineurial sheath surrounding motor axons (but not their terminals), which forms an electrically insulated "tube" around motor fibre bundles. Thus, an electrode positioned in this "tube" records extracellular currents flowing between axons and their terminals. Using this approach several groups have analyzed presynaptic spike currents in mammalian and amphibian motor nerve terminals. Their results suggest the existence of multiple  $K^+$  ( $gK^+$ ) and  $Ca^{++}$  ( $gCa^{++}$ ) conductances in this structure, which may be modulated by neurotransmitters, neurotoxins, and nerve activity. Here we shall describe in some detail our analysis of presynaptic conductances in frog cutaneous pectoris motor nerve terminals.

Recordings from nerve bundles containing one or several motor axons disclose a "fast"  $gK^+$  in the corresponding nerve terminals, which may contribute to rapid spike repolarization. This  $gK^+$  persists in  $Ca^{++}$ -free solutions but is blocked by 10  $\mu M$  or more of 3,4-diaminopyridine (DAP). Following DAP application, a second  $gK^+$  is revealed, which has a slower time course, and is blocked by exposure to  $Mn^{++}$  or  $Cd^{++}$  and by extracellular  $Ca^{++}$  washout. This presumed  $Ca^{++}$ -activated  $gK^+$  is suppressed also by 1-5 mM tetraethylammonium (TEA), which also block the "fast"  $gK^+$ . Both presynaptic  $gK^+$ s are sensitive to blockade by the neuromuscular transmitter acetylcholine (ACh). However, the high (0.5-2 mM) ACh doses required for this action and its insensitivity to d-tubocurarine and atropine, suggest it is not exerted via classical cholinergic receptors.

When preparations are incubated in 10 mM TEA, which presumably blocks most  $gK^+$  in the motor nerve terminals, large signals reflecting inward currents at the terminals can be recorded. They are identified as presynaptic  $Ca^{++}$  currents by several criteria: a) their magnitude is positively related to  $[Ca^{++}]_o$ ; b) they are reversibly reduced by  $Mn^{++}$  or  $Cd^{++}$ ; c) they persist when  $Ca^{++}$  is replaced by  $Sr^{++}$ ; d) they are reduced by verapamil (provided the nerve terminals are depolarized by elevated  $[K^+]_o$ ). These presumed  $Ca^{++}$  currents are not blocked by the dihydropyridine antagonist nifedipine, suggesting the presynaptic  $Ca^{++}$  channel type is not the ubiquitous "L" type.

Repetitive (20-100 Hz) motor nerve activation in standard Ringer solution induces the buildup of presynaptic currents,



which resemble the presumed  $\text{Ca}^{++}$  currents encountered in TEA. They are similarly reduced by lowering  $[\text{Ca}^{++}]_o$  or by adding  $\text{Mn}^{++}$  or  $\text{Cd}^{++}$ . It is possible that repetitive nerve activation causes partial gK inactivation, thereby prolonging presynaptic spike depolarization and  $\text{Ca}^{++}$  influx. Such a mechanism may contribute to frequency modulation of transmitter release from motor nerve terminals.

Supported by grants from the USA-Israel BSF and the Israeli Center for Psychobiology.

# **MOLECULAR STUDIES OF THE POSTSYNAPTIC 43K PROTEIN AND CALCIUM CHANNELS FROM SKELETAL MUSCLE.**

**Stanley C. Froehner, William J. LaRochelle, and Mary E. Morton,  
Dartmouth Medical School, Hanover, New Hampshire 03756 USA**

Proper alignment of macromolecules at the neuromuscular junction is necessary for rapid signal transmission across the synapse. For example, high concentrations of acetylcholine receptors occur on the crests of postjunctional folds directly across the synaptic gap from presynaptic active zones where voltage-sensitive calcium channels are thought to be localized. The cellular mechanisms responsible for forming and maintaining the specialized distributions of these two ion channels are largely unknown. We have examined peripheral membrane proteins of the postsynaptic membrane thought to be involved in anchoring receptors at synaptic sites and have also begun to develop immunological probes for voltage-activated calcium channels.

The Torpedo electrocyte postsynaptic membrane contains, in addition to the acetylcholine receptor, a major, peripheral membrane protein of  $M_r$  43,000 (43K protein). Indirect evidence has implicated this protein in the mechanisms that restrict receptor mobility. In Torpedo electrocytes, the 43K protein is coextensively distributed with the receptor, can be chemically crosslinked to the beta subunit, and occurs in concentrations approximately equimolar with the receptor. This stoichiometric relationship is found throughout electric organ development of the electric organ (studies done in collaboration with V. Witzemann). The receptor and the 43K protein increase in a parallel manner from approximately 0.2-0.4 pmoles/mg protein in 44mm embryos to approximately 200 pmoles/mg in adult tissue. At each developmental stage examined, the equimolar ratio of 43K protein and AChR was maintained.

Monoclonal antibodies to the Torpedo 43K protein recognize a protein of similar size in mammalian muscle cells. The 43K protein is associated with patches of AChR that arise spontaneously on C2 myotubes. In these cells, the 43K protein and AChR are coordinately expressed in stoichiometric amounts. In collaboration with Zach Hall's laboratory, we have examined the expression of the 43K protein in genetic variants of C2 cells that lack functional AChR. In one variant that fails to synthesize the alpha subunit, 43K protein was expressed at approximately one-third the level found in wild-type cells. The variant did express the AChR beta subunit at levels comparable to that found for the 43K protein. These results suggest that expression of the receptor and the 43K protein are coordinated and may be subject to the same regulatory controls.

To examine the distribution and molecular structure of calcium channels, we have prepared monoclonal antibodies to the dihydropyridine (DHP)-binding complex/calcium channel from rabbit muscle transverse tubules. Although the t-tubule calcium channels are pharmacologically distinct from those found in most nerve terminals, structural similarities may exist. One monoclonal antibody, mab 1A, immunoprecipitates the digitonin-solubilized DHP-binding complex. This complex, when purified by WGA chromatography, sediments as a 21S component. The sedimentation coefficient is increased to about 24S after incubation with mab 1A IgG. Four polypeptides with apparent molecular weights under nonreducing conditions of 220kDa, 200kDa, 61kDa, and 33kDa cosediment with the 21S complex. Mab 1A recognizes the 200kDa polypeptide, as shown by Western blotting analysis. The electrophoretic mobility of this protein is unaffected by disulfide bond reduction. DHP-binding complex purified by WGA chromatography followed by immunoaffinity chromatography on a mab 1A column is comprised primarily of the same four polypeptides. Thus, the 200 kDa protein is a component of the DHP-binding complex from rabbit skeletal muscle, and in association with the other polypeptides, may comprise the voltage-sensitive calcium channel.

# ACTION OF ANTICHOLINESTERASES ON ACETYLCHOLINE RECEPTORS

Mohyee E. Eldefrawi

Dept. of Pharmacology & Exp. Therap., University of Maryland

School of Medicine Baltimore, Maryland 21201.

The interactions of carbamate and organophosphate anticholinesterases with the nicotinic acetylcholine (ACh) receptor of *Torpedo* electric organ and muscarinic receptors of rat brain and neuroblastoma N1E-115 cell culture were studied. The effects on the nicotinic receptor were investigated by the changes occurring in its binding of  $^{125}\text{I}$ - $\alpha$ -bungarotoxin and  $^3\text{H}$ -phencyclidine and in receptor regulated  $^{22}\text{Na}^+$  flux, and on the muscarinic receptor by changes in its binding of  $^3\text{H}$ -quinuclidinyl benzilate and  $^3\text{H}$ -cis-methyldioxolane and in  $^3\text{H}$ -cGMP synthesis.

On the nicotinic receptor, the organophosphates soman and echothiophate interacted with the ACh binding site, acting as partial agonists, while VX was an allosteric inhibitor of the receptor's open channel conformation. The carbamates neostigmine and pyridostigmine acted as partial agonists while physostigmine was an open channel blocker. Tetraalkylammonium anticholinesterases interacted with the different receptor sites. Tetramethylammonium acted as an agonist. Increasing the chain length of the symmetrically substituted tetraalkylammonium compounds increased the affinity of the receptor's allosteric site for them but decreased the affinity of the ACh-binding site. Edrophonium acted as a depolarizing blocker.

The population of muscarinic receptor with a very high affinity for  $^3\text{H}$ -cis-methyldioxolane had a very high affinity for certain organophosphates (e.g. VX). The carbamates also inhibited the muscarinic receptors but only at very high concentrations.

Oxadiazolidinones, the nonesteratic irreversible inhibitors of ACh-esterase reacted reversibly, but with much lower potency with both nicotinic and muscarinic ACh receptors.

The nicotinic ACh receptor of *Torpedo* electric organ, was used to develop a biosensor for organophosphate nerve agents. The pure ACh-receptor alone and with ACh-esterase were incorporated into liposomes made of a mixture of phosphatidylcholine and cholesterol. The reconstituted liposomes were interfaced with capacitance sensors developed at the Applied Physics Laboratory of The Johns Hopkins University. The capacitance, measured by a GR-1657-RLC Digibridge, increased when the biosensor was exposed to ACh in a dose-dependent and reversible manner. A d-tubocurare-treated biosensor failed to respond to ACh. Effects of anticholinesterases on the ACh receptor-based biosensor will be reported.

CERTAIN MUSCARINIC ANTAGONISTS ARE NONCOMPETITIVE INHIBITORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR.

G. Amitai<sup>\*</sup>, J. Herz<sup>#</sup>, R. Bruckstein<sup>\*</sup> and S. Chapman<sup>\*</sup>, <sup>\*</sup>Dept. of Pharmacology, IIBR, P.O. Box 19 Ness Ziona, Israel and <sup>#</sup>Dept. of Pharmacology M-036, School of Medicine, UCSD, La Jolla Ca. 92093, USA.

The muscarinic antagonists, atropine, aprophen and benactyzine may be used as antidotes for the treatment of organophosphorus (OP) poisoning. We have studied the interaction of these drugs, focusing mainly on aprophen and benactyzine, with nicotinic acetylcholine receptor (AChR) in BC3H-1 intact muscle cells and with receptor-enriched membranes of *Torpedo californica*. Aprophen and benactyzine diminish the the maximal carbamylcholine (carb)-elicited sodium influx into muscle cells without shifting  $K_{act}$  (carb concentration eliciting 50% of the maximal  $^{22}Na$  influx). The concntration dependence for the inhibition of sodium influx by aprophen and benactyzine occurs at lower concentrations ( $K_{ant} = 3$  and  $50\mu M$ , respectively), than those needed for the displacement of [ $^{125}I$ ]- $\alpha$ -bungarotoxin from the agonist/antagonist sites of AChR ( $K_D = 83$  and  $800\mu M$ , respectively). The effective concentration for the inhibition of AChR response by atropine ( $K_{ant} = 150\mu M$ ) is significantly higher than those obtained for aprophen and benactyzine. Both aprophen and benactyzine interact with AChR in its desensitized state in BC3H-1 cells without further enhancing agonist affinity. Furthermore, in BC3H-1 muscle cells, aprophen and benactyzine do not alter  $K_{des}$  (equilibrium concentration of carb which diminishes 50% of the maximal response). However, both compounds preferentially associate with the high-affinity state rather than the resting state of *Torpedo* AChR. The  $K_D$  values obtained for aprophen and benactyzine from equilibrium displacement of [ $^3H$ ]PCP in *Torpedo* are:  $16.4$  and  $384\mu M$ , compared to  $0.7$  and  $28.0\mu M$ , in the presence of carb, respectively. These data imply that aprophen and benactyzine binding to *Torpedo* AChR is allosterically regulated by the agonist site.

While previous studies have shown that aprophen and benactyzine are muscarinic antagonists at  $10$ - $100nM$ , the present study demonstrates that these ligands are effective noncompetitive inhibitors of AChR at  $3$ - $50\mu M$ , in either *Torpedo* or mammalian muscle cells. These effective concentrations correspond very well with the plasma level of these drugs found *in-vivo* to produce a therapeutic response against OP poisoning.

# BINDING PROPERTIES AND TRANSMEMBRANE SIGNALLING OF MUSCARINIC RECEPTOR SUBTYPES

E. Heldman, Z. Pittel, Y. Karton and A. Fisher.

Israel Institute for Biological Research, Ness-Ziona 70450, Israel.

The existence of various muscarinic receptor subtypes in the central nervous system is indicated by multiaffinity binding curves for agonists such as carbachol (CCh) and by differential changes of the binding properties of muscarinic receptors, from various brain regions, in response to chemical treatments such as N-ethylmaleimide. However, it is unclear whether these various receptor subtypes use different transmembrane signalling mechanisms to achieve the physiological response.

In the present work we used a novel selective agonist, cis-2-methylspiro(1,3-oxathiolane-5,3')quinuclidine (AF102B), designed and synthesized at our laboratory, as a tool to study the transduction mechanism of the M1 receptor subtype. The binding properties and the biochemical effects of this agonist were compared to those of the ganglionic M1-selective agonist, McN-A-343 and to oxotremorine which has a relative high selectivity toward M2 receptor subtype. The potency of AF102B in displacing the nonselective antagonist <sup>3</sup>H-QNB from cerebellar homogenate (rich in M2 receptor subtype) was much lower than that of oxotremorine. However AF102B was similar to McN-A-343 in displacing <sup>3</sup>H-QNB from forebrain homogenate (rich in M1 receptor subtype). These data indicated the relative M1-selectivity of AF102B. Displacements of the selective M1 antagonist, <sup>3</sup>H-pirenzepine and the nonselective agonist, <sup>3</sup>H-cis-methyl-dioxolane, also showed that AF102B was the most selective M1 compound when compared to oxotremorine, McN-A-343, AF102A (the trans isomer) cis-AF30 and trans-AF30 (the dioxolane analogs, respectively). The agonistic nature of AF102B was shown in binding studies, where nonhydrolyzable GTP analogs, as in case of CCh, shifted the displacement curve to the right, as well as in functional studies where AF102B, same as CCh, was able to induce atropine-sensitive contractions of smooth muscles (isolated guinea-pig ileum and trachea). However, unlike the agonist CCh, AF102B affected neither the adenylate cyclase activity nor did it potentiate phosphoinositide (PI) turnover. Nevertheless, AF102B, inhibited the CCh-induced hydrolysis of phosphatidylinositol biphosphate but did not affect the CCh-induced inhibition of adenylate cyclase. Thus it seems that although activation of M1 receptors in the brain does not potentiate PI turnover, this biochemical function is somehow associated with the M1 receptor subtype. Indeed, the distribution of M1 subtypes receptors in the various brain regions is similar with that of CCh-induced PI turnover (e.g. cortex and striatum), while the distribution of M2 subtypes receptors is similar with that of CCh-induced inhibition of adenylate cyclase (e.g. cerebellum).

Supported by Snow Brand, Japan.

BIOCHEMICAL AND BEHAVIORAL EFFECTS OF ACETYLCHOLINESTERASE INHIBITION IN BRAIN

E. Giacobini and K.A. Sherman, Department of Pharmacology, Southern Illinois University School of Medicine, P.O. Box 3926, Springfield, IL 62708 USA

The effect of acute (single or multiple dosage) and chronic (up to 50 days) administration of three drugs producing reversible inhibition of acetylcholinesterase (AChE) in brain (physostigmine, tetrahydroaminoacridine and metrifonate) was compared in rats. The results reveal major differences in biochemical effects such as percent and duration of AChE inhibition, regulation of acetylcholine synthesis and release, uptake of choline and binding to cholinergic receptors. Behavioral effects such as "stereotypy" and tolerance are also markedly different. These results suggest differences in mechanism of action of various AChE inhibitors in brain. These experimental findings have potential clinical implications for the symptomatic therapy of Alzheimer patients, suggesting new strategies and novel models of administration of cholinesterase inhibitors. (Supported by grants from the Natl. Inst. Aging #AG05416-01A1 and Illinois Dept. Public Health).

MOLECULAR BASIS OF ANTICHOLINESTERASE ACTIONS ON NICOTINIC AND GLUTAMATERGIC SYNAPSES.

Albuquerque, E.X., Alkondon, M., Aracava, Y., Cintra, W.M., and Swanson, K.L.

Department of Pharmacology and Experimental Therapeutics,  
University of Maryland School of Medicine, Baltimore,  
Maryland 21201 USA

The understanding of the interactions of cholinesterase (ChE) inhibitors, including certain insecticides, and the ChE-reactivating oximes with the macromolecular entity comprising the nicotinic receptor and its ion channel (AChR) is of fundamental importance for the proper treatment of insecticide poisoning and selection of appropriate therapeutic approaches to central cholinergic disorders. In addition to their ChE-inhibitor properties, both reversible and irreversible anticholinesterase agents, (carbamates and organophosphorus compounds) have direct actions on the peripheral nicotinic AChR: acting as agonists, blocking the ion channel in its open conformation via noncompetitive mechanisms or enhancing receptor desensitization. The pyridinium compounds with oxime groups, such as 2-PAM and HI-6, and another bispyridinium compound which lacks the oxime group, namely SAD-128, have been shown in our laboratory to modulate the ionic currents occurring at the frog endplate region. Voltage-clamped endplate currents (EPCs) are increased in peak amplitude and prolonged by ChE inhibition, but EPCs were decreased in amplitude and either shortened or converted into biphasic decays in voltage-dependent manner by the noncompetitive actions of 2-PAM, HI-6 and SAD-128. Acetylcholine (ACh)-induced channel openings (open times) were also shortened by HI-6 in a voltage-dependent manner as revealed by patch clamp studies. The AChR channel-blocking effect of these pyridinium compounds may remain as one of the mechanisms by which they produce antidotal effects against organophosphate agents. The strength of this hypothesis is further enhanced by the significant protection against lethality of organophosphorus agents offered by (+)physostigmine, which in the absence of significant reversible ChE inhibition may be attributed to a noncompetitive blockade of AChR. Other aspects of anti-ChE agents independent of ChE inhibition are also under investigation. Furthermore, studies with forskolin and its analogs have disclosed a possible involvement of phosphorylation in the regulation of nicotinic AChR activation. Ion channel blockade produced by nicotinic noncompetitive antagonists at the locust glutamatergic synapse raises the possibility of certain similarities between ACh and glutamate receptors.

The biochemical and electrophysiological aspects of the central nervous system nicotinic AChR are being investigated using selective and stereospecific agents. Although some differences in agonist effects at central and peripheral



receptors have been encountered, the present study disclosed marked homology between the putative hippocampal AChRs and those on the muscle. In binding experiments, (+)anatoxin-a (Mol. Pharmacol. 29: 250, 1986) was a potent competitor of [<sup>3</sup>H](−)nicotine binding to rat brain membranes ( $K_i = 3 \times 10^{-10} M$ ); the (−)anatoxin enantiomer was two orders of magnitude less effective. To see if (+)anatoxin-a also acts as an agonist in the CNS, the toxin was tested in a model system based on the presynaptic, nicotinic facilitation of transmitter release. Synaptosomes from rat hippocampus were loaded with [<sup>3</sup>H]choline so that perfusion with Kreb's bicarbonate buffer into which pulses (100  $\mu l$ ; 50  $\mu M$ ) of (−)nicotine were introduced resulted in the release of discrete peaks of [<sup>3</sup>H]ACh. This release of neurotransmitter could be partially blocked by the nicotinic antagonist dihydro $\beta$ erythroidine (10  $\mu M$ ). Similarly, hippocampal synaptosomes loaded with [<sup>3</sup>H]GABA responded to pulses of nicotinic agonist by releasing this radiolabelled transmitter. The higher labelling [<sup>3</sup>H]GABA allowed lower agonist concentrations to be tested. In this case, 10  $\mu M$  (−)nicotine and 1  $\mu M$  (+)anatoxin-a released comparable amounts of [<sup>3</sup>H]GABA. The results suggest that (+)anatoxin-a is at least 5 times more effective than (−)nicotine at presynaptic nicotinic receptors in mammalian brain. (D.R.E. Macallan, G.G. Lunt, S. Wonnacott, Y. Aracava, H. Rapoport and E.X. Albuquerque, Proc. Nat. Acad. Sci. U.S.A., submitted). The hippocampal AChRs showed a similar sensitivity to histrionicotoxin, a probe for ion channel sites, as the muscle AChRs (FEBS Lett. 212:292, 1987). Using (+)anatoxin-a and ACh as probes of nicotinic AChR and employing the patch-clamp technique, we recorded channel activation in hippocampal neurons cultured from fetal rats (10 to 20-day-old culture). Channel activity was recorded from an area close to the axon hillock of the hippocampal neurons. Both ACh (0.4  $\mu M$ ) and (+)anatoxin-a (0.1-0.4  $\mu M$ ) activated single channel currents whose conductances and durations were quite similar to those recorded at the perijunctional region of the muscle endplate. Additionally, AChRs activated by either ACh or (+)anatoxin-a were sensitive to  $\alpha$ -bungarotoxin and dihydro $\beta$ erythroidine. These studies demonstrate the presence of functional nicotinic AChRs on the neurons of rat hippocampus. The sensitivity of central nicotinic receptors to (+)anatoxin-a and analogues and physostigmine has also been tested using the patch-clamp technique in isolated hippocampal pyramidal cells, ganglion cells of the retina and brain stem respiratory neurons. This study may provide more efficacious and specific analogues for further biochemical and electrophysiological analyses of various receptors, including those involved in cholinergic disorders.

ROLE OF LIPIDS IN THE REGULATION OF THE BINDING  
PROPERTIES OF RAT HEART MUSCARINIC RECEPTORS  
AND THEIR INTERACTION WITH G-PROTEINS

YOAV I. HENIS, ETTY MOSCONA-AMIR and MORDECHAI SOKOLOVSKY  
Department of Biochemistry, The George S. Wise Faculty of  
Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.

In order to investigate the dependence of the properties of cardiac muscarinic receptors, and especially their interactions with G-proteins, on the membrane lipid composition, we employed primary myocyte cultures prepared from the hearts of newborn rats. The membrane lipid composition in these cells undergoes dramatic changes with the culture's age (number of days in culture), and it can also be manipulated by treatment with liposomes of specific compositions. The changes in the lipid composition resulted in significant alterations in the organisation of the plasma membrane lipids in lateral domains. Concomitant alterations were observed in several properties of the muscarinic receptors. Aging of the cells in culture resulted in reduced muscarinic binding capacity, and in changes in the proportion of high and low affinity states towards agonists. In parallel, major changes were observed in the coupling of the muscarinic receptors with G-proteins: while guanine nucleotides converted high affinity agonist binding sites to the low affinity form in homogenates of young cultures, a reverse effect (conversion from low to high affinity sites) was observed in aged cultures. These alterations in the properties of the muscarinic receptors appear to be intimately associated with the age-dependent alterations in cellular lipid composition and organisation, since manipulations of the lipid composition of aged cultures back to that of young cultures by treatments with phosphatidylcholine-containing liposomes returned all the muscarinic parameters measured back to those observed in young cultures.

NEUROTRANSMISSION AND SECOND MESSENGERS IN  
XENOPUS OOCYTES

Y. Lass, B. Gillo, R. Boton, E. Gershon and N. Dascal  
Department of Physiology and Pharmacology, Sackler  
School of Medicine, Tel Aviv University, Ramat Aviv,  
Israel

Xenopus oocytes present a convenient experimental system for the study of second messenger-mediated neurotransmitter responses. These cells display a muscarinic response, consisting of a two component Cl current, accompanied by Cl current fluctuations and a less prominent slow K current. The muscarinic response is most reliably observed in intact follicles (oocytes that still retain enveloping support tissues). The muscarinic Cl current response is mimicked by intracellular injection of Ca or IP<sub>3</sub>. It is blocked by intracellularly injected EGTA. Application of ACh results in increased polyphosphoinositide breakdown, enhanced <sup>45</sup>Ca efflux from preloaded cells, and inhibition of the response to adenosine, probably through the activation of protein Kinase C. Thus, the muscarinic membrane response (Cl current) in the oocyte is mediated through the phospholipase C - Ca mobilization pathway.

When Xenopus oocytes are injected with exogenous messenger RNA, they express membrane receptors and ion channels characteristic of the source tissue from which mRNA was extracted. This approach allows the study of ion channels and neurotransmitter responses in a standard membrane environment. In addition, since oocytes are large (> 1 mm in diameter) cells, one can employ techniques, such as double electrode voltage clamp and intracellular injections, that are impossible in the source tissues.

In Xenopus oocytes, elevation of internal Ca causes an increase in Cl conductance. We further characterized this conductance using the ionophore A23187. At 0.25-1 mM, Ca evoked an inward current that reached a plateau in about 10 s., and declined gradually within many minutes in the presence of Ca, but within seconds upon washout of Ca. At higher concentrations, Ca caused a two component Cl current response, with the appearance of a fast component. The fast component was more sensitive to 1-4 mM 9-antracene carboxylic acid (9 AC) blocker. Exposure of the cell to low (0.1-0.2 mM) Ca concentration for several minutes greatly diminished the amplitude of Cl current evoked by a subsequent application of a higher dose of Ca, suggesting that the inactivation of the Cl current was Ca-dependent.

Shallow, submembrane injections of IP3 in the animal hemisphere of the oocyte evoked a two-component response comprised of a rapid transient component followed by a slow sustained component. When the injection pipette was further inserted into the cell (to 300  $\mu\text{m}$  below the cell membrane), the fast component diminished and the slow component remained unchanged or even increased. Similar two-component response was obtained by the injection of a single large dose (20-50  $\mu\text{mol}$ ) of  $\text{CaCl}_2$ .

Cardiac voltage dependent Ca channels (VDCC) appeared in the oocyte following injection of mRNA obtained from the rat heart. Thus, the oocyte may serve as a useful model for the study of Ca channel formation and modulation.

STRUCTURAL STUDIES AIMED AT UNDERSTANDING THE FUNCTION OF  
THE ACETYLCHOLINE RECEPTOR

J.P. Earnest, M.J. Shuster, M.P. McCarthy and R.M. Stroud  
Dept. of Biochemistry, Univ. of San Francisco, San  
Francisco, CA 94143-0448

The three-dimensional structure of the acetylcholine receptor has been determined for the first time in the absence of attached cytoskeletal components. This permits a difference map which identifies loci of attachment of 43 kD cytoskeletal proteins. The distribution of molecular mass shows that there is little of the protein which is ordered on the cytoplasmic side of the plasma membrane.

The topology of chains within subunits has been mapped by antibody binding to native tissue. Antibody experiments on subcellular fractions which utilize detergent or small amphiphiles are prone to serious error since these treatments can undo regions of protein on one side of the membrane selectively and so may give incorrect assignments of location. Results of proteolytic cleavage lead to assignments of other regions as they emerge from the plasma membrane and thus define important aspects of the folding of this molecule.

The status of amphipathic helices and their contribution to channel formation is discussed alongside experiments with a bacterial channel-forming protein whose structure is being worked out by x-ray crystallography. The direct answer to structure of the ACh receptor will come from x-ray studies of three-dimensional crystals. Progress in understanding the x-ray diffraction from crystals grown in our laboratory is discussed. Effects of lipids, detergents, and their ratios upon crystallization seem critical for the subsequent crystallization of affinity-purified protein. Effects of cholesterol and local anaesthetics on receptor conformation and stability are discussed since they bear directly on issues concerned with functional reconstitution of ACh receptor.

The origin of gating in the ACh receptor is discussed in light of studies using terbium/calcium exchange. Evidence towards an electrostatic gate is presented.

## **Antibodies as Probes of the Structure and Function of the Nicotinic Acetylcholine Receptor**

**A. Maelicke, G. Fels, R. Plümer-Wilk and M. Schreiber**  
**Max-Planck-Institut für Ernährungsphysiologie, Rheinlanddamm 201, D-4600 Dortmund,**  
**FRG**

1. Antibodies were raised against eight synthetic peptides matching in sequence preselected stretches of the aminoacid sequence of the nicotinic acetylcholine receptor (nAChR) from *Torpedo marmorata*. To avoid ambiguity as to the exact sequence location of the antibody epitopes, synthetic peptides of only 5-7 aminoacids in length were employed. The results of epitope mapping support a model with three transmembrane domains, one membrane associated  $\alpha$ -helical domain and extensive  $\beta$ -structure at the extracellular and cytoplasmatic surfaces of the receptor molecule.

2. Monoclonal antibodies raised against the native receptor protein were employed to study the functional organization of *Torpedo* nAChR. We report on antibodies (i) competing with selected groups of cholinergic ligands for binding to the nAChR, (ii) acting as allosteric ligands, (iii) blocking the agonist-induced cation flux into *Torpedo* membrane vesicles, (iv) blocking agonist-induced single channel activity in embryonic muscle cells, and (v) interfering with desensitization of the nAChR-integral ion channel.

THE HELIX-II MODEL OF THE ION CHANNEL OF THE NICOTINIC  
ACETYLCHOLINE RECEPTOR

Ferdinand Hucho

Fachbereich Chemie, Institut für Biochemie, Freie Universität Berlin

A model of the ion channel of the nicotinic acetylcholine receptor is proposed, picturing the channel as being formed by the transmembrane Helix M2. The following features of the channel will be discussed: Channel entrance (extracellular) 30 Angstrom diameter; constant diameter down to level of lipid membrane; funnel-shaped transmembrane portion lined by Helix M2; binding site of channel blockers (ser 262 in delta chain) close to intracellular exit of channel. There too the narrowest part and the selectivity filter having a diameter of 6.4 Angstrom. Upper part of channel hydrophobic, selectivity filter polar. Channel filled with water. Experimental support for this model from this and other laboratories will be discussed.

## CORRELATING STRUCTURE WITH FUNCTION OF THE CHOLINERGIC BINDING SITE

Jonathan M. Gershoni, Ami Aronheim, Yoav Eshel, Yoav Evron,  
Rachel Moskovitz and Bella Ohana

Department of Biophysics, Weizmann Institute of Science  
Rehovot, Israel

The nicotinic acetylcholine receptor (AChR) has been subjected to extensive experimental scrutiny and indeed much has been learned about this multimeric protein complex. However, in spite of the impressive amount of data that has accumulated we still can not explain the mechanisms responsible for its action. One approach which has been adopted in our laboratory has been to focus on a single, well defined functional domain of the receptor and systematically analyse it with the intent to correlate its structure with its function. Thus, over the past few years, we have been studying the cholinergic binding site.

Karlin and his co-workers demonstrated that the ligand binding-site is situated 1nm away from a sensitive disulfide. As a result and with the appearance of the complete amino acid sequence of the  $\alpha$ -subunit, models quickly appeared placing the binding-site in the vicinity of cysteine residues postulated to be extracellular. Biochemical analyses have allowed the mapping of the binding-site to the area of cys-192/cys-193. This has been accomplished by the protein blot analysis of proteolysed  $\alpha$ -subunits probed with sequence specific antibodies. Furthermore, cys-192 was found by Karlin to be that which is affinity alkylated and is apparently disulfide linked to cys-193.

As much attention has been placed on the cysteine residues related to ligand binding, it was of interest to establish the disulfide arrangement of the  $\alpha$ -subunit. For this native receptors have been selectively alkylated with 3-(N-maleimido-propionyl)biocytin (MPB). The  $\alpha$ -subunits of the various biontinylated receptors were isolated, digested with V8-protease and blotted. The blots were probed with  $^{125}\text{I}$ -labeled-avidin revealing those fragments which contain modified cysteines. It was found that three disulfides exist: cys-128 to cys-142; cys-192 to cys-193; cys-412 to cys-418, and that cys-222 is unpaired.



In order to investigate the specific contributions of the various residues which lie in the region of the binding-site, genetically engineered binding-sites have been produced that continue to bind cholinergic ligands. Synthetic oligonucleotides corresponding to the amino acid sequence  $\alpha$ -184-200 of *T. californica* AChR have been cloned using the bacterial expression vector pATH2. Such transformed cells can be induced for the selective expression of the *trpE* fusion-protein which contains the AChR sequence at its COOH-terminus. These fusion-proteins can be highly enriched and have been analysed for their capacity to bind cholinergic ligands. Thus  $\alpha$ -184-200 binds  $\alpha$ -bungarotoxin with an affinity of  $10^{-7}$  M. Tubocurarine competes this binding with an  $IC_{50}$  of  $10^{-4}$  M and carbamylcholine competes with an  $IC_{50}$  of  $10^{-2}$  M. The bacterially expressed binding sites are being subjected to mutagenesis so to evaluate the involvement of individual residues in the binding process.

In addition, we have engaged in a survey of naturally occurring variants of the ligand binding-site. Two biological systems are being analysed. Genomic libraries have been prepared for the snake, cobra and the moth *Spodoptera littoralis* and are currently being screened for  $\alpha$ -subunit homologues.

# STUDIES OF THE BINDING OF AGONISTS TO THE ACETYLCHOLINE RECEPTOR

G. Navon<sup>1</sup>, T. Yamane<sup>2</sup> and L.W. Jelinski<sup>2</sup>

<sup>1</sup>School of Chemistry, Tel-Aviv University, 69 978 Tel-Aviv, Israel

<sup>2</sup>AT & T Bell Laboratories, Murray Hill, N.J. 07974, USA.

The nicotinic acetylcholine receptor (AChR) is a membrane protein that changes the permeability of the postsynaptic membrane to sodium ions, following binding of the neurotransmitter acetylcholine. Direct NMR study of the AChR is made difficult by its high molecular weight and the requirement of detergents for its solubilization. We have shown that the binding of agonists to the AChR may be studied by two-dimensional nuclear Overhauser effect (2-D NOE) and measurement of selective  $T_1$  ( $T_1^{sel}$ ) of the agonist protons.

It was pointed out a few years ago that  $T_1^{sel}$  is very sensitive to the binding of ligands to large macromolecules<sup>(1)</sup>. Indeed, significant shortening of the  $T_1^{sel}$  of acetylcholine, carbamylcholine and nicotine was found in the presence of solubilized AChR from the Torpedo California electric tissue. The effect was abolished by the addition of  $\alpha$ -bungarotoxin which binds very tightly to the receptor.  $T_1^{sel}$  can also be used for the determination of binding constants of ligands<sup>(2)</sup>. Since binding constants of agonists to the AChR are very large, only relative binding constants could be obtained, by competition experiments. Thus, by following  $T_1^{sel}$  of the nicotine aromatic protons as a function of the concentrations of other agonists, relative binding constants of 1 : 7 : 0.2 : 0.04 were found for nicotine, acetylcholine, carbamylcholine and muscarine, respectively.

2-D NOE experiments on nicotine in the presence of AChR yielded

negative cross-peaks corresponding to NOE's between the various protons of the bound agonist as well as NOE's due to transfer of magnetization from the receptor to the agonist. A combination of the NOE and  $T_1^{\text{rel}}$  data allows us to calculate the distances<sup>(3)</sup> between the protons of the agonist in the bound state, from which the conformation of the bound agonist may be derived. Those groups on the AChR which are in close contact with the agonist are being identified on the basis of transferred NOE from the AChR to the agonist protons.

- (1) G. Valensin, T. Kushnir and G. Navon, J.Mag.Reson. 46, 23 (1982).
- (2) T. Kushnir and G. Navon, Bull.Magn.Reson. 6, 60 (1984).
- (3) D. Kaplan and G. Navon, J.Chem.Soc. Perkin Trans.II 10, 1374 (1981).

# EXPRESSION OF FUNCTIONAL NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS FROM CLONED cDNA SEQUENCES

Jim Patrick, Jim Boulter, Evan Denaris, John Connolly,  
Keiji Wada, Dan Goldman, and Steve Heinemann

Salk Institute  
San Diego, California

A family of genes coding for proteins homologous to the muscle nicotinic acetylcholine receptor  $\alpha$ -subunit has been identified in the rat genome. Three members of this family,  $\alpha$ 2,  $\alpha$ 3, and  $\alpha$ 4 genes are transcribed in the central and peripheral nervous systems in areas known to contain functional nicotinic receptors. We have identified an additional gene,  $\beta$ 2, which encodes a protein homologous to the  $\alpha$ -subunits but which lacks the cysteine residues thought to be close to the ligand binding site. The  $\beta$ 2 gene encodes a protein which, in combination with either the  $\alpha$ 2,  $\alpha$ 3, or  $\alpha$ 4 proteins will form functional nicotinic acetylcholine receptors in *Xenopus* oocytes. Oocytes expressing either  $\alpha$ 2,  $\alpha$ 3, or  $\alpha$ 4 protein in combination with the  $\beta$ 2 protein produced a strong response to acetylcholine. Oocytes expressing only the  $\alpha$ 4 protein gave a weak response to acetylcholine. These receptors are activated by both acetylcholine and nicotine. They are not blocked by  $\alpha$ -bungarotoxin, which blocks the muscle nicotinic acetylcholine receptor. Thus, the receptors formed by the  $\alpha$ 2,  $\alpha$ 3,  $\alpha$ 4, and  $\beta$ 2 subunits are pharmacologically similar to the ganglionic type neuronal nicotinic acetylcholine receptor. These results demonstrate that the  $\alpha$ 2,  $\alpha$ 3,  $\alpha$ 4 and  $\beta$ 2 genes code for functional nicotinic acetylcholine receptor subunits which are expressed in the brain and peripheral nervous systems.

SINGLE-CHANNEL AND LIGHT-FLASH MEASUREMENTS ON MOUSE-TORPEDO  
ACETYLCHOLINE RECEPTOR HYBRIDS EXPRESSED IN *XENOPUS* OOCYTES.  
Lei Yu, Reid J. Leonard, Cesar Labarca, Henry A. Lester.  
Division of Biology, Caltech, Pasadena CA 91125, USA

This work extends previous studies on equilibrium properties of receptors expressed in oocytes by injection of SP6 RNA. We have examined voltage sensitivity at the level of single-channel recording with several hybrid receptors:  $\alpha_M\beta_M\gamma_M\delta_M$ ,  $\alpha_M\beta_M\gamma_M\delta_T$ ,  $\alpha_M\beta_M\gamma_T\delta_M$ ,  $\alpha_M\beta_T\gamma_T\delta_T$ ,  $\alpha_T\beta_T\gamma_T\delta_M$ , and  $\alpha_T\beta_T\gamma_T\delta_T$ . In outside-out patches, all combinations showed a linear single-channel current-voltage relationship; but open duration depended on voltage. Average channel duration,  $\tau$ , was measured at -60 mV and +60 mV. The extent of the voltage dependence of each combination was estimated by the ratio of  $\tau_{-60mV}/\tau_{+60mV}$ , and the results were in agreement with our previous conclusions from the macroscopic measurements. Closed times had less than 1/5 the voltage sensitivity of the open times. Thus, of the three possible parameters underlying voltage sensitivity (channel conductance, opening rate, and closing rate), the latter makes the major contribution to the voltage sensitivity of the macroscopic ACh-induced conductance.

In an attempt to identify portions of the subunits' structure that may be involved in formation of the ion channel of the AChR, we are also comparing the effects of local anesthetics on the response of hybrid AChRs. The data show that some hybrids differing in mean open time in the absence of local anesthetic exhibit very similar open times in the presence of the blocker QX-222, thus indicating that the forward blocking rate is only weakly influenced by subunit composition. The flash-activated channel blocker, EW-1, is also being used with macroscopic agonist-induced currents to provide efficient screening of the blocking/unblocking kinetics. Results show that the  $\beta$  subunit strongly influences the pharmacological properties of the *cis* and *trans* isomers. The *cis* isomer is a potent channel blocker in all-mouse receptors and in several other hybrids; for these receptors, effects of EW-1 resemble those previously reported for *Electrophorus* electroplaques. However, the *trans* isomer is also a potent blocker in those hybrids containing the *Torpedo*  $\beta$  subunit. Sponsored by NS-11756 and MDA (fellowship to R.J.L. and grant).

# ION CONDUCTANCE OF GENETICALLY MODIFIED ACETYLCHOLINE RECEPTOR CHANNELS

U. Methfessel\*, Max Planck Institut für Biophysikalische Chemie, Göttingen

Functional nicotinic Acetylcholine Receptor (AChR) channels are synthesized and inserted into the plasma membrane of *Xenopus* oocytes following the microinjection of mRNA extracted from tissues that express the AChR protein. Injection of specific mRNAs, obtained by in vitro transcription from cloned cDNAs that encode the AChR subunits, leads to a high channel density in the oocyte membrane so that single AChR channels can easily be investigated with the patch clamp technique. Their conductance and gating behavior closely agree with those of native AChR channels studied in the neuromuscular endplate or in cultured muscle cells.

The AChR proteins are oligomers composed of four different peptide subunits. Therefore, the four corresponding mRNAs must be injected simultaneously into oocytes to obtain proper AChR channels. However, by deleting subunits or by exchanging subunits from the AChRs of different species, modified AChR channels may be synthesized whose properties illuminate the role played by different subunits in receptor and channel function.

With modern methods of genetic technology, the cDNA coding for an AChR subunit can be modified directly and specifically, and then transcribed in vitro to obtain mRNA encoding a mutated AChR subunit. This, when injected into *Xenopus* oocytes together with the other required subunits, can direct the synthesis of novel mutant AChR channels with known primary structure, whose function can then be studied in detail with patch recording. For example, the delta subunits of bovine and Torpedo AChR differ in their primary sequence and in several of the properties that they confer to the complete receptor channel complex. By producing chimaeric delta subunits and incorporating them into AChR channels in oocytes, some of the functional differences between the two parental subunits could be assigned to specific locations on the primary sequence. Thus, the M2 segment of the channel has been associated with the control of ion permeation. Similarly, the effect on channel function of a single specific point mutation at practically any desired position along the primary sequence can be studied.

The permeation of ions through the open AChR channel has been studied for a number of native, chimaeric and modified AChR types. The conductance, the *i*-*V* relationship and the effects of divalent ions are affected by some of the differences in primary structure between the various kinds of AChR. Therefore, such experiments can illuminate the relation between channel structure and function.

However, since there is no definitive three-dimensional structure available for the AChR as yet, it is necessary to devise models of ion permeation that can assist in the interpretation of these results. Numerous such models of various complexity can be found in the literature.

\* present address: Bayer AG, ZF-IPE4, D-5090 Leverkusen, FRG

It was found that a quite simple model, consisting of a two-barrier single-well Eyring rate-limited pore together with the Grahame-McLaughlin description of the effects of surface charge, is quite satisfactory to represent the permeation of ions through AChR channels. An important feature of the model is that the central energy well within the channel is not necessarily a binding site. Instead, the saturation of channel conductance arises from the accumulation of permeant ions by surface charges near the channel pore. The shielding of surface charges also predicts the observed effects of divalent ions on channel conductance. The numbers of charged amino acid residues near the M2 segments of various AChR subunits are found to correlate with the observed conductance behavior as suggested by the model.

## RECEPTORS FOR ACETYLCHOLINE IN THE NERVOUS SYSTEM OF INSECTS

H. Breer and W. Hanke

Fachbereich Biologie/Chemie, Universität Osnabrück  
Federal Republic of Germany

The central nervous system of arthropods is highly cholinergic innervated; thus insect ganglia appear most appropriate for studying neuronal acetylcholine receptors (AChR). Using specific ligands, high concentrations of cholinergic binding sites have been detected; in contrast to the vertebrate brain, the nicotinic receptor type predominates in insects, whereas only a small portion displayed muscarinic properties. Subtypes of muscarinic receptors could be distinguished; the  $M_2$  type appears to be located at nerve terminals and to be involved in the feedback regulation of acetylcholine release.

Attempts were made to identify the nicotinic acetylcholine receptor from locust nervous tissue. A large complex receptor protein has been purified which appeared to be composed of 4-5 identical or very similar polypeptides. When reconstituted in planar lipid bilayers, the native protein gave a functional ion translocating system. Agonists such as acetylcholine, carbamylcholine and suberyldicholine induced fluctuations of single channels which were blocked by d-tubocurarine, suggesting that the protein represents a functional cholinergic receptor channel. The channel was selectively permeable for monovalent cations but was impermeable for anions. The conductance of the channel (75 pS in 100 mM NaCl) was independent from the type of agonist used. Kinetic analysis of the channel gating revealed that at high agonist concentration multiple gating events and bursting appeared. Approaches to determine the cooperativity of channel activation showed that the nicotinic acetylcholine receptor from nerve cells of insects is apparently activated by only one agonist molecule. Immunological approaches revealed that the receptors are localized in the neuropile and that there are obviously significant molecular similarities between the constituents of the neuronal insect receptor and the peripheral heterooligomeric vertebrate receptor. This was confirmed when the N-terminal amino acid sequence of an insect receptor polypeptide fragment was determined. As a first step towards an application of recombinant DNA techniques, RNA preparations from locust nervous tissue were probed for receptor specific mRNA using reticulocytes and *Xenopus* oocytes as expression systems. Oocytes microinjected with insect polyA<sup>+</sup>-RNA produced neuronal AChR polypeptides, which were inserted into the oocyte surface membrane and displayed specific binding of  $\alpha$ -toxins. Ion flux studies have provided evidences that the binding sites represent indeed ACh-gated ion channels, functional AChRs.



The membrane environment of the nicotinic acetylcholine receptor  
F. J. Barrantes. Instituto de Bioquímica, Univ. Nac. Sud/CONICET,  
8000 Bahía Blanca, Argentina.

Detailed knowledge of the membrane framework surrounding the nicotinic acetylcholine receptor (AChR) is key to understanding its structure, dynamics and function. Theoretical models based on the application of thermodynamic criteria to the known primary sequence of the AChR polypeptide chains assign portions of these to the bilayer region. The nature of the protein-lipid interactions occurring in the bilayer is not known, nor is the structural relationship between the two moieties.

The composition of the lipids in which the transmembrane AChR chains are inserted has been characterized in three *Torpedinidae* species. The marked unsaturation of the major phospholipids found may explain some of the physical properties of the bulk lipid in AChR-rich membranes; more than 50% of the fatty acids are long chain polyunsaturates. Docosahexanoate makes up more than 70% of the latter in *T. marmorata*. Phospholipid classes and fatty acyl chains bear considerable resemblance among species, perhaps providing this evolutionarily conserved protein with a similarly constant milieu for its optimal functioning.

Changes in physical properties of the AChR membrane are known to follow on from extraction of non-receptor, peripheral proteins. These changes may bear relationship to the recently found selective depletion of certain phospholipid classes which accompanies peripheral protein extraction.

Metabolic studies conducted both *in vivo* and *in vitro* using radiolabelled precursors indicate the presence of active pools among membrane phospholipids, particularly in the minority polyphosphoinositides.

Studies aimed at defining the topography of lipids in the membrane show the asymmetrical distribution of phospholipid classes between the two half-layers. Although we still ignore which lipids are in the immediate microenvironment of the AChR, ESR studies reveal the presence of an annulus of relatively immobilized lipid, consisting of about 40 phospholipid molecules per AChR monomer, in active exchange with the bulk bilayer lipid. Lateral diffusion of lipid in the plane of the membrane appears to be a free process as measured by fluorescence anisotropy decay.

BIOPHYSICAL STUDIES OF ACETYLCHOLINE RECEPTOR IN RECONSTITUTED  
MEMBRANES: ROLE OF LIPIDS IN REGULATING FUNCTION

Mark G. McNamee, Department of Biochemistry and Biophysics,  
University of California, Davis, CA 95616.

Nicotinic acetylcholine receptor (AChR) from the electric tissue of the electric ray Torpedo californica has been purified by affinity chromatography in cholate solution and reincorporated into membranes of defined lipid composition by dialysis. The interactions of the AChR with lipids have been examined by several different biophysical techniques including fluorescence quenching, EPR-spin labelling, and FTIR spectroscopy. Important lipid-protein interactions detected by the biophysical studies have been correlated with the functional effects of the lipids on both the ligand binding and ion permeability control properties of the AChR.

Using a variety of different lipid mixtures, it was determined that the low-to-high binding affinity transition for activating ligands requires an optimal membrane fluidity, as measured by the order parameter of a fatty acid spin label incorporated into reconstituted membranes. Membranes that had either too high or too low a value for the order parameter were unable to undergo the transitions induced by carbamylcholine even though they could bind alpha-bungarotoxin. The effects were reversible as judged by temperature dependence and re-reconstitution into the proper lipid environment. Receptor-mediated ion permeability also required an optimal fluidity since the affinity transition appears to be a necessary, but not sufficient, condition for functional receptors. However, the ion permeability properties also showed a requirement for specific lipids under the reconstitution conditions used. Only those lipid mixtures containing cholesterol and negatively-charged lipids were active in ion flux assays.

In parallel studies, the effects of different lipid mixtures on the overall conformation of the AChR were analyzed by FTIR spectroscopy. Cholesterol appeared to increase the average alpha helix content of the AChR as monitored by an increased intensity at 931 cm<sup>-1</sup> and negatively charged lipids appeared to increase the beta sheet content as monitored by increased spectral intensity at 988 cm<sup>-1</sup>. The combined increases in both parameters correlate

well with the lipid requirements for functional ion channels. The results suggest that cholesterol, or related analogs, may stabilize alpha helical structures associated with the ion channel.

A special role for cholesterol in AChR structure and function has also been revealed by fluorescence quenching studies using brominated analogs of phosphatidylcholine and cholesterol. The brominated analogs partially quench the intrinsic fluorescence of the AChR by a static mechanism. Competition between brominated and non-brominated lipids provides quantitative data that can be used to calculate relative binding constants for different lipids to the membrane-surface areas of the receptor. In the case of cholesterol, additional binding sites on the protein that cannot be displaced by phospholipids are detected. These sites may represent regions of the protein that have a relatively high affinity for cholesterol. Experiments are in progress to determine if the extra cholesterol binding sites are related to the role of cholesterol in stabilizing alpha helical structures and in providing an appropriate lipid environment for ion channel activity in reconstituted membranes.

# NEW APPROACHES TO STUDIES OF NEURONAL RECEPTORS

George P. Hess  
270 Clark Hall  
Cornell University  
Ithaca, NY 14853  
U.S.A.

During the past years, 40 chemical signals (neurotransmitters) and a variety of different receptor proteins responsible for the transmission of signals between nerve cells and between nerve and muscle cells have been identified in electrophysiological experiments. Investigations of the relationship between the signal transmission process and the function and structure of the receptors have been hampered by the time resolution of the available chemical kinetic techniques, and by the availability of receptor proteins in sufficient quantities for the structure to be determined. Three different approaches adopted in this laboratory to overcome the problem will be discussed.

(a) Two kinetic techniques have been developed that allow one to measure the ligand-binding steps, channel-opening steps, and receptor desensitization (inactivation) over a wide concentration range of neurotransmitter and inhibitors, directly on a cell surface: (i) a cell flow method with a 5 ms time resolution, and (ii) synthesis of inactive neurotransmitter precursors, which can be equilibrated with receptors on cell surfaces and then photolyzed to the active neurotransmitter with  $t_1/2$  of 50  $\mu$ s.

(b) Yeast can be grown in large quantities. We have shown that it is capable of synthesizing the acetylcholine receptor subunits and inserting them into its plasma membrane, and we are studying the structural and functional properties of the polypeptide chains. The expectations are that large enough quantities of a variety of receptor proteins can be produced and assembled by yeast for their structure and function to be studied.

(This work was supported by grants from the National Institutes of Health, the National Science Foundation, and the Cornell Biotechnology Program, which is supported by the New York State Science and Technology Foundation and a consortium of industries.)

THE BINDING SITE AND PHOSPHORYLATION SITES OF THE NICOTINIC ACETYLCHOLINE  
RECEPTOR

Sara Fuchs, Drorit Neumann and Anat Safran

Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel.

The nicotinic acetylcholine receptor (AChR) is a neurotransmitter-regulated ion channel which mediates synaptic transmission at the post-synaptic membrane of the neuromuscular junction. The purified AChR is a 250 kDa transmembrane glycoprotein and consists of four subunits with a stoichiometry of  $\alpha_2\beta\delta$ . Synthetic peptides corresponding to sequences from the AChR and their respective antibodies, are being employed for mapping and analysing the cholinergic binding site and phosphorylation sites of the receptor. We have previously shown that a synthetic dodecapeptide corresponding to residues 185-196 of Torpedo AChR  $\alpha$ -subunit, contains the essential elements for  $\alpha$ -bungarotoxin ( $\alpha$ -BTX) binding. By quantitative analysis of the cholinergic binding properties of this peptide we have demonstrated that this dodecapeptide also includes the neurotransmitter binding site. Synthetic peptides corresponding to residues 185-196 of human and mouse AChR  $\alpha$ -subunits are also being analysed. These studies along with specific chemical modifications point at the importance of the cysteine and tryptophan residues for the binding. We are now attempting to elucidate the structure of the snake AChR binding site, which unlike other muscle AChRs, does not bind  $\alpha$ -BTX but does respond to cholinergic ligands. Phosphorylation of AChR, and in particular of its  $\delta$ -subunit by cAMP dependent protein kinase (PKA), calcium/phospholipid dependent protein kinase (PKC) and tyrosine-specific protein kinase has been studied. We have mapped the PKA and PKC phosphorylation sites in the  $\delta$ -subunit and demonstrated that the phosphorylation sites for both enzymes reside in very close proximity, within three consecutive serine residues at positions 360, 361 and 362.

REGULATION OF THE NICOTINIC ACETYLCHOLINE RECEPTOR BY PROTEIN PHOSPHORYLATION, Richard L. Huganir, The Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University New York, New York 10021

The nicotinic acetylcholine receptor is a neurotransmitter-dependent ion channel that mediates the depolarization of the postsynaptic membrane in response to acetylcholine at nicotinic cholinergic synapses. The nicotinic receptor is a  $M_r$ -255,000 pentameric complex which consists of four types of subunits  $\alpha$  ( $M_r$  40,000),  $\beta$  ( $M_r$  50,000),  $\gamma$  ( $M_r$  60,000) and  $\delta$  ( $M_r$  65,000) in the stoichiometry of  $\alpha_2\beta\gamma\delta$ . We have demonstrated that isolated postsynaptic membranes enriched in the nicotinic receptor contain at least four different protein kinases, cAMP-dependent protein kinase, calcium/calmodulin-dependent protein kinase, protein kinase C and a tyrosine-specific protein kinase. Three of these endogenous protein kinases phosphorylate the nicotinic acetylcholine in the isolated postsynaptic membranes. cAMP-dependent protein kinase rapidly and stoichiometrically phosphorylates serine residues on the  $\gamma$  and  $\delta$  subunits of the receptor. Protein kinase C rapidly and stoichiometrically phosphorylates serine residues on the  $\delta$  subunit and also causes a slower but significant phosphorylation on serine residues on the  $\alpha$  subunit. The endogenous tyrosine kinases which are immunologically related to pp60<sup>csrc</sup> rapidly and stoichiometrically phosphorylate the  $\beta$ ,  $\gamma$  and  $\delta$  subunits. All of the phosphorylation sites are unique and thus three different protein kinases phosphorylate the acetylcholine receptor on seven different sites.

The phosphorylation sites on the  $\gamma$  and  $\delta$  subunits for cAMP-dependent protein kinase have recently been identified by protein sequencing techniques. The cAMP-dependent protein kinase phosphorylates serine 353 on the  $\gamma$  subunit and serine 361 on the  $\delta$  subunit. The locations of the other phosphorylation sites have been proposed to be adjacent to the cAMP-dependent phosphorylation sites and are located on a common region of each of the subunits with the three phosphorylation sites on the  $\delta$  subunit being within 20 amino acids of each other. This suggests that phosphorylation of the receptor by all three kinases regulates a common property of the receptor. The phosphorylation sites are located on the major intracellular loop in theoretical models of receptor structure.

Recently we have directly examined the functional effects of phosphorylation of the nicotinic acetylcholine. The ion transport properties of the purified and reconstituted acetylcholine receptor were investigated before and after phosphorylation by cAMP-dependent protein kinase. It was found that phosphorylation of the nicotinic acetylcholine receptor on the  $\gamma$  and  $\delta$  subunits by cAMP-dependent protein kinase dramatically increased the rate of the rapid desensitization of the receptor, the process by which the receptor is inactivated in the presence of acetylcholine.

Moreover, recent studies have shown that the nicotinic acetylcholine receptor is phosphorylated in intact muscle cells by cAMP-dependent protein kinase and that this phosphorylation regulates the rate of desensitization of the muscle receptor. Primary muscle cells were prelabelled with radioactive inorganic phosphate and then the cells were stimulated with various agents that regulate the intracellular levels of cAMP. Under basal conditions, the receptor was phosphorylated on the  $\beta$  and  $\delta$  subunits. Addition of forskolin, a potent activator of adenylate cyclase, or cAMP analogues dramatically stimulated the phosphorylation of the  $\delta$  subunit of the receptor. Exposure of rat primary muscle cells to forskolin and cAMP analogues under identical conditions increases the rate of desensitization of the receptor. The increase in the rate of desensitization after forskolin treatment shows a very similar dose response curve and time course as the increase in the phosphorylation of the  $\delta$  subunit of the receptor.

These *in vivo* results together with the *in vitro* results provide strong evidence that phosphorylation of the nicotinic receptor by cAMP-dependent kinase regulates its rate of desensitization. In contrast, the role of phosphorylation of the receptor by protein kinase C and the tyrosine specific protein kinase is not clear. It has recently been reported that activators of protein kinase C (i.e. phorbol esters) increase the rate of desensitization of the nicotinic acetylcholine receptor in cultured myotubes. This suggests that protein kinase C phosphorylation of the receptor also regulates the desensitization of the receptor. This is not surprising in light of the proposal that the phosphorylation sites on the  $\delta$  subunit for cAMP-dependent protein kinase and protein kinase C are located within twenty amino acids of each other. Moreover, since tyrosine phosphorylation occurs directly in between these sites on the  $\delta$  subunit it is likely that desensitization of the receptor is also regulated by tyrosine phosphorylation.

The neurotransmitters or hormones that regulate the activity of these protein kinases and the phosphorylation of the nicotinic acetylcholine receptor have not been identified. However, recent evidence has shown that the neuropeptide calcitonin gene-related peptide (CGRP) is present in the presynaptic terminals at the neuromuscular junction and increases intracellular levels of cAMP in chick myotubes. In addition, CGRP increases the phosphorylation of the nicotinic acetylcholine in primary rat myotubes. CGRP is therefore a likely candidate for a physiological regulator of nicotinic receptor phosphorylation and desensitization.

In conclusion, the nicotinic acetylcholine receptor has provided an excellent model system to study receptor-receptor interactions. It is likely that there are three neurotransmitters or hormones which act on three receptors to regulate the sensitivity of a fourth receptor, namely the nicotinic receptor, through three distinct protein kinase systems.

A STRUCTURAL AND DYNAMIC MODEL FOR THE NICOTINIC  
ACETYLCHOLINE RECEPTOR

Edward M. Kosower

Biophysical Organic Chemistry Unit,  
School of Chemistry, Sackler Faculty of Exact Sciences,  
Tel-Aviv University, Ramat-Aviv, Tel-Aviv 69978 ISRAEL  
and Department of Chemistry, State University of New York,  
Stony Brook, New York 11794-3400 USA

Folding of the five polypeptide subunits ( $\alpha_2\beta\gamma\delta$ ) of the nicotinic acetylcholine receptor (nAChR) into a functional structural model is described. The principles used to arrange the sequences into a structure include: (1) Hydrophobicity  $\rightarrow$  membrane crossing segments (2) amphipathic character  $\rightarrow$  ion-carrying segments (ion channel with single group rotations) (3) molecular shape (elongated, pentagonal cylinder)  $\rightarrow$  folding dimensions of exobilayer portion (4) choice of acetylcholine binding sites  $\rightarrow$  specific folding of exobilayer segments (5) location of reducible disulfides (near agonist binding site)  $\rightarrow$  additional specification of exobilayer arrangement (6) genetic homology  $\rightarrow$  consistency of functional group choices (7) noncompetitive antagonist labeling  $\rightarrow$  arrangement of bilayer helices. The AChR model is divided into 3 parts (a) exobilayer: 11 antiparallel  $\beta$ -strands from each subunit (b) bilayer: 4 hydrophobic and 1 amphiphilic  $\alpha$ -helices from each subunit and (c) cytoplasmic: one (folded) loop from each subunit.

The exobilayer strands can form a closed "flower" (the "resting state") which is opened ("activated") by agonists bound perpendicular to the strands. Rearrangement of the agonists to a strand-parallel position and partial closing of the "flower" leads to a desensitized receptor. The actions of acetylcholine and succinyl and suberoyl bis-cholines are clarified by the model. The opening and closing of the exobilayer "flower" controls access to the ion channel which is composed of the 5 amphiphilic bilayer helices. A molecular mechanism for ion flow in the channel is given. Openings interrupted by short duration closings (50  $\mu$ sec) depend upon channel group motions. The unusual photolabeling of intrabilayer serines in  $\alpha$ ,  $\beta$  and  $\delta$ , but not in  $\gamma$ -subunits near the binding site for non-competitive antagonists (NCAs) is explained along with a mechanism for the action of NCAs such as phencyclidine. The unusual  $\alpha$  192cys-193cys disulfide may have a special peptide arrangement, such as a cis-peptide bond to a following proline. (G.A. Petsko and E.M. Kosower, unpublished results) The position of phosphorylatable sites and proline-rich segments are noted for the cytoplasmic loops.

The dynamic behavior of the AChR channel and many different experimental results can be interpreted in terms of the model. An example is the lowering of ionic conductivity on substitution of bovine for Torpedo  $\delta$  M2 segment. The model represents a useful construct for the design of experiments on AChR.



TRANSITIONS IN MOLECULAR FORMS OF ACETYLCHOLINESTERASE  
DURING THE DEVELOPMENT OF DROSOPHILA

M Arpagaus (1), D Fournier (2), JP Toutant (3)

(1)Phytopharmacie INRA, 78000 Versailles

(2)Centre de Recherche INRA, 06606 Antibes Cédex

(3)Physiologie Animale INRA, 34060 Montpellier Cédex

The major molecular form of native acetylcholinesterase (AChE, EC 3.1.1.7) present in the heads of adult *Drosophila* is an amphiphilic dimer (G2) associated to the membrane through a glycolipid anchor (references a,b,c). We have investigated the AChE molecular forms present in late embryos (E), larval stages L1, L2 and L3, and pupae (P). Entire animals were homogenized in a low salt buffer containing 1% Triton X100 and a cocktail of anti proteolytic agents. These extracts were analyzed by ultracentrifugation in sucrose gradients in the presence of Triton X100, Brij 96 or in the absence of detergent and by non denaturing electrophoresis.

The AChE activity expressed as nmoles AcSCh hydrolyzed/min/g of wet weight showed a transient peak at the L1 stage, reincreased in pupae and was maximal in the adult.

Figure 1 shows that four molecular forms (at most) were present at every developmental stage (bands 1, 1', 2 and 3). By extensive correlation between AChE peaks in sucrose gradients with these bands on non denaturing electrophoresis and by analogy with the adult enzyme, we demonstrated that the four electromorphs corresponded to an amphiphilic dimer (1), an amphiphilic monomer (1') and hydrophilic dimer (2) and monomer (3).

Since endogenous proteolytic activity during metamorphosis of *Drosophila* is high (see ref. d), we checked that the molecular forms observed in this study did not result from the breakdown of the major G2 form




Figure 1: Non denaturing electrophoresis of AChE present in crude extracts of late embryos (E), Larval (L), pupal (P) and adult (Ad) *Drosophila*. The gel (7.5% acrylamide) and the running buffer contained 0.5% Triton X100. Migration for 3 Hours at 10 V/cm.

during the homogenization step.

Our data support the hypothesis that a native amphiphilic G1 form of AChE occurs during the development of *Drosophila*. The existence of this native form at the L1 and pupal stages (when AChE is actively synthesized) further suggests that amphiphilic G1 form might represent the precursor of the amphiphilic G2 form which is the mature, membrane-bound form of the enzyme.

Developing *Drosophila* (particularly L1 and P stages) therefore constitutes a favourable system for the study of the biosynthesis of the glycolipid-anchored molecules of AChE. For example it should be possible to demonstrate, with this model, whether the amphiphilic monomer possesses a glycolipidic domain or a hydrophobic sequence which could be further exchanged (see ref. e).

References: a) JP Toutant, M Arpagaus, D Fournier. J Neurochem, in press. b) D Fournier, J Bergé, C Bordier. J Neurochem, in press. c) AL Gnagey, M Forte, TL Rosenberry (87) J Biol Chem, in press. d) SA Dewhurst, RE McCaman, WD Kaplan (70) Biochem Gen 4, 499-508. e) Cross GAM (87) Cell 48, 179-181.

POLYMORPHISM OF MYOSIN LIGHT CHAINS AND ACETYLCHOLINESTERASE  
DURING THE DEVELOPMENT OF NEW-BORN RABBIT FAST AND  
SLOW DENERVATED MUSCLES

F. BACOU, P. VIGNERON

Station de Physiologie animale, I.N.R.A.-E.N.S.A.M.  
34060 Montpellier Cedex, France

The rabbit Semimembranosus proprius (SMp) and Semimembranosus accessorius (SMa) muscles represent a good model for studying the transformations of muscle properties during the postnatal differentiation. In the adult, these muscles are respectively homogeneous in slow twitch (SMp) and fast twitch (SMa) fibers<sup>1</sup>. However, they are heterogeneous at birth, and express their adult characteristics from two months postnatal onwards. During this period, we have studied the influence of motor innervation on the development of their properties, particularly at the level of acetylcholinesterase (AChE) molecular forms and myosin slow (LCs) and fast (LCf) light chains.

The postnatal alteration of SMa and SMp muscles is characterized by the disappearance of the neonatal heterogeneity and the acquisition of the homogeneous fast or slow fiber type pattern. The fibers of these muscles denervated at birth are altered differently : dramatic atrophy of fast twitch fibers whatever muscles are studied, preservation of SMp slow twitch fibers characteristics and fatty degeneration of SMa.

At birth, both muscles present a similar pattern of myosin fast and slow LC. In control muscles, the alteration of fiber populations to homogeneous types lead to the disappearance of supernumerary chains from 15 days onwards. In the slow muscle, neonatal denervation prevents LCf disappearance. In the fast muscle, denervation influences essentially the installation of LCf which is delayed by 15 days.

At birth, the polymorphism of AChE is similar in SMp and SMa muscles. One month after denervation, the specific activity of AChE is twice that of control. Its polymorphism is not much perturbed, while in the adult denervation induces an important increase in AChE specific activity (x10) and particularly a great alteration in its polymorphism according to the fast or slow muscle fiber types<sup>2,3</sup>.

#### REFERENCES.

1. Appel H.J. and Hammersen F. 1979. Cell Tissue Res., 196, 531.
2. Bacou et al. 1982. Nature, 296, 661.
3. Lai et al. 1986. Nature, 321, 72.

ACETYLCHOLINE RELEASE FROM RAT BRAIN SYNAPTOSOMES AS MEASURED BY  
THE CHEMILUMINESCENCE METHOD

Bennett M.\*, Morot Gaudry-Talarmin Y., and Israel M.

Département de Neurochimie, Laboratoire de Neurobiologie  
Cellulaire et Moléculaire, C.N.R.S., Gif-sur-Yvette, France.

Rat brain synaptosomes (RBS) were prepared by density-gradient ultracentrifugation on an isotonic Ficoll density interface at pH 7.4 and 4° C. Release of acetylcholine (ACh) was measured by the choline oxidase-peroxidase-luminol method at pH 7.8-8.2. RBS were depolarized with KCl, gramicidin and the calcium ionophore A23187. The amount of ACh released was 1% of that released by Torpedo synaptosomes of the same protein content. Release induced by KCl is calcium dependent and follows an identical time course to the flunarizine-independent increase in intracellular free Ca which has been observed in fluorescence measurements with Indo-1. The prompt ACh release is accompanied by a slow (34 min t.c.) calcium-independent release of choline, as identified by measurements performed after 30-60 min of incubation with 10 micromolar phospholine. The synaptosomes release an interfering substance when lysed with detergent. Total ACh content was measured after trichloroacetic acid extraction and oxidation with sodium metaperiodate. Substantial amounts of choline are present in the initial preparation. After the synaptosomes have been stored for 32 hr, ACh release is still 30-50% of initial values.

Cetiedil blocks the release of ACh from RBS depolarized with KCl and gramicidin as it does in Torpedo synaptosomes. The apparent  $K_i$  for cetiedil is approximately 25 micromolar. There is no effect of cetiedil on choline release.

\* Permanent address: Department of Anesthesiology, Oregon Health Sciences University, Portland, Oregon.

NEGATIVELY CHARGED PHOSPHOLIPIDS, A POSSIBLE TARGET FOR THE PRESYNAPTIC  
PHOSPHOLIPASE NEUROTOXIN FROM SNAKE VENOMS

C. BON, F. RADVANYI, G. LAURE, B. SALIOU and M.P. LAMBEZAT

Unité des Venins - Unité associée PASTEUR/INSERM N° 285  
Institut Pasteur, 25 rue du Dr. Roux - 75015 Paris - FRANCE.

Crotoxin, the major toxic component of the South American Rattlesnake, *Crotalus durissus terrificus*, is a potent neurotoxin which possesses a phospholipase A<sub>2</sub> activity and blocks neuromuscular transmission primarily at the presynaptic level, although at higher doses it also reduces the postsynaptic response to acetylcholine by stabilizing the cholinergic receptor in an inactive conformational state.

Crotoxin, which is in fact a mixture of very similar isoforms, consists of two non identical subunits. The basic component-B carries the phospholipase A<sub>2</sub> activity of the toxin and possesses a low toxicity and the acidic component-A has no enzymatic activity although it resembles a phospholipase A<sub>2</sub> in its primary structure. Component-A, is not toxic by itself but considerably enhances the lethal potency of the phospholipase component-B. Upon interaction with biological or artificial membranes, the two subunits dissociate: component-A is released free in solution and component-B is bound. The isolated phospholipase component-B binds in a non saturable manner to either erythrocyte or postsynaptic membranes. Component-A which does not bind to membranes, considerably reduces the non specific adsorption of the phospholipase subunit, without preventing its saturable (specific) binding to a limited number of binding sites on the synaptic membrane.

The isolated component-B possesses a low affinity for unilamellar vesicles constituted of zwitterionic phospholipids, but binds with a high affinity to negatively charged phospholipids. The non enzymatic component-A enhances the selectivity of component-B for negatively charged phospholipids since it completely inhibits the low affinity binding of component-B to vesicles of zwitterionic phospholipids. These observations strongly suggest that negatively charged phospholipids are physiological target of crotoxin or at least an important part of this target. This hypothesis implies that, at variance with other plasma membranes, the presynaptic plasma membrane (or some specialized area of the plasma membrane) exposes negatively charged phospholipids on its external surface.

VERATRIDINE-INDUCED ASYNCHRONOUS QUANTAL RELEASE OF TRANSMITTER IN EXCITATORY AND INHIBITORY NERVE-MUSCLE SYNAPSES OF CRAYFISH

W. Finger and C. Martin

Physiologisches Institut der Technischen Universität München  
Biedersteiner Str. 29, 8000 München 40, F.R.G.

$10^{-5}$ - $10^{-4}$  mol/l veratridine in the superfusate caused within seconds high-frequency asynchronous release of excitatory and inhibitory transmitter quanta in crayfish neuromuscular junctions. This quantal release gave rise to vigorous current fluctuations in the postsynaptic membrane of voltage clamped muscle fibres. The current fluctuations were evaluated by means of noise analysis and the total amount of transmitter quanta liberated in the reaction with veratridine was estimated. After veratridine was applied, in many fibres of the claw opener muscle the quantal release rate  $\bar{n}$  increased within seconds from  $\bar{n} < 1$  quantum/s to a maximum  $\bar{n}(\text{max}) = 5,000$ - $15,000$  quanta/s. Thereafter,  $\bar{n}$  declined exponentially either with a single or with two time constants. For excitatory quantal release the single time constant for the exponential decay of  $\bar{n}$  was  $\tau = 55$  s while it was  $\tau = 75$  s for inhibitory quantal release. Altogether, in a single reaction with veratridine at the claw opener muscle, the average total number of excitatory quanta released from the terminals on a fibre of  $\approx 1$  mm length was  $\bar{S} = 300,000$ . The equivalent number of inhibitory quanta was  $\bar{S} = 600,000$ . Veratridine could induce vigorous quantal release only once in a single muscle fibre suggesting exhaustion of quantal stores of transmitter by veratridine. The size,  $\bar{S}$ , and the decline,  $\tau$ , of the readily releasable quantal store of transmitter obtained by veratridine are similar to results obtained by 100 mmol/l  $K^+$  (Martin and Finger 1985, Neurosci Lett 53:309-314). Stimulation at 40 Hz of the excitatory nerve for  $>40$  min caused release of  $>5$  million quanta, and at this time

there was still no sign of transmitter deficiency. Possibly, transmitter recycling or synthesis occurs during repetitive nerve activity. Such processes might be absent, however, during strong tonic depolarizations of nerve endings (Finger and Martin 1987, Pflügers Arch 408 ,Suppl 1,:R67/260).

In the abdominal superficial extensor muscle in which fibres are innervated by two excitatory axons up to  $\bar{s} = 3,000,000$  excitatory quanta could be released from the terminals on a 2-mm-long fibre by application of veratridine.

In low- $\text{Ca}^{++}$  superfusate (normal  $\text{Ca}^{++}$  removed), about 75 % of the total number of releasable excitatory quanta could be liberated by veratridine in the claw opener. In the abdominal superficial extensor muscle only 8 % of excitatory quanta could be released in low- $\text{Ca}^{++}$  saline. This suggests a different dependence of quantal release on extracellular  $\text{Ca}^{++}$  for these two nerve-muscle preparations (Finger and Martin 1987, Neurosci Lett 75:293-298). When extracellular  $\text{Na}^+$  was replaced by  $\text{Li}^+$ , the total amount of excitatory and inhibitory quanta liberated by veratridine was 70-90 % lower than that obtained in normal superfusate. The remaining quanta were released, however, after normal  $\text{Na}^+$  was reestablished and  $\text{Li}^+$  removed from the bath.



# MOLECULAR CLONING AND STRUCTURAL CHARACTERIZATION OF HUMAN CHOLINESTERASE GENES

Averell Gnat and Hermona Soreq  
Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University,  
Jerusalem 91904, Israel

Cholinesterases (ChEs) are highly polymorphic proteins capable of rapidly degrading the neurotransmitter acetylcholine. ChEs can be differentiated by their catalytic properties into two major classes, both expressed in various tissues. These are acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), which exist in several molecular forms, composed of a single, two or four catalytic subunits. Heavier forms contain collagen-like "tail" non-catalytic subunits, covalently bound to one up to three tetramers as above [1]. It is not known as yet whether different genes code for the various ChE forms, or whether control is post-transcriptional.

ChEs in various species display extensive homology at the level of their amino acid sequence [2,3] and appear to be derived from a single ancient gene [4]. Homology was retained also at the level of nucleotide sequence and between evolutionarily-remote species such as *Torpedo californica* and man [5]. In humans, the genes coding for ChE are intensively expressed in various embryonic tissues, including oocytes, as was shown by *in situ* hybridization to frozen ovarian sections [6]. This makes the ChE genes good candidates for the appearance of inheritable, re-inserted processed genes. In addition, genetic linkage studies have shown that defects in the expression of serum ChE may be linked to either chromosome 3 genes like transferrin [7] or chromosome 16 genes such as haptoglobin [8]. Indeed, chromosomal mapping of human ChE genes by *in situ* hybridization revealed three loci containing ChE-coding sequences, two on chromosome No. 3 and one on chromosome No. 16 [9].

In order to find out how many functional ChE genes exist in humans, what their structure and mode of regulation are and which of the polymorphic ChE forms they encode, molecular cloning and gene isolation experiments were initiated. Several different phage libraries of human genomic DNA fragments were screened, including complete genomic libraries, libraries enriched by size fractionation of enzymatically restricted DNA and libraries prepared from isolated chromosomes. The full-length cDNA clone coding for human ChE<sup>S</sup> or fragments isolated from this clone [5] were labeled and used as probes in these experiments. The screening resulted in the isolation of several different DNA fragments, which were subjected to DNA sequencing by the Sanger technique, using M13 single stranded phages and synthetic oligodeoxynucleotide primers synthesized according to the ChEcDNA sequence.

The existence of differently restricted fragments from the ChE genes on two different chromosomes, together with the results obtained by *in situ* hybridization to chromosomes and DNA blot hybridization studies, indicate the presence of at least three ChE genes in humans. One of these, localized on chromosome No. 3, appears to contain at least three intervening sequences and may represent the original human ChE gene. Two other ChE genes appear to be processed genes derived from the latter by post-transcriptional processing events. These do not contain introns within their coding regions and they include point changes in nucleotides as compared with the human ChEcDNA. The two processed ChE minigenes are localized on chromosomes 3 and 16, respectively, and the ChE minigene on chromosome 16 is most probably an actively expressed processed gene, coding for the C5 variant of serum ChE [8].

In order to define the structural organization and intrinsic differences between the various human ChE genes, pulse-field DNA electrophoresis followed by DNA blot hybridization is currently employed, aiming to identify, clone and isolate the human ChE genes in their fully intact forms so that their promoter regions and expression properties can be approached.

#### References

1. Massoulie, J. and Bo, S. (1982) *Ann. Rev. Neurosci.* 5, 57-106.
2. Schumacher, M., Camp, S., Manlet, Y., Newton, M., McPhee-Quigley, K., Taylor, S. S., Friedman, T. and Taylor, P. (1986) *Nature* 319, 407-409.
3. Prody, C., Zevin-Sonkin, D., Gnatt, A., Goldberg, O. and Soreq, H. (1987) *PNAS* 84, 3555-3559.
4. Mori, N., Itoh, N. and Salvaterra, P. M. (1987) *PNAS* 84, 2813-2817.
5. Soreq, H. and Gnatt, A. (1987) *Molecular Neurobiology*, in press.
6. Zakut, H., Malinger, G. and Soreq, H. (1987). This conference.
7. Sparkes, R. S., Field, L. L., Sparkes, M. C., Crist, M., Spence, M. A., James, K. and Garry, P. J. (1984) *Hum. Hered.* 34, 96-100.
8. Lovrien, E. W., Magenis, R. E., Rivas, M. L., Lamvik, N., Rowe, S., Wood, J. and Hemmerling, S. (1978) *Cytogenet. Cell Genet.* 22, 324-326.
9. Zamir, R., Sindel, L., Zakut, H. and Soreq, H. (1987). This conference.
10. Maniatis, T., Fritsch, E. F. and Sambrook, J. Cold Spring Harbor, 1982.
11. American Type Culture Collection.

Supported by the Silverman Foundation and by the U.S. Army Medical Research and Development Command.

ENERGETICS OF ACTIVATION OF THE ACETYLCHOLINE RECEPTOR. Meyer B. Jackson, Department of Biology, University of California, Los Angeles.

Mathematical techniques applicable to a system with an arbitrary number of channels (Jackson, 1985, Biophys. J. 47:129) were used to analyze the channel gating kinetics of the acetylcholine receptor from 0 to 20  $\mu$ M carbachol. This analysis, which included fitting single channel dose-response curves to appropriate theories, provided estimates of the unliganded, singly liganded, and doubly liganded receptor channel gating rate constants and equilibrium constants. The dissociation constants to the first and second binding sites were estimated for a closed channel, and the principle of detailed balance was used to calculate the dissociation constants to the receptor with an open channel. This constitutes a complete energetic description of this allosteric protein.

The equilibrium constants of the gating transitions are  $1.9 \times 10^{-6}$ ,  $4.4 \times 10^{-4}$ , and 14 for unliganded, singly liganded, and doubly liganded receptor, respectively. For a closed channel, the first dissociation constant is 5  $\mu$ M and the second is 10 mM. For an open channel, the two dissociation constants are .025 and .31  $\mu$ M, respectively. Thus the binding strengths of the two sites are very different when the channel is closed but very similar when the channel is open. The binding sites for the closed state differ further in the degree to which binding accelerates the rate of opening. Binding at the first site accelerates the rate of opening 40 fold over the rate of spontaneous opening; binding at the second site accelerates the rate of opening an additional 7000 fold.

These results can be interpreted by considering how binding energy can be utilized by the receptor. For the first binding site much of the energy of binding is utilized to stabilize the complex with the closed state. The binding of the second ligand to the closed receptor channel is weaker because more of the binding energy is used to stabilize the open channel conformation.

Konrad Kaufmann  
Fachbereich Physik  
Universität Essen GHS  
D-4300 Essen 1, F.R.G.

The control of synaptic functions by membrane proteins has seduced even the most critical scientists to consider the central factor to be a local, molecular mechanism. However, even the details of the amino acid sequences have taught nothing about the physical basis of membrane excitation. Membrane theory, in contrast, still continues to proceed along unrelated and mutually exclusive lines:

- chemiosmotic theories, where protons are crucial, describe the observed free energy coupling;
- electrical theories, where protons are ignored, model mathematically the deterministic shape of propagating action potentials;
- allosteric theories, where neither protonic free energy nor deterministic propagation matter, were to explain the fluctuating ion channels.

In contradiction to any molecular interpretation, though, the observed membrane excitation is macroscopic. Action potentials, for example, extend for some millimeters in space in the squid giant axon membrane. Ion channels obey macroscopic statistical fluctuations. Protonic free energy coupling, too, since reversible, requires a cooperative property of a macroscopic number of membrane molecules.

This situation is reminiscent of the propagation mechanism of sound which would have remained unknown were it investigated on the level of single, isolated molecules.

The macroscopic action potential likewise obeys the principles of thermodynamics and can therefore be neither molecular nor purely electrical in nature. The thermodynamic properties of the macroscopic membrane surface itself are not considered in the above membrane theories. This surface is constituted from the hydrated phospholipid layers and does not require the presence of proteins a priori. The application of classical thermodynamics gives rise to remarkable responses of phospholipid layers to stimulation, e.g., by ATP or ACh hydrolases:

- free energy-rich proton-phospholipid bilayer conformations consistent with local and with global aspects of chemiosmotic coupling;
- propagation of the hydrodynamic excitation along the bilayer with saltatory velocity of sound and accompanied by increase and decrease of temperature, membrane displacement, electrical polarisation, and optical density in consistence with the observed action potential;
- fluctuating opening and closing of aqueous ion channels across the otherwise impermeable lipid bilayer lattice due to the strength of the thermal motion of the flexible surface in the more compressible states.


A proof for the lipid bilayer mechanism of biological membrane functions can be obtained in any one of the following ways:

- Unification of the previously unrelated theories of chemiosmosis, action potential, and ion channel fluctuations by the entropy, forces, and fluctuations in the lipid bimolecular layer.
- Evidence of the mechanism which is free of adjustable parameters and only requires existence of the bilayer, validity of classical thermodynamics, and applicability of Langmuir monolayer diagrams of state.
- Resolution of long-standing paradoxes:  
Hill's observation of temperature increase and *d e c r e a s e* during the excitation;  
Tasaki's observations of mechanical and optical pulses during the action potential, and its persistence in the absence of monovalent cations;  
the presence of ion channel opening and closing in the absence of proteins;  
the dependence even of protein-induced ion channel fluctuations on the lipid surface variables of pressure, electrical potential, or pH.  
Crucial experimental test of the theory:  
the predictable induction of ion channels in pure phospholipid bilayers by the electrochemical proton potential, by surface pressure, or by temperature, as observed by Hanke, Silman, Corcia, and myself;  
the appearance of deterministic millisecond pulses comparable to action potentials in pure lipid bilayers, induced by reversible pulses in any one of the surface variables;  
free energy-coupling conformational bilayer transitions induced by protons directly or by ATP and ACh hydrolases.

The results of experiments on pure lipid bilayers in collaboration with Israel Silman, Wolfgang Hanke, and Ayus Corcia, as well as of the hydrodynamic theory for the electro-mechanical coupling during action potentials in collaboration with Helmut Brand, are striking, since no other membrane component is capable of explaining ion channels and excitation but the macroscopic phospholipid surface. These are and will be reported elsewhere.

In consequence, sensory receptors couple free energy into the phospholipid entropy, propagation of the excitation is by the mechanism and with the velocity of first sound, while ion channels open and close, controlled by the strength of the thermal motion. The sensory stimuli, whether peripheral or synaptic, mediated by proteins or directly applied, induce the bilayer excitation via any one of the phospholipid surface variables: electrical or chemical potential of the protons; mechanical displacement; electrical polarisation; electrochemical potential of calcium and other aqueous ions or hydrophobic membrane constituents. Receptors for voltage, pH, acoustical sound, for photons, taste and smell seem predictable, respectively.

Synaptic transmission is reversible if the junction is tight, in the order of the mechanical displacement; this is some 10 Å according to Iwasa and Tasaki. Transmission is also controlled by the chemiosmotic proton potential. The cholinergic synapse is thus controlled by the fastest protonic free energy source known in the nervous system and might therefore be even more efficient than the mitochondrial ATPase system: the catalytic activity of the phospholipid-anchored membrane acetylcholinesterase. Thus, free energy coupling across synapses is controlled in a chemically modifiable fashion.



SPONTANEOUS RELEASE OF ACETYLCHOLINE FROM THE TORPEDO ELECTRIC ORGAN

Roxana Licht and Daniel M. Michaelson

Department of Biochemistry, Tel Aviv University.

In the present work we investigated the mechanisms underlying spontaneous acetylcholine (ACh) release. This was done by characterizing the release of ACh from Torpedo electric organ neurons and the effects thereon of cholinergic ligands.

Incubation of Torpedo electric organ prisms in modified Torpedo buffer in the presence of the acetylcholinesterase (AChE) inhibitors phospholine iodide (100  $\mu$ M) or paraoxon (150  $\mu$ M) results in spontaneous ACh release. Release is linear for about 10 min after which it levels off to a plateau. The inhibition of ACh release at the plateau is completely lost when electric organ prisms are transferred to fresh media, whereas when the tissue is transferred to medium which has been preincubated with electric organ prisms, release is completely blocked. Inhibition of ACh release by the conditioned medium is abolished by heating the media to 90°C for 10 min. Incubation of Torpedo electric organ prisms in the absence of AChE inhibitors results in basal ACh release whose initial rate (0-10 min) is similar to that observed in the presence of AChE inhibitors. However, at longer incubation times (10 - 30 min) ACh release in the absence of AChE inhibitors is not inhibited and proceeds at the initial rate.

The effects of the vesicular ACh uptake inhibitor 2(4-phenylpiperidino) cyclohexanol (AH5183) on basal ACh release were examined. Addition of AH5183 (0.1-1  $\mu$ M) in the absence of AChE inhibitors results in repressed basal release whereas in the presence of either phospholine iodide or paraoxon AH5183 does not affect ACh release. Spontaneous ACh release and the effects thereon of AH5183 are pH dependent. Maximal release is obtained at acidic pH whereas release is most sensitive to AH5183 at neutral and basic pH.

# PRESSURE EFFECTS ON THE CARBAMYLATION OF BUTYRYLCHOLINESTERASE

Patrick MASSON<sup>†</sup> and Claude BALNY<sup>\*</sup>

- - - - -

<sup>†</sup> Centre d'Etudes et de Recherches Biophysiques appliquées à la Marine, Division de Biochimie, B.P. 610, 83800 TOULON-NAVAL, France.

<sup>\*</sup> INSERM U128, CNRS, B.P. 5051, 34033 MONTPELLIER, France.

The effect of hydrostatic pressure on the reaction of human plasma cholinesterase (EC.3.1.1.8) tetrameric form with the carbamyl ester, N-methyl- (7-dimethylcarbamoyl) quinolinium iodide, was studied under single-turnover conditions at 35°C up to 0.8 kbar.

The enzyme carbamylation was followed by monitoring the formation of the fluorescent quinolinium ion in a high-pressure stopped-flow apparatus operating in fluorescence mode. The apparent activation volume change ( $\Delta V^+$ ) accompanying the reaction was determined from the pressure-dependence of the carbamylation rate.  $\Delta V^+$  consists of two contributions : the volume change of the substrate binding step ( $\Delta V_b$ ) and the activation volume change of the carbamylation step ( $\Delta V_c^+$ ). These two contributions were obtained from experiments performed under pressure at different non-saturating substrate concentrations.

The rate of carbamylation displays a biphasic non-linear pressure dependence. Up to 0.4 kbar, the non-linearity is caused by a change in the enzyme-substrate dissociation constant ( $K_D$ ) and in the carbamylation rate constant ( $k_2$ ) with pressure. The curvilinear plots (fig. 1) are the fit of the experimental points according to the equation :

$$k_{obs} = \frac{k_2 \exp(-p \Delta V_{k_2}^+ / RT) [S]}{K_D \exp(-p \Delta V_{K_D} / RT) + [S]}$$

with (fig. 2)

$$\Delta V^+ = -RT \left( \frac{\partial \ln k_{obs}}{\partial P} \right)_T = \Delta V_{k_2}^+ - \frac{1}{1 + S/K_D} \cdot \Delta V_b$$

From the pressure-induced changes in  $K_D$  and  $k_2$ , we calculated  $\Delta V_b = -129 \pm 15 \text{ ml.mol}^{-1}$  and  $\Delta V_c^+ = 119 \pm 10 \text{ ml.mol}^{-1}$  for the reaction at atmospheric pressure. These large values cannot be simply explained in terms of molecular interactions ; they could reflect important structural changes.

Therefore, the volume change associated with each step must be regarded as the sum of individual contributions: bonds formation/disruption, conformational changes and water structuration changes.

Beyond 0.4 kbar, the curvatures become more marked and the inhibition of the carbamylation occurs in a narrow pressure range. The corresponding great positive  $\Delta V^\ddagger$  suggest that, above 0.4 kbar, pressure induces a conformational change and/or an extensive hydration change of the enzyme. However, high-pressure electrophoresis data show no change in quaternary structure and no unfolding of the enzyme. In addition, the inhibition is reversible after pressure release.

At low substrate concentration ( $S = 10 \mu\text{M}$ ), the pressure effects are markedly different. Since  $\Delta V^\ddagger$  is dominated by the binding contribution, the carbamylation is not pressure-inhibited. Surprisingly,  $\Delta V^\ddagger$  appears to be pressure-independent at least up to 0.8 kbar. Data can be fitted by a straight line assuming  $\Delta V_b = -5 \text{ ml.mol}^{-1}$  and  $\Delta V_o^\ddagger = 0$ .

The pressure effect depending on substrate concentration could be discussed in terms of enzyme conformation perturbation. It may be suggested that the binding of substrate induces a conformational change leading to a pressure-sensitive conformational state.




Fig.1 - Pressure dependence of the observed rate of carbamylation at  $35^\circ\text{C}$ ,  $\text{pH} = 7.4$ ;  $e = 6.25 \text{ IU.}\mu\text{l}^{-1}$  ( $\text{I.U.} = \mu\text{mol BuCh hydrolyzed.min}^{-1}$  at  $V_{\text{max}}$  in  $0.1\text{M}$  phosphate  $\text{pH} 7$ ,  $25^\circ\text{C}$ ).




Fig.2 - Apparent activation volume change ( $\Delta V^\ddagger$ ) as a function of carbamyl ester concentration ( $\mu\text{M}$ ).



## A NEUTRALIZING MONOCLONAL ANTIBODY TO CROTOXIN

John L. Middlebrook<sup>1</sup> and Ivan I. Kaiser<sup>2</sup>

<sup>1</sup>Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick MD 21701 and <sup>2</sup>Department of Molecular Biology, The University of Wyoming, Laramie, Wyoming 82071, USA

The purpose of this study was to define the immunological relationships among rattlesnake neurotoxins by using monoclonal antibodies. Crotoxin is a potent presynaptic neurotoxin found in the venom of the South American rattlesnake, *Crotalus durissus terrificus*. The toxin is a heterodimeric protein composed of an acidic and a basic subunit. Mice were immunized with either the intact toxin or its basic subunit. Monoclonal antibody-secreting hybridoma cell lines were then obtained using standard techniques. One of the lines was found to produce antibody (Ab 1) which neutralized crotoxin and became the subject of further study.

After production from ascites tumors, Ab 1 was purified on a protein A-Sepharose column and typed as subclass IgG<sub>1</sub>. Ab 1 reacted with crotoxin and the related mojave and virgandis toxins, but did not react with concolor toxin or phospholipase A<sub>2</sub>s from *C. atrox* or *C.*

*adamanteus*. Mouse lethality of both purified crotoxin and mojave toxin was neutralized by Ab 1. Ab 1 was approximately 50-fold more effective at neutralizing purified crotoxin than was commercial horse antiserum. However, Ab 1 was ineffective at protecting from lethality due to *C. d. terrificus* venom under conditions where the horse antisera worked well. Paradoxically, Ab 1, when added to horse antisera, markedly potentiated the latter's effectiveness at protecting from *C. d. terrificus* venom.

We conclude that several, but not all rattlesnake neurotoxins have a common epitope and that antibodies against this epitope can neutralize the toxin, but not necessarily the venom.

Int. workshop on structural and functional aspects of the cholinergic synapse, Neve-Ilan Guest House, near Jerusalem, Aug 31 - Sept. 4, 1987.

**THE EFFECT OF AH 5183 ON THE RELEASE AND STORAGE OF NEWLY SYNTHESIZED ACETYLCHOLINE IN FROG MUSCLE**

P.C. Molenaar and G.Th.H. van Kampen - Department of Pharmacology, University of Leiden, Leiden, The Netherlands

It has been reported that the compound AH 5183 is a potent inhibitor of acetylcholine (ACh) uptake in vitro into synaptic vesicles prepared from the electric organ of the electric ray (see for review: ref. 1). In the present experiments we present evidence strongly suggesting that AH 5183 has a selective inhibitory effect on ACh uptake into synaptic vesicles of preparations of frog skeletal muscle.

Sartorius muscles of R. esculenta were treated with an irreversible cholinesterase inhibitor (soman) and then stimulated via the nerve for 30 min (1 per s trains, 100 Hz for 0.1 s). Muscles were left in Ringer containing 50  $\mu$ M choline-d9 for 3 h and then stimulated for a second 30 min period. AH 5183 (10  $\mu$ M) was or was not present throughout the incubation. ACh-do and ACh-d9 were measured by mass spectrometry in incubation medium, 'bound', presumably vesicular, and 'free' extracts of the tissue (2).

It was found that ACh release was exhausted by 30 min stimulation and that a 3 h rest period was sufficient to restore the pools of both releasable and bound ACh. Whereas AH 5183 had no effect on ACh released during the first period it caused an about ten-fold decrease of the newly synthesized ACh-d9 released during the second period. Further, AH 5183 strongly reduced the ACh-d9 which was incorporated into the bound fraction. AH 5183 had no inhibitory effect on the amounts of ACh-d9 synthesized during the period of rest after the first stimulation period.

It is concluded that, whereas AH 5183 did not influence the depletion of the releasable ACh pool per se, it had a strong inhibitory action on both the regeneration of releasable ACh and the transfer of ACh from the free into the bound ACh fraction of the muscle.

Parsons S.M. et al. (1987) Ann.N.Y.Acad.Sci. 493, 220-233.

Miledi R. et al. (1982) J.Physiol. 333, 189-199.

AN ANTISERUM SPECIFIC FOR THE MEDIATOPHORE, AN ACETYLCHOLINE RELEASING  
PROTEIN, EXHIBITS A PRESYNAPTIC BINDING IN TORPEDO AND RAT  
NEUROMUSCULAR JUNCTIONS.

Morel N., Israel M., Manaranche R. and Lesbats B.

Dept Neurochimie, lab.Neurobiologie Cellulaire et Moleculaire,  
C.N.R.S., 91190 Gif sur Yvette, France.

Recently we purified from the presynaptic plasma membrane of Torpedo electric organ a protein (the mediatophore) that mediates calcium dependent release of acetylcholine from proteoliposomes (Israel et al, 1986, Proc.Natl.Acad.Sci.USA, 83, 9226-9230). By immunoblot techniques, using a rabbit antiserum to the purified mediatophore, this antigen was shown to be most abundant in presynaptic plasma membranes purified from Torpedo electric organ, present in lesser amounts in synaptic vesicle fractions and hardly detectable in electric nerve membranes or plasma membranes of the electroplaques. It was also possible to demonstrate by indirect immunofluorescence the presence of a related antigen in Torpedo and rat neuromuscular junctions. The fluorescence pattern is typical of a presynaptic binding. These immunological results show that the protein mediatophore is specific for the presynaptic plasma membrane and that a related protein is also present in Torpedo and rat neuromuscular junctions.

INHIBITORY EFFECT OF CETIEDIL ON PRESYNAPTIC ACETYLCHOLINE  
RELEASE

Morot Gaudry-Talarmin Y., Israel M., Morel N., Lesbats B., and  
Manaranche R.

Département de Neurochimie, Laboratoire de Neurobiologie  
Cellulaire et Moléculaire, C.N.R.S., Gif-sur-Yvette, France.

The effects of cetiedil, a vasodilator substance, on cholinergic function, were examined at the nerve electroplaque junction of *Torpedo marmorata* using both synaptosomes and slices of intact tissue. Cetiedil abolished the calcium dependent release of acetylcholine (ACh) triggered by depolarization with KCl, gramicidin D application, Glyceral neurotoxin effect or by the addition of the calcium ionophore A23187, placing the site of action after the calcium entry step. In addition, a direct effect on the release process itself was supported by the fact that cetiedil was able to block the calcium dependent release of ACh mediated from ACh-containing proteoliposomes reconstituted from synthetic lecithin and the recently isolated presynaptic membrane protein "mediatophore". This effect was obtained at a  $K_i$  close to that observed in synaptosomes or in intact tissue ( 5-8 micromolar). Under the conditions used in these experiments, neither the synthesis, nor its compartmentation within the nerve terminal were altered. However, the drug appears able to reduce high-affinity choline uptake and the vesicular ACh incorporation when given together with radioactive acetate precursor. Thus, cetiedil has a broad inhibitory action on cholinergic membrane uptake process.

## REGULATION OF CHICKEN MUSCLE ACETYLCHOLINE RECEPTOR GENE EXPRESSION

Stephen J. Moss, David M.W. Beeson, Mark G. Darlison and Eric A. Barnard. MRC Molecular Neurobiology Unit, MRC Centre, Hills Road, Cambridge, CB2 2QH and Department of Biochemistry, Imperial College of Science and Technology, South Kensington, London, SW7 2AZ, United Kingdom.

The nicotinic acetylcholine receptor (nAChR) within the electric organ and vertebrate skeletal muscle has been shown to be an oligomeric, integral membrane, ion-gating, glycoprotein consisting of four subunits of a stoichiometry  $\alpha_2\beta\gamma\delta$ . The analysis of complementary DNA (cDNA) and genomic equivalents has shown that within the electric organ each polypeptide is encoded by a distinct gene. Parallel studies on the calf nAChR reveal a similar pattern of genomic organisation. Regulation of the expression of these genes *in vivo* is of great interest but as yet little information is available on this matter. We have taken advantage of the accessibility of the chicken to investigate the developmental expression of the chicken skeletal muscle nAChR transcripts, and their response to chronic denervation. Subunit-specific probes derived from cDNA and genomic clones generated within this laboratory for the  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$  subunits of the chicken muscle nAChR have been used to probe poly(A)<sup>+</sup> RNA derived from embryonic, denervated and innervated chicken skeletal muscle. High levels of each subunit transcript are seen early in development peaking at D<sub>12</sub>-D<sub>14</sub>, decreasing rapidly towards D<sub>18</sub>. Much lower levels of the  $\alpha$ ,  $\beta$  and  $\delta$  transcripts could be detected in innervated muscle. Upon denervation of 8-week-old chicken muscle, levels of all four transcripts were observed to approach embryonic values. The importance of these results will be discussed with regard to the regulation of the genes encoding the nAChR oligomer.

# REGULATION OF CHICKEN MUSCLE ACETYLCHOLINE RECEPTOR GENE EXPRESSION

Stephen J. Moss, David M.W. Beeson, Mark G. Darlison and  
Eric A. Barnard. MRC Molecular Neurobiology Unit, MRC  
Centre, Hills Road, Cambridge, CB2 2QH and Department of  
Biochemistry, Imperial College of Science and Technology,  
South Kensington, London, SW7 2AZ, United Kingdom.

The nicotinic acetylcholine receptor (nAChR) within the  
electric organ and vertebrate skeletal muscle has been  
shown to be an oligomeric, integral membrane, ion-gating,  
glycoprotein consisting of four subunits of a stoichiometry  
 $\alpha_2\beta\gamma\delta$ . The analysis of complementary DNA (cDNA) and  
genomic equivalents has shown that within the electric  
organ each polypeptide is encoded by a distinct gene.  
Parallel studies on the calf nAChR reveal a similar pattern  
of genomic organisation. Regulation of the expression of  
these genes *in vivo* is of great interest but as yet little  
information is available on this matter. We have taken  
advantage of the accessibility of the chicken to investi-  
gate the developmental expression of the chicken skeletal  
muscle nAChR transcripts, and their response to chronic  
denervation. Subunit-specific probes derived from cDNA and  
genomic clones generated within this laboratory for the  
 $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$  subunits of the chicken muscle nAChR have been  
used to probe poly(A)<sup>+</sup> RNA derived from embryonic, denerv-  
ated and innervated chicken skeletal muscle. High levels  
of each subunit transcript are seen early in development  
peaking at D12-D14, decreasing rapidly towards D18. Much  
lower levels of the  $\alpha$ ,  $\beta$  and  $\delta$  transcripts could be detected  
in innervated muscle. Upon denervation of 8-week-old  
chicken muscle, levels of all four transcripts were  
observed to approach embryonic values. The importance of  
these results will be discussed with regard to the  
regulation of the genes encoding the nAChR oligomer.

## HUMAN MEMORY MODELLING : SYNAPSE LEVEL

Simeon Jordanov Mrchev (ul. "Jordan Mishev" 21 A, 8600 Jambol, Bulgaria)

The stable synapse-modification (a base of the long-term space traces) is connected with the molecular-chemical processes in the synapse forms, the genetic apparatus of the neurons taking part. Two basic hypotheses dominate :

- The adaptation hypothesis - a sequence of the following events : 1. Increasing of the secretorius functions of the synapse when it is included in the activated system of inter-neuron links, which lead to intensification of the interaction between the mediator and the receptor proteins of the post-synapse membrane; 2. Causing of increased forming of the depressor (in the synthesis of the receptor protein in the membrane) and its diffusion in the nucleus in an increased quantity; 3. The synthesis of the corresponding mRNA in the nucleus is increased and also its coming out in the cytoplasm, which to increasing of the receptor protein synthesis; 4. With the help of the factor "building in" (which is formed in the membrane when the synapse is activated) increased building in of accessory amounts of this protein in the sub-synapse membrane is caused and as a final result the synapse effectiveness increases. Consequently the basic plastic processes in the synapse apparatus take place in the post-synapse membrane and probably the apparatus of the spine growths takes part in the memory processes and the teaching. Despite the existence of a lot of indirect facts, there is not a direct provement of the adaptation hypothesis up to now because of the absence of an adequate biological model ;

- A structure-chemical hypothesis : The role of the genome is reduced to securing of the synthesis of specific (for determined neurons) proteins or peptids, i.e. to securing of markers, which determine the genetic type of the brain structures (one for all) and to forming of the inborn (unconditional) reflexes. The genetically determined neuron systems (proto-chains) are in fact a structural brain code with high plasticity, i.e. the record and storing of the ontogenetic information in the Long-term Memory (LM) is realized in a chemical way. The plasticity features secure forming of new neuron chains (meta-chains), i.e. synapse-modifications are realized (the increase of the synapse effectiveness is determined anatonically; new synapse networks are formed). Of most complete character is the hypothesis of G. Ungar, namely : 1. The simultaneous activation of the neuron chains (of the unconditional reflex) and some of the afferent systems leads to a trans-synapse transport of the peptids-markers in the network of specialized inter-neurons ("memory cells"); 2. The trans-peptidases of the last cells "sew together" from the markers a new peptide - a non-genetic level of coding of the ontogenetic information; 3. By building in of the "sewn together" peptide in the membrane synapse protein (of the "memory cells") the links of the newly-formed meta-chains are consolidated, i.e. a conditioned reflex link appears.

IN SEARCH OF THE LIGAND BINDING SITE OF THE SNAKE NICOTINIC ACETYLCHOLINE  
RECEPTOR

<sup>1</sup>Drorit Neumann, <sup>1</sup>Mia Horowitz, <sup>2</sup>Zvi Vogel, <sup>3</sup>Elazar Kochva, <sup>1</sup>Dora Barchan  
and <sup>1</sup>Sara Fuchs

Departments of <sup>1</sup>Chemical Immunology and <sup>2</sup>Neurobiology, The Weizmann Insti-  
tute of Science, Rehovot, Israel, <sup>3</sup>Department of Zoology, Tel Aviv Univer-  
sity, Tel Aviv, Israel.

The acetylcholine receptor (AChR) in the neuromuscular junction (NMJ) of Elapid snakes responds to cholinergic ligands but unlike other muscle AChRs, does not bind  $\alpha$ -bungarotoxin ( $\alpha$ -BTX). Hence, dissecting the structure of the snake AChR and its cholinergic binding site is of unique interest. By determining the amino acid sequence of the snake AChR  $\alpha$ - subunit and comparing it to that of muscle AChR from other species as well as to neuronal AChR, we may gain insight into the unique pharmacological profile of the snake receptor. The antigenic specificity of the snake muscle AChR was initially tested. Polyclonal rabbit anti Torpedo AChR antibodies cross-reacted with the snake AChR in sections of snake muscle thus indicating that the snake nicotinic AChR shares a certain degree of homology with AChR from other species. To verify that the AChR of the snake was in fact resistant to  $\alpha$ -BTX, we examined the effect of intraperitoneal injection of this neurotoxin on snake mortality. Indeed, administration of  $\alpha$ -BTX in concentrations several orders of magnitude higher than its LD<sub>50</sub> for other species did not result in snake death. In search of the snake AChR gene we have prepared Southern blots of snake DNA, digested with several restriction enzymes. By employing a <sup>32</sup>P-labeled cDNA probe of the mouse AChR  $\alpha$ -subunit (kindly provided by S. Heinemann), we could demonstrate a cross-reaction of this probe with fragments of snake DNA digested with XbaI, BamHI, EcoRI, BglII and HindIII. A genomic library from snake DNA was prepared in a  $\lambda$ gt10 vector by isolating genomic DNA fragments in the range of 4-6 Kb, obtained by EcoRI digest of DNA. A positive clone hybridizing to the mouse probe was isolated. The snake AChR thus provides a useful system for elucidating the structural requirements for agonist binding and for discriminating between the  $\alpha$ -BTX and the cholinergic binding site in muscle receptor.



# ALTERNATE TERMINATION SITES IN HUMAN CHOLINESTERASE GENES

Catherine Prody<sup>1,2</sup>, Ronit Zamir<sup>1,3</sup>, Haim Zakut<sup>3</sup> and Hersena Soreq<sup>1</sup>

1. Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem 91904, Israel

2. Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel

3. Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel Aviv University, Israel.

Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are polymorphic enzymes that exist in parallel arrays of multiple molecular forms with similar kinetic properties. They differ in the number of catalytic subunits, in their level of hydrophobicity and mode of glycosylation, and in their cellular and subcellular localization [1]. We recently isolated a full length cDNA encoding BuChE from fetal human tissues [2,3]. Both the encoded protein and its nucleotide sequence display striking homologies to sequences for Torpedo AChE [4,5]. To examine whether the isolated cDNA also shares homologous sequences with other nervous system cholinesterase (ChE) cDNAs in humans, we searched by screening cDNA libraries for cDNA clones that hybridize with this cDNA but are not identical to it. Libraries were prepared from glioblastoma tissues [6] and neuroblastoma cells [7]. These were found to contain different patterns of ChE molecular forms from those of normal brain tissues [6].

The probes used were the original BuChEcDNA, and oligodeoxynucleotides synthesized according to nucleotide sequences that are homologous in both BuChEcDNA and in AChEcDNA clones from Torpedo californica [4] and Torpedo marmorata [8]. 10<sup>6</sup> phages from each library were screened by both methods. 175 and 200 BuChEcDNA-positive phages were found in the glioblastoma and neuroblastoma libraries, respectively. When screened with the oligodeoxynucleotide probes, similar numbers of positive phages were detected in both libraries, and most of these overlapped with the BuChEcDNA positive phages.

Two glioblastoma clones, however, appeared by comparative hybridization to include the pursued oligonucleotides but to contain different cDNA sequences and were further characterized by DNA sequencing. We found that these were derived from an mRNA transcript that includes ca. 230 nucleotides from the 5' region of the BuChEcDNA, but that it extended beyond the BuChEcDNA at its 5' end and continued with a different sequence in the 3' direction.

About 25% of the hybridization signals obtained with BuChEcDNA were significant but weak, suggesting sequence differences. Out of these, 5 glioblastoma and 3 neuroblastoma clones displayed different restriction patterns from that of the original cDNA. One of these glioblastoma clones and all three neuroblastoma ones contained an additional 0.5 fragment (designated FI) at the 3' untranslated region of the cDNA. Another one of the glioblastoma clones contained yet another 0.5 kb fragment (designated FII), also at the 3' end. This fragment was not detected in any of the neuroblastoma clones. To establish that the cDNAs containing these fragments were authentic transcripts of the cholinesterase (ChE) genes, and to define their chromosomal location, we employed in situ hybridization to lymphocyte chromosomes [9]. We found that both FI and FII hybridize to the long arm of chromosome 3, similar to the original BuChEcDNA, and that FI also hybridizes to the same area of chromosome 16 to which the original clone hybridizes [10]. Furthermore, FI was also found on a ChE genomic clone from chromosome 3 [11].

The screening results indicate that sequences hybridizing to BuChEcDNA occur in glioblastoma and neuroblastoma cells at a frequency of ca 10<sup>-4</sup>, which is higher than found in fetal brain, and may be due to the differentiation state of the tissues. We also found that there are multiple termination sites in the BuChE gene, and obtained evidence for alternate splicing. Because these phenomena were not detected in cDNA libraries from normal tissues, it will be interesting to see if these changes are related to the different patterns of ChE molecular forms in the glioblastoma and neuroblastoma tissues.

# References

1. Massoulie, J. and Bon, S. (1982) *Ann. Rev. Neurosci.* 5, 57-106.
2. Prody, C. A., Zevin-Sonkin, D., Gnatt, A., Koch, R., Zisling, R., Goldberg, O. and Soreq, H. (1986) *J. Neurosci. Res.* 16, 25-36.
3. Prody, C. A., Zevin-Sonkin, D., Gnatt, A., Goldberg, O. and Soreq, H. (1987) *Proc. Natl. Acad. Sci.* 84, 3555-59.
4. Schumacher, M., Camp, S., Maulet, Y., Newton, M., McPhee-Quigley, K., Taylor, S. S., Friedman, T. and Taylor, P. (1986) *Nature*, 319, 407-409.
5. Lockridge, O., Bartels, C. F., Vaughan, T. A., Wong, C. K., Norton, S. E. and Johnson, L. L. (1987) *J. Biol. Chem.* 262, 549-557.
6. Razon, N., Soreq, H., Roth, E., Bartal, A. and Silverman, I. (1984) *Exp. Neurol.* 84, 681-695.
7. Tumilowicz et al. (1970) *Cancer Res.* 30, 2110.
8. Sikorav, J. L., Krejci, E. and Massoulie, J. (1987) *EMBO J.*, in press.
9. Soreq, H., Zamir, R., Zevin-Sonkin, D. and Zakut, H. (1987) *Human Gen.*, in press.
10. Zamir, R., Sindel, L., Zakut, H. and Soreq, H., this conference.
11. Gnatt, A. and Soreq, H., this conference.

Supported by the U.S. Army Medical Research and Development Command. C. Prody is a Fellow of the Muscular Dystrophy Associations of America.

THE COEXISTENCE AND CORELEASE OF ACETYLCHOLINE AND ENKEPHALINS  
FROM TORPEDO NERVE TERMINALS

Riva Rosenblum, Yosef Sarne\* and Daniel M. Michaelson

Departments of Biochemistry and Physiology and Pharmacology\*, Tel  
Aviv University, Israel.

In the present study we investigated the coexistence of acetylcholine (ACh) and enkephalins in Torpedo electromotor neurons and their corelease following presynaptic stimulation.

Analysis by HPLC of TCA extracts of the electric lobe, electromotor nerve and electric organ of the Torpedo revealed that they contain Met-enkephalin and Leu-enkephalin-like immunoreactivities. The specific concentrations of these opioid peptides is about thirty-fold higher in the electric lobe than in the electric organ (respectively 350 and 12 fmol/mg prot). Subcellular fractionation of electric organ homogenates revealed that ACh and the enkephalins comigrate following differential and density gradient centrifugation and that the purified synaptosomes and the microsomal fraction are highly enriched in both ACh and enkephalins. This suggests that ACh and the enkephalins coexist presynaptically and that the enkephalins are compartmentalized in small vesicles.

K<sup>+</sup> depolarization of isolated electric organ prisms in the presence of Ca<sup>2+</sup> and the acetylcholinesterase inhibitor phospholine iodide results in the corelease of ACh and enkephalin and in the concomitant decrease of the tissue enkephalins content. ACh release proceeds linearly for at least 10 min whereas release of the enkephalins is transient. The extent to which this difference is due to the release process or to hydrolysis of the released enkephalins by endogenous peptidase and enkephalinase activities is discussed.

PHOSPHORYLATION OF THE ACETYLCHOLINE RECEPTOR: STUDIES WITH SYNTHETIC  
PEPTIDES AND THEIR ANTIBODIES

Anat Safran, Ronit Sagi-Eisenberg, Drorit Neumann and Sara Fuchs, Department  
of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100,  
Israel.

The acetylcholine receptor (AChR) is a 250 kDa transmembrane glycoprotein which consists of four subunits assembled in a molar stoichiometry of  $\alpha_2\beta\gamma\delta$ . Synthetic peptides corresponding to defined sequences of AChR and their respective antibodies are being employed for the study of receptor phosphorylation. We have previously demonstrated that the cAMP dependent protein kinase (PKA) phosphorylation site resides within sequence 354-367 of the  $\delta$  subunit of affinity purified as well as membrane bound Torpedo AChR. The phosphorylation site of the  $\text{Ca}^{+2}$ /phospholipid dependent protein kinase (PKC) was recently shown to be included within the same sequence of the  $\delta$  subunit. Thus, the phosphorylation sites for both PKA and PKC reside in close proximity, within three consecutive serine residues at positions 360, 361 and 362 of the  $\delta$  subunit. Phosphorylation by these two kinases may therefore affect biological functioning similarly. Alternatively, these two kinases may operate in an additive, synergistic or antagonistic manner, opening the possibility for pleiotropic effects achieved through phosphorylation of the receptor. The role of AChR phosphorylation in receptor function is currently being studied using muscle cells in culture.

## RECONSTITUTION OF ISOLATED ACETYLCHOLIN RECEPTORS

### - A CRITIQUE -

Th. Schürholz, J. Weber, E. Neumann, Faculty of Chemistry, University of Bielefeld, D-4800 Bielefeld, F.R.G.

"Finkelstein's socks is a decisive parameter for reconstitution of channel proteins into planar bilayers". This sentence nicely caricatures the kind of arguments, used in acetylcholin receptor-channel (AcChR) reconstitution, too. The reason: although some papers suggest the contrary, there are many features of AcChR reconstitution uncontrolled.

AcChR-"molecules" can be purified by affinity chromatography, "reconstituted" into protein-lipid-vesicles and afterwards into planar membranes via, in principle, two methods: fusion or assembly from two vesicle-spread monolayers. In the presence of agonists different kinds of channel openings can be recorded: fast single channels, bursts, and long openings with short closures in between. Similar results have been shown with reconstituted membrane fragments. In addition we see "fuzzy channels" and less defined events of conductivity, which reemerge all the time again. Often, with the same sample, nothing can be seen. Such data have not been published or mentioned yet, because they don't fit into the common idea of how channels have to look like or are thought to be garbage as 99% of the recorded data, too.

Although few articles give evidence, that reconstituted AcChRs can be activated by agonists and blocked by antagonists, the data don't yield more than just evidence, as they lack a profound statistical basis. Besides, single channel recordings are, by principle, not suitable to answer questions like agonist activation.

Reconstitution is a sonorous word for a simple mixing of some molecules. Many people don't realize that, e.g., during dialysis phase separation or structural changes of protein lipid complexes can happen. These partition processes will influence the structure and the composition of the resulting vesicles. Such metastable structures depend on composition and the velocity and sequence of the steps. This phenomena should receive more attention in future.

A major lack of the channel data shown so far is that the number of channels in the measurement cannot be correlated to the number of AcChRs incorporated into the bilayer.

AcChR-channel openings are usually recorded long after application of agonist. Therefore the channels seen in the bilayer cannot be compared with those induced in the synapse; they rather seem to arise from desensitized receptor states. In contrast to the very short distance in the synaptic junction (20 nm) the agonist has to diffuse across a relatively thick unstirred layer (0.1mm) towards the planar bilayer. Therefore the agonist concentration at the membrane will rise from a low concentration in the minute time range, causing desensitisation before an agonist concentration is reached that is high enough for AcChR-channel activation.

To overcome these problems an experimental strategy is proposed which hopefully will evoke a fruitful discussion.

Acknowledgement. We gratefully acknowledge financial support by the DFG (grant SFB 223/D3 to E.N.)

MOLECULAR FORMS AND LOCALIZATION OF ACETYLCHOLINESTERASE AND NONSPECIFIC  
CHOLINESTERASE IN REGENERATING SKELETAL MUSCLE

Janez Sketelj, Neva Črne and Miro Brzin

Institute of Pathophysiology, School of Medicine, 61105 Ljubljana, Yugoslavia

The soleus and EDL muscles of rats were isolated, incubated with an irreversible AChE inhibitor and a myotoxic substance, and autotransplanted back in the place of the contra lateral EDL muscle. Ischemic necrosis was followed by muscle regeneration within the tubes of old basal laminae. Reinnervation of muscle regenerates was prevented by high axotomy of the sciatic nerve.

Molecular forms and histochemical localization of acetylcholinesterase and nonspecific cholinesterase were analysed in muscle regenerates. Regenerating myotubes and myofibres produce the 16S AChE form in the absence of innervation. The asymmetric molecular forms are present throughout the length of muscle regenerates. The 4S globular form predominates in early regenerates whereas the tetrameric 10S AChE form becomes predominant after cross-striations appear in muscle regenerates. Although the patterns of AChE molecular forms in normal EDL and soleus muscles differ significantly no such differences were observed in noninnervated regenerates from both muscles.

Two types of local accumulation of AChE appear on the sarcolemma of regenerating muscles: first, in places of former motor endplates and, second, in extra-junctional regions. The 'junctional' AChE accumulations appeared also in regenerates prepared from muscles that had been predenervated for one month. AChE in the 'extrajunctional' accumulations can be detached by collagenase treatment of nonhomogenized regenerates indicating the presence of the asymmetric molecular forms. The 4S form of nonspecific cholinesterase is prevailing in regenerating myotubes whereas its asymmetric forms nor focal accumulations could not be identified reliably.


The satellite cells which survive after muscle degeneration probably originate from some type of late myoblasts and transmit the information concerning the ability to synthesize the asymmetric AChE forms and to focally accumulate AChE to regenerating muscle cells. Synaptic basal lamina from former motor endplates may locally induce AChE accumulations in regenerating muscles. The inducing substance does not need a continuous presence of the motor nerve and may be produced by the muscle.

CONFORMATIONAL STABILITY OF NON-AGED AND AGED ORGANOPHOSPHORYL  
CONJUGATES OF  $\alpha$ -CHYMOTRYPSIN.

N. Steinberg, J. Grunwald<sup>1</sup>, Y. Ashani<sup>1</sup> and I. Silman. Dept of Neurobiology,  
Weizmann Institute, Rehovot; <sup>1</sup>Israel Institute for Biological Research,  
Ness-Ziona, Israel.

Organophosphorus (OP) esters inhibit serine hydrolases such as  
chymotrypsin (Cht), trypsin and acetylcholinesterase (AChE), by formation  
of a stoichiometric covalent conjugate with the active-site serine.

The inhibited enzyme can subsequently undergo one of two competing  
processes: either reactivation or 'aging', with the latter resulting in  
a conjugate which is completely resistant to reactivation (Robbiger, 1955;  
Aldrige & Reiner, 1972). Aging involves detachment of a substituent from  
the phosphorus atom, with concomitant introduction of a negative charge  
into the active-site, according to the following scheme:



where R is an alkyl, alkoxy or aryloxy group, R' is an alkyl or aryl group,  
and X is a leaving group. Kinetic studies show that the electrostatic barrier  
provided by the negative charge cannot, alone, explain the complete resistance  
to reactivation observed experimentally (Behrman et al., 1970).

The aim of this study was to investigate the susceptibility to confor-  
mational changes of the active-site region of non-aged and aged Cht.

The susceptibility to denaturation of pyrenebutylethylphosphoryl-Cht  
(PBEP-Cht) (non-aged) and of pyrenebutylhydroxyphosphoryl-Cht (PBP-Cht)  
(aged) was studied by measurement of their circular dichroism (CD) spectra  
at various concentrations of guanidinium hydrochloride (Gu.HCl). Reactiva-  
tion studies, after incubation with Gu.HCl, were performed in parallel.

The CD spectrum of PBEP-Cht exhibits four conformational transitions:  
The first, at 0.3-0.4 M Gu.HCl, in the range of 310-340 nm; the second, at  
about 0.7 M Gu.HCl, near 350 nm; the third, at 1-2 M Gu.HCl, in the range  
of 290-310 nm; and the fourth, at 2-3 M Gu.HCl, in the range of 215-290 nm.  
In contrast, PBP-Cht exhibits only two conformational transitions: The  
first, at ca. 0.7 M Gu.HCl, is observed at about 350 nm; the second, at  
2-3 M Gu.HCl, is observed in the whole spectral range of 215-370 nm.

The optical activity above 310 nm originates in the pyrene chromophore;  
it thus reflects the conformation of the catalytic site, whereas the tran-  
sition at ca. 235 nm may be ascribed primarily to the polypeptide linkages  
of the whole protein. In both conjugates conformational changes in the

pyrene absorption region occur at Gu.HCl concentrations which are much lower than that required for total denaturation of the enzyme, which is 2-3M, as was also established in control experiments with unmodified Cht. However, reactivation studies which were performed with PBEP-Cht at the various Gu.HCl concentrations demonstrated that its ability to undergo reactivation with 3-pyridinealdoxime methiodide (3-PAM) (Cohen & Erlanger, 1960) is maintained as long as total denaturation has not been achieved; the catalytic activity of unmodified Cht is similarly maintained unless total denaturation is achieved. Thus, there appears to be no disruption of the active sites of either the OP-Cht conjugates or of the unmodified enzyme prior to full denaturation. We may, therefore, conclude that all the conformational transitions observed above 310 nm and at Gu.HCl concentrations below 2M result from different orientations of the pyrene probe within the active site, rather than from disruption of the active site itself. It should be noted, however, that there is a marked difference between the tendency of PBEP-Cht and that of PBP-Cht to undergo orientational changes within their active sites. The non-aged conjugate undergoes more such reorientations, the first occurring at a Gu.HCl concentration as low as 0.3M; in contrast, the first observed orientational change observed for the aged conjugate, PBP-Cht, occurs only at 0.7M Gu.HCl. These results clearly support the contention that the aged form has undergone a conformational stabilization in its active site, relative to the non-aged form.

#### REFERENCES

- Aldrige, W.N. & Reiner, E. (1972) *Enzyme Inhibitors as Substrates*, Elsevier, Amsterdam.
- Behrman, E.J., Biallas, M.J., Brass, H.J., Edwards, J.O. & Isaks, M. (1970) *J. Org. Chem.* 35, 3069.
- Hobbiger, H. (1955) *Brit. J. Pharmacol.* 10, 356.

Supported in part by the Center for Structural Biology, the Weizmann Institute of Science, Rehovot, Israel.



PHYSICAL PARAMETERS OF THE TRANSFORMATIONS AND DISTRIBUTION OF  
INFORMATIONS.

S.N. TIWARI, DEPT. OF PHYSICS, UNIVERSITY OF GORAKHPUR,  
INDIA.

Action Potentials and electronic potentials are conducted to the limits of the cell only, with the exception of some very specialized structures where the adjacent cells are not affected by potential changes in certain cell. The nervous system, however, is a network with strong functional coupling of cells and in addition information has to be transmitted from receptor cells to nerve cells, and from these to effectors like muscle or gland cells. The transmission occurs at synapses, at morphologically highly specialized contacts between cells. In most cases a chemical transmitter substance mediates the information transfer.

The action potential reaching the nerve terminal induce the release of the content of synaptic vesicles into the synaptic cleft. The vesicles contain a transmitter substance which in case of the neuromuscular junction is acetylcholine. This transmitter diffuses across the synaptic cleft and reacts with receptors in the postsynaptic membrane, which cause the opening of synaptic ion channels. The resulting ionic currents generate postsynaptic potentials which may trigger action potentials in the postsynaptic cell, completing the synaptic transmission process.

A number of chemical transmitters are known which act at different synapses. The best investigated ones are: Acetylcholine, Epinephrine/Norepinephrine,  $\gamma$ -amino butyric acid and glutamate. For these substances the release of transmitter after stimulation was proven chemically. For the functional role of the following transmitters some final evidence is still missing: glycine, aspartate, serotonin, dopamine, nucleotides like adenosine and some peptides which also may act as hormones. All these molecules are relatively small and some of them occur in the metabolism of many cells at relatively high concentration. These substances only can act as transmitters at locally very high concentrations and by means of special supportive mechanisms. Very probably many more transmitters will be found in addition to the listed ones.

The mode of release corresponds to an electrophysiological observation which is obtained in all synapses studied thoroughly. Postsynaptic potentials or currents are composed of small units of quanta. To understand the mechanism of release of transmitters, synaptic current will be proposed to measure in different conditions.

The release of transmitter by the presynaptic neuron is induced by the action potential. It is not necessary, however, that the neuron is excited also passive depolarization leads to release of transmitter. At the giant synapse the presynaptic potential can be varied by application of current. The release of transmitter depends very much on the  $\text{Ca}^{2+}$  concentration in the extracellular fluid. The postsynaptic potential increases about proportional to the 4th power of  $\text{Ca}^{2+}$  concentration. This relationship may indicate that the release of one quantum of transmitter is induced by the cooperative reaction of four  $\text{Ca}^{2+}$  with regulatory sites in the membrane. An increase of the intracellular  $\text{Ca}^{2+}$  concentration directly before the release of transmitter has been already measured. We have planned to study the effect of other anions on the release of transmitters. We have also proposed to measure the excitatory postsynaptic potentials and inhibitory postsynaptic potentials which depolarize and hyperpolarize the membrane respectively.

MOLECULAR FORMS OF ACETYLCHOLINESTERASE IN  
ADULT DROSOPHILA : STRUCTURE AND HYDROPHOBIC INTERACTIONS

JP Toutant (1), M Arpagaus (2), D Fournier (3)

- (1) Physiologie Animale, INRA, Montpellier Cédex
- (2) Phytopharmacie, INRA, 78000 Versailles
- (3) Centre de Recherche INRA, 06606 Antibes Cédex

Drosophila acetylcholinesterase (AChE, EC 3117) from crude extracts of adult heads or after purification by affinity chromatography was studied by ultracentrifugation in sucrose gradients and by non denaturing electrophoresis in the presence of Triton X100, Brij 96 or sodium deoxycholate.


The major molecular form of AChE sedimented at 6.1 S in the presence of Triton X100, at 4.2 S in the presence of Brij 96 and formed fast sedimenting aggregates in the absence of detergent. Treatments of this form by proteases or phosphatidylinositol phospholipase C (PIPLC) suppressed the interaction with detergents but the catalytic activity of the lytic form remained unaffected. The native 6.1 S form is therefore referred to as an amphiphilic enzyme.

Autolysis (storage at +4°C for several weeks) converted the amphiphilic form into two components (sedimenting at 6.5 S and 4.2 S) which no longer interacted with detergents. These 6.5 S and 4.2 S forms were always present in minor amount in rapidly-extracted material (in the presence of antiproteolytic agents).

Partial disulfide bridge reduction of the amphiphilic 6.1 S form produced a catalytically active component sedimenting at 3.5 S in Triton X100, at 2.0 S in the presence of Brij 96 and forming aggregates in the absence of detergent.

These results, as well as the data from non denaturing electrophoresis (illustrated on the poster) demonstrate that the major molecular form of *Drosophila* AChE is a disulfide-linked amphiphilic dimer (G<sub>2</sub>) which can be converted into a detergent interacting monomer (G<sub>1</sub>) by reduction or into hydrophilic G<sub>2</sub> and G<sub>1</sub> on autolysis. The hydrophobic domain of amphiphilic G<sub>2</sub> and G<sub>1</sub> is constituted by a glycolipid (see also Gnagay et al., J Biol Chem, in press).

The figure summarizes these conclusions:



#### References:

Fournier D, Bergé J, Bordier C. AChE from *Musca domestica* and *Drosophila melanogaster* heads are linked to membranes by a glycopospholipid anchor sensitive to an endogenous phospholipase. J Neurochem, in press.

Toutant JP, Arpagaus M, Fournier D. Native molecular forms of head AChE from adult *Drosophila melanogaster*: Quaternary structure and hydrophobic character. J Neurochem, in press.

**MONOCLONAL ANTIBODIES TO CHICKEN ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE**

Tsim, K.W.K., Randall, W.R.<sup>+</sup> and Barnard, E.A.

MRC Molecular Neurobiology Unit  
MRC Centre, University of Cambridge  
Cambridge CB2 2QH, UK

<sup>+</sup>Department of Anatomy and Cell Biology  
University of Miami School of Medicine  
Miami, Florida 33101, USA

The asymmetric (20 S) acetylcholinesterase (AChE) from one-day old chick muscle was purified on an immunoaffinity column of immobilized antibody to chick brain AChE and used for immunization. Eight monoclonal antibodies (mAbs) against the muscle enzyme were isolated and characterized. Five antibodies (4A8, 1C1, 10B7, 7G8 and 8H11) recognised the 110-kDa AChE catalytic subunit, one antibody (7D11) recognised the 72-kDa butyrylcholinesterase (BuChE) catalytic subunit and 2 antibodies (6B6 and 7D7) reacted with the 58-kDa collagenous tail unit. Those 3 polypeptides can be recognised in the 20 S enzyme used, which is a hybrid enzyme. Four of the anti-110-kDa subunit mAbs stained the AChE on immunoblots. Sucrose density gradient analysis of the antibody enzyme complexes showed that the anti-110-kDa subunit mAb cross-links the 20 S AChE molecules and migrates to the bottom of the tube, while there is only a 2 - 3 S shift with the mAbs specific for the 72-kDa or the 58-kDa subunit, suggesting that these subunits are more inaccessible in the structure for cross-linking by one IgG molecule. The 4A8, 10B7, 7D11 and 7D7 mAbs showed cross-reactivity to the corresponding enzyme from quail muscle; however, none of the eight mAbs reacted with either enzyme from mammalian muscle and Torpedo electric organ. The antibodies showed immunocytochemical localization of AChE at the neuromuscular junction of chicken and quail. Using the AChE- and BuChE-specific mAbs, the amounts of homogenous BuChE and hybrid AChE/BuChE asymmetric enzymes in the 1-day old muscle crude extracts could be compared.

GLYCOLIPID ANCHORAGE OF A TAILED ASYMMETRIC 16S  
ACETYLCHOLINESTERASE VARIANT IN RAT SUPERIOR  
CERVICAL GANGLION NEURONAL MEMBRANES.

Martine Verdière-Sahuqué\*, Luis Garcia\*, Patrick A.  
Dreyfus\* and François Rieger\*

\*Inserm U. 153, Paris - France.

\*\*Present address, Dept. of Chemical Biology, Hebrew  
University, Jerusalem - Israël.

Tailed asymmetric 16S acetylcholinesterase (AChE ;  
EC 3.1.1.7) is present in rat superior cervical ganglion (SCG)  
neurons *in vivo* and *in vitro*. Two pools of 16S AChE can be  
revealed by differential extraction : one, classically, by high  
salt (HS) and another one by detergent treatment. The  
detergent extractable (DE) 16S AChE constitutes a significant  
proportion of total SCG neuronal 16S AChE (30 %). Upon  
preincubation in the presence of Bacillus Cereus phospholipase  
C (EC ; 3.1.4.3.) DE 16S AChE is quantitatively released  
from a SCG membrane preparation suggesting that it exists a  
specific pool of 16S AChE attached to the neuronal  
membranes through a phospholipid anchor.

Moreover, exposure of the membranes to a  
phosphatidyl inositol specific phospholipase C (PIPLC ;  
monophosphatidyl inositol phosphodiesterase ; EC 3.1.4.10)  
results in the release of up to one-third of the DE pool of  
16S AChE. Thus, at least part of DE 16S AChE is anchored  
to neuronal membranes through a phosphatidyl-inositol  
glycolipid. Furthermore, by studying 1) SCG pretreated by an  
irreversible AChE inhibitor, methylphosphorothiolate (MPT) in  
the presence of a reversible non-permeant inhibitor (BW 284  
C 51 compound) in order to protect extracellular AChE and  
2) primary neuronal SCG cultures in which 16S AChE is  
essentially internal, we found that both external and internal  
AChE had a pool of DE 16S AChE released by PIPLC. Thus,  
a phosphatidyl inositol glycolipid can anchor both external  
and internal DE 16S AChE.

These results suggest an internal assembly of PI  
containing residues with the AChE polypeptides and makes  
plausible the occurrence of differential splicing of mRNAs  
originating from a single AChE gene.

CHOLINESTERASE SYNTHESIS IN DEVELOPING HUMAN OOCYTES REVEALED BY IN SITU HYBRIDIZATION TO FROZEN OVARIAN SECTIONS

H. Zakut\*, G. Malinger\* and H. Soreq\*

\*Department of Obstetrics and Gynaecology, The Edith Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel-Aviv University.

\*Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem, Israel.

In addition to their well known involvement in neuromuscular junctions and in brain cholinergic synapses, cholinergic mechanisms have been implicated in the growth and maturation of oocytes and in fertilization processes in various species [1]. Functional acetylcholine receptors were electrophysiologically demonstrated in amphibian and mammalian oocyte membranes [2,3] and cholinergic antagonists were shown to interfere with fertilization [4]. The neurotransmitter acetylcholine was detected in mammalian sperm cells [5] and activity of the acetylcholine hydrolyzing enzyme, acetylcholinesterase (AChE) was biochemically measured in the exceptionally big oocytes of the frog *Xenopus laevis* [6,7]. However, biochemical methods could not reveal whether AChE was produced within the oocytes themselves or in the surrounding follicle cells. Furthermore, this issue is particularly important for understanding growth and fertilization processes in the much smaller human oocytes, in which the sensitivity of AChE biochemical measurements is far too low to be employed.

To directly determine whether the human cholinesterase (ChE) genes are transcriptionally active in oocytes, and, if so, at what stages in their development, the presence of ChEmRNA was pursued. For this purpose frozen ovarian sections were subjected to in situ hybridization using (35S)-labeled human ChEcDNA. Highly pronounced hybridization signals were localized within oocytes in primordial, pre-antral and antral follicles, but not in other ovarian cell types, demonstrating that within the human ovary ChEmRNA is selectively synthesized in viable oocytes at different developmental stages. Sucrose gradient centrifugation followed by (3H)-acetylcholine hydrolysis measurements revealed in the ovarian extracts the presence of low levels of soluble AChE dimers, sensitive to the specific AChE inhibitor BW284C51 but resistant to the BuChE inhibitor iso-OMPA [8]. In view of the low numbers of oocytes out of total cells in the ovary, these findings strongly suggest that AChE is a prominent protein in human oocytes throughout their development and further support the hypothesis that cholinergic mechanisms may be involved in oocyte growth and maturation and/or in sperm-egg interaction in human.

Furthermore, the pronounced synthesis of ChE transcripts in oocytes suggests that the ChE genes are particularly good candidates for the formation and re-insertion of inheritable processed genes.

References

1. Eppig, J. J. and Downs, S. M. (1984) Biol. Repr. **30**, 1-11.
2. Kusano, K., Miledi, R. and Stinnakre, J. (1977) Nature **270**, 739-741.
3. Eusebi, F., Mangia, F. and Alfei, L. (1979) Nature **277**, 651-653.
4. Florman, H. M. and Storey, B. T. (1981) Exp. Zool. **216**, 159-167.
5. Sastry, B. V. R. and Sadavongvivad, C. (1979) Pharmacol. Rev. **30**, 65-132.
6. Soreq, H. (1985) CRC Crit. Rev. Biochem. **18**, 199-238.
7. Gundersen, C. B. and Miledi, R. (1985) Neurosci. **10**, 1487-1495.
8. Malinger, G., Zakut, H. and Soreq, H. (1987), submitted.

Supported by the Research Fund at the Edith Wolfson Medical Center and by the U.S. Army Medical Research and Development Command.

# CHROMOSOMAL MAPPING OF HUMAN CHOLINESTERASE GENES BY IN SITU HYBRIDIZATION

Ronit Zamir\*, Liliana Sindel\*, Haim Zakut\* and Hermona Soreq\*

\*Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem 91904

\*Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel Aviv University, Israel.

In order to map the structural human ChE genes to distinct chromosomal regions, a cloned human cDNA for cholinesterase (ChE) [1] was used as a probe for in situ hybridization to chromosomes. For this purpose, lymphocyte chromosome spreads were prepared following short-term culture, and hybridized with ChEcDNA fragments labeled with [<sup>35</sup>S] by different techniques. These included direct labeling of electrophoretically purified cDNA inserts by nick-translation, synthesis of a labeled second DNA strand to this cDNA subcloned into the single-stranded M13 phages, in vitro transcription of such cDNA into labeled RNA and the use of random oligonucleotides as primers for DNA polymerase I synthesis. Following the hybridization procedure [2], chromosome spreads were exposed under photography emulsion to create silver grains in sites of hybridization and were then R-banded to enable karyotype analysis and to localize specific silver grains on particular chromosome regions. Using this analysis, the recent genetic linkage assignment of the CHE1 gene to the long arm of chromosome 3 [3] was confirmed and further refined to 3q21-q26, in close proximity to the genes coding for transferrin (TF) [4] and transferrin receptor (TRFC) [5]. The CHE1 locus localizes to a 3q region that is commonly aberrated, and related with abnormal megakaryocyte proliferation, in acute myelodysplastic anomalies [6]. In view of earlier findings that ChE inhibitors induce megakaryocytopoiesis in culture [7,8], this localization may indicate that ChEs are involved in regulating the differentiation of megakaryocytes. Cumulative histograms of in situ hybridization of ChEcDNA to chromosome No. 3 further suggest that there might be two sites carrying ChE sequences on the long arm of this chromosome.

A second site for ChEcDNA hybridization was found on chromosome 16q11-q23, demonstrating that the CHE2 locus of the cholinesterase gene, which directs the production of the common C5 variant of serum ChE [9], also codes for a structural subunit of the enzyme and is localized on the same chromosome with the haptoglobin (HP) gene [10], both genes found on the long arm of chromosome 16. Further in situ hybridization experiments using human haptoglobin cDNA (gratefully received from Drs. S. Oliviero and G. Cortese) revealed that these two genes are at least 1000 kb apart from each other. The finding of various sites for ChEcDNA hybridization [12] suggests that the different loci coding for human ChEs may include non-identical sequences, responsible for the biochemical differences between ChE variants.

## References

1. Prody, C., Zevin-Sonkin, D., Gnatt, A., Goldberg, O. and Soreq, H. (1987) PNAS **84**, 3555-3559.
2. Rabin, M., Fries, R., Singer, D. and Ruddle, F. H. (1985) Cytogenet. Cell Genet. **39**, 206-209.
3. Arias, S., Rolo, M. and Gonzalez, M. (1985) Cytogenet. Cell Genet. **40**, 571.
4. Huerre, C., Uzan, G., Greschik, K. H., Weil, D., Levin, M., Hors-Cayla, M. C., Boue, J., Kahn, A. and Junien, C. (1984) Ann. Genet. **27**, 5-10.
5. Kidd, K. K. and Gusella, R. (1985) Cytogenet. Cell Genet. **40**, 107-127.
6. Bernstein, R., Pinto, M. R., Behr, A. and Mendelow, B. (1982) Blood **60**, 613-617.
7. Burstein, S. A., Adamson, J. W. and Waker, L. A. (1980) J. Cell. Physiol. **103**, 201-208.
8. Paulus, J. P., Maigen, J. and Keyhani, E. (1981) Blood **58**, 1100-1106.
9. Lovrien, E. W., Magenis, R. E., Rivas, M. L., Lamvik, N., Rowe, S., Wood, J. and Hemmerling, M. (1978) Cytogenet. Cell. Genet. **22**, 324-326.
10. Simmers, R. N., Stupons, I. and Sutherland, G. R. (1986) Cytogenet. Cell Genet. **41**, 38-41.
11. Mattei, M. G., Phillip, N., Passage, E., Moisan, J. P., Mandel, J. L. and Mattei, J. E. (1985) Hum. Genet. **69**, 268-271.
12. Soreq, H., Zamir, R., Zevin-Sonkin, D. and Zakut, H. (1987) Human Genetics, in press.

Supported by the Research Fund at the Edith Wolfson Medical Center and by the U.S. Army Medical Research and Development Command.



ANTIBODIES TO CLONE-PRODUCED HUMAN CHOLINESTERASE: INTERACTION WITH DENATURED AND NATIVE CHOLINESTERASES AND WITH THYROGLOBULIN

Rivka Zisling\*, Patrick Dreyfus\*, Shlomo Seidman\*, Dina Zevin-Sonkin\*, Haim Zakut\* and Hermona Soreq\*

\*Department of Biological Chemistry, The Life Sciences Institute, The Hebrew University, Jerusalem 91904

\*Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel Aviv University, Israel.

In order to study the polymorphism of human cholinesterases (ChEs) at the levels of primary sequence and structure, a fragment of human butyrylcholinesterase (BuChE)cDNA [1] was subcloned into the pEX bacterial expression vector [2] in conjunction with the  $\beta$ -galactosidase gene. The production of fusion protein from this plasmid was induced and its polypeptide product analyzed. Gradient gel electrophoresis followed by immunoblot analysis revealed that the clone-produced BuChE peptides interact specifically with antibodies against human and Torpedo acetylcholinesterase (AChE) (gratefully received from Drs. U. Brodbeck and P. Taylor, respectively). Rabbit polyclonal antibodies were then prepared against the purified clone-produced BuChE polypeptides and were subjected to immunoblots with denatured serum BuChE as well as with purified and denatured erythrocyte AChE (gratefully received from E. Schmell). In contrast, these antibodies interacted differently with various ChEs at their native forms. Native BuChE tetramers from human serum, but not AChE dimers from erythrocytes, interacted with these antibodies to produce antibody-enzyme complexes which could be precipitated by second antibodies and which sedimented faster than the native enzyme in sucrose gradient centrifugation. Similar analysis revealed changes in the sedimentation properties of both AChE and BuChE dimers from muscle extracts, but not of any other form of muscle ChE. These findings demonstrate that the polymorphic human ChEs share sequence homologies and suggest the existence of considerable structural differences between various molecular forms of ChE within particular tissues, as well as between similarly sedimenting molecular forms of ChE from different tissues.

In addition to the homologies between various ChEs from different species, molecular cloning studies have recently revealed impressive sequence homologies between bovine thyroglobulin (Tg) [3] and Torpedo [4] and human [5] ChEs, suggesting that hyperthyroidism-induced autoantibodies to Tg in the serum of Grave's ophthalmopathy patients may cross-interact with ChEs and induce cholinergic symptoms [6]. To examine this hypothesis, the polypeptide products of human ChEcDNA expressed in bacteria were separated by SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose and incubated with rabbit anti-Tg antibodies, as well as with IgG fractions from the serum of 9 patients suffering from Grave's ophthalmopathy and 6 clinically healthy controls. Incubation with <sup>125</sup>I-protein A and autoradiography revealed specific immunoreaction between the rabbit anti-Tg antibodies and human ChE-derived peptides. Antibodies to the ChE peptides were clearly detected in the serum of 7 out of the 9 patients but not in the controls. Reciprocal analyses with the rabbit antibodies elicited against the human ChE-derived peptides and against purified rat brain AChE [7] (gratefully received from J. Massoulie and M. Vigny), revealed that both antibodies interact specifically with purified human Tg (in collaboration with M. Ludgate and G. Vassart).

To further reveal whether the anti-ChE antibodies may interact in situ with ChEs in neuromuscular junctions, bundles of muscle fibers were microscopically dissected from the region in fetal human diaphragm which is innervated by the phrenic nerve. Muscle fibers incubated with the examined antibodies and with <sup>125</sup>I-protein A were subjected to emulsion autoradiography, followed by cytochemical ChE staining. The anti-ChE antibodies created patches of silver grains in the muscle endplate region stained for ChE. To this end, the anti-cloned ChE antibodies, as well as six of the above described patient sera and anti-Tg antibodies, were examined and found positive, using this technique. This was performed under conditions where control sera do not induce the appearance of silver grains at endplate regions. Our findings demonstrate that the sequence homology between Tg and ChE is physiologically significant, and suggest that autoantibodies to Tg may cross-react with ChEs and be implicated in creating cholinergic symptoms in Grave's ophthalmopathy patients.

#### References

1. Prody, C., Zevin-Sonkin, D., Gnatt, A., Koch, R., Zisling, R., Goldberg, O. and Soreq, H. (1986) *J. Neurosci. Res.* **16**, 25-36.
2. Stanley, K. K. and Luzio, J. P. (1984) *The EMBO J.*, **3**, 1429-1434.
3. Mercken, L., Simons, M. J., Swillens, M., Massaer, M. and Vassart, G. (1985) *Nature*, **316**, 647-651.
4. Schumacher, M., Camp, S., Maulet, Y., Newton, M., McPhee-Quigley, K., Taylor, S. S., Friedman, T. and Taylor, P. (1986) *Nature* **319**, 407-409.
5. Prody, C., Zevin-Sonkin, D., Gnatt, A., Goldberg, O. and Soreq, H. (1987) *PNAS*, **84**, 3555-3559.
6. Ludgate, M., Swillens, S., Mercken, L. and Vassart, G. (1986) *Lancet* **II**, 219, 1986.
7. Meflah, K., Bernard, S. and Massoulie, J. (1984) *Biochimie* **66**, 59-69.

Supported by the U.S. Army Medical Research and Development Command and by the Silvermann Foundation.

## LIST OF PARTICIPANTS

### LECTURERS

Dr. Edson X. Albuquerque  
Professor and Chairman  
Department of Pharmacology and Experimental Therapeutics  
University of Maryland School of Medicine  
655 West Baltimore Street  
Baltimore, MD 21201  
U. S. A.

Dr. G. Amitai  
Israel Institute for Biological Research  
P.O. Box 19  
Nes-Ziona  
ISRAEL

Dr. Lili Anglister  
Dept. of Anatomy  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Prof. F.J. Barrantes  
Instituto de Investigaciones Bioquímicas  
Universidad Nacional del Sur  
Gorriti 43 - Dirección Postal: C C. 857  
8000 Bahía Blanca  
ARGENTINA

Dr. M.P. Blaustein  
Professor and Chairman  
Dept. of Physiology  
University of Maryland School of Medicine  
655 West Baltimore Street  
Baltimore, MD 21201  
U. S. A.

Dr. H. Breer  
Fachbereich Biologie/Chemie  
Universität Osnabrück  
Postfach 4469  
Barbarastrasse 11  
D-4500 Osnabrück  
WEST GERMANY

Prof. Miro Brzin  
Institut za Patolosko Fiziologio  
Medicinska Fakulteta  
Zaloska 4, p.p. 11  
61105 Ljubljana  
JUGOSLAVIJA

Dr. J.-P. Changeux  
Unite de Neurobiologie Moleculaire  
Institut Pasteur  
25 Rue du Dr. Roux  
75724 Paris Cedex 15  
FRANCE

Dr. B.P. Doctor  
Division of Biochemistry  
Water Reed Army Institute  
Washington D.C. 20307  
U.S.A.

Dr. Patrick Dreyfus  
Dept. of Biochemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Dr. M.E. Eldefrawi  
Dept. of Pharmacology and Experimental Therapeutics  
University of Maryland School of Medicine  
655 West Baltimore Street  
Baltimore, MD 21201  
U. S. A.

Dr. Stanley C. Froehner  
Dept. of Biochemistry  
Dartmouth Medical School  
Hanover, New Hampshire 03756  
U. S. A.

Prof. Sara Fuchs  
Dept. of Chemical Immunology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Dr. A.H. Futerman  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
Israel

Prof. Peter W. Gage  
Dept. of Physiology  
The John Curtin School of Medical Research  
The Australian National University  
G.P.O. Box 334  
Canberra, A.C.T. 2601  
AUSTRALIA

Dr. Jonathan Gershoni  
Dept. of Biophysics  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Dr. E. Heldman  
Israel Institute for Biological Research  
P.O. Box 19  
Nes-Ziona  
ISRAEL

Dr. Yoav Henis  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. George P. Hess  
Section of Biochemistry  
270 Clark Hall  
Cornell University  
Ithaca, NY 14853  
U. S. A.

Prof. Dr. Ferdinand Hucho  
Institut für Biochemie  
Freie Universität Berlin  
Theilallee 63  
1000 Berlin 33  
WEST GERMANY

Dr. Richard L. Huganir  
Laboratory of Molecular and Cellular Neuroscience  
Rockefeller University  
1230 York Avenue  
New York, NY 10021  
U. S. A.

Dr. Maurice Israel  
Département de Neurochimie  
Laboratoire de Neurobiologie Cellulaire  
C. N. R. S.  
91190 Gif sur Yvette  
FRANCE

Dr. Arthur Karlin  
Dept. of Neurology  
College of Physicians and Surgeons  
of Columbia University  
630 W. 168th Street  
New York, NY 10032  
U. S. A.

Dr. Edward Kosower  
School of Chemistry  
Tel-Aviv University  
Ramat Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. Yoram Lass  
Dept. of Physiology and Pharmacology  
Sackler Faculty of Medicine  
Tel-Aviv University  
Ramat Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. Henry A. Lester  
Division of Biology  
California Institute of Technology  
Pasadena, CA 91125  
U. S. A.

Dr U.J. McMahan  
Dept. of Neurobiology  
Stanford University School of Medicine  
Stanford, CA 94305  
U. S. A.

Dr Mark McNamee  
Dept. of Biochemistry  
University of California at Davis  
Davis, CA 95616  
U. S. A.

Prof. Dr. A. Maelicke  
Max-Planck-Institut fur Ernahrungsphysiologie  
Rheinlanddamm 201  
D-4600 Dortmund 1  
WEST GERMANY

Dr. Jean Massoulie  
Laboratoire de Neurobiologie  
Ecole Normale Supérieure  
46 Rue d'Ulm  
75230 Paris Cedex 05  
FRANCE

Dr. Halina Meiri  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Dr. Christoph Methfessel  
Abteilung Zellphysiologie  
Max-Planck-Institut für Biophysikalische Chemie  
D-3400 Göttingen-Nikolausberg  
WEST GERMANY

Dr. D.M. Michaelson  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. G. Navon  
School of Chemistry  
Tel-Aviv University  
Ramat Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. Erwin Neher  
Max-Planck-Institut für Biophysikalische Chemie  
D-3400 Göttingen-Nikolausberg  
WEST GERMANY

Dr. I. Parnas  
Neurobiology Unit  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Dr. Stanley M. Parsons  
Dept. of Chemistry  
University of California, Santa Barbara  
Santa Barbara, CA 93106  
U. S. A.

Dr. James Patrick  
Molecular Neurobiology Laboratory  
The Salk Institute  
P.O. Box 85800  
San Diego, CA 92138-9216  
U. S. A.

Dr. M-m. Poo  
Section of Molecular Neurobiology  
Yale University School of Medicine  
333 Cedar Street  
P.O. Box 3333  
New Haven, CT 06510  
U. S. A.

Dr. H. Rahamimoff  
Dept. of Biochemistry  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Dr. R. Rahamimoff  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Dr. W.H. Randall  
Dept. of Anatomy and Cell Biology (R-124)  
University of Miami School of Medicine  
1600 N.W. 10th Avenue  
Miami, FLORIDA 33101  
U. S. A.

Dr. Thomas S. Reese  
Laboratory of Neurobiology  
Marine Biological Laboratory  
Woods Hole, MA 02543  
U. S. A.

Dr. Shlomo Rotshenker  
Dept. of Anatomy  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Dr. Richard L. Rotundo  
Dept. of Anatomy and Cell Biology (R-124)  
Rosenstiel Medical Sciences Building  
University of Miami School of Medicine  
1600 N.W. 10th Avenue  
Miami, FLORIDA 33101  
U. S. A.



Dr. Eli D. Schmell  
Office of Naval Research  
Department of the Navy  
Arlington, VA 22217-5000  
U. S. A.

Dr. A. Shainberg  
Dept. of Life Sciences  
Bar-Ilan University  
Ramat Gan 52100  
ISRAEL

Dr. K.A. Sherman  
Dept. of Pharmacology  
Southern Illinois University  
Springfield  
IL 62708  
U.S.A.

Prof. I. Silman  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
Israel

Dr. Hermona Soreq  
Dept. of Biochemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Dr. Palmer Taylor  
Division of Pharmacology  
Dept. of Medicine  
University of California, San Diego  
La Jolla, CA 92093  
U. S. A.

Dr. Zvi Vogel  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Dr. Bruce Wallace  
Dept. of Neurobiology  
Stanford University School of Medicine  
Stanford, CA 94305  
U. S. A.

Dr. R. Werman  
Neurobiology Unit  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Dr. Yoel Yaari  
Center for Neurobiology and Behavior  
College of Physicians and Surgeons  
Columbia University  
722 West 168th St.  
New York, NY 10032  
U. S. A.

Dr. Robert S. Zucker  
Dept. of Physiology-Anatomy  
University of California, Berkeley  
Berkeley, CA 94720  
U. S. A.

REGISTRANTS

Dr. M. Adler  
U.S. Army Medical Research Institute of Chemical Defense  
Aberdeen Proving Ground  
MD 21210  
U.S.A

Dr. Martine Arpagaus  
30 Allee du Bois de Graville  
91190 Gif sur Yvette  
FRANCE

Dr. Francis Bacou  
Station de Physiologie Animale  
I. N. R. A.  
9, Place Viala  
34060 Montpellier cedex  
FRANCE

Dr. M. Bennett  
Departement de Neurochimie  
Laboratoire de Neurobiologie Cellulaire  
C. N. R. S.  
91190 Gif sur Yvette  
FRANCE

Dr. Cassian Bon  
Unite des Venins  
Institut Pasteur  
28, rue du Dr. Roux  
75724 Paris Cedex 15  
FRANCE

Dr. Wolfgang Finger  
Physiologisches Institut  
Technischen Universitat Munchen  
Biedersteiner Strasse 29  
8000 Munchen 40  
WEST GERMANY

Dr. R.D. Gordon  
Max-Planck-Institut fur Biochemie  
Am Klopferspitz 18  
8033 Martinsried bei Munchen  
WEST GERMANY

Dr. R. Gruener  
Dept. of Physiology  
University of Arizona College of Medicine  
Tucson  
AZ 85724  
U.S.A.

Dr. Meyer Jackson  
Max-Planck-Institut für Biophysikalische Chemie  
D-3400 Göttingen-Nikolausberg  
WEST GERMANY

Dr. Konrad Kaufmann  
Abt. Neurobiologie  
Max-Planck-Institut für Biophysikalische Chemie  
D-3400 Göttingen-Nikolausberg  
WEST GERMANY

Dr. Roger E. Koeppe II  
Dept. of Chemistry and Biochemistry  
115 Chemistry Building  
J. William Fulbright College of Arts and Sciences  
University of Arkansas  
Fayetteville, Arkansas 72701  
U. S. A.

Dr. P. Masson  
Ecole d'Application du Service Santé pour la Marine  
H.I.A. Sainte Anne  
B.P. 610  
83800 Toulon Naval  
FRANCE

Dr. John L. Middlebrook  
Chief, Dept. Of Toxinology  
US Army Medical Research Institute of Infectious Diseases  
Fort Detrick  
Frederick, MD 21701-5011  
U. S. A.

Dr. P.C. Molenaar  
Dept. of Pharmacology  
Sylvius Laboratories  
University of Leiden  
Wassenaarseweg 72  
2333 AL Leiden  
THE NETHERLANDS

Dr. Nicolas Morel  
Département de Neurochimie  
Laboratoire de Neurobiologie Cellulaire  
C. N. R. S.  
91190 Gif sur Yvette  
FRANCE

Dr. Y. Morot Gaudry  
Laboratoire de Neurobiologie Cellulaire  
Center National de la Recherche Scientifique  
91190 Gif-sur-Yvette  
FRANCE

Stephen J. Moss  
MRC Molecular Neurobiology Unit  
University of Cambridge Medical School  
Hills Road  
Cambridge CB2 2QH  
ENGLAND

Dr. Simeon Jordanov Mirchev  
ul. "Jordan Mishev" 21A  
8600 Jambol  
BULGARIA

Dr. Rajendra Prasad Ojha  
Dept. of Physics  
University of Gorakhpur  
Gorakhpur - 273001  
INDIA

Dr. Dietmar Paschke  
Abteilung Biophysik  
Biologisches Institut  
Universitat Stuttgart  
Pfaffenwaldring 57  
7000 Stuttgart 80  
WEST GERMANY

Dr. Theo Schurholz  
Fakultat Chemie  
Universitat Bielefeld  
Postfach 8640  
D-4800 Bielefeld  
WEST GERMANY

Kathleen A. Sherman  
Dept. of Pharmacology  
Southern Illinois University School of Medicine  
P.O. Box 3926  
Springfield, IL 62702  
U. S. A.

Dr. Alexander Siebel  
Abteilung fur Neuropsychopharmakologie  
Psychiatrische Klinik (WE 12)  
Universitätsklinikum Charlottenburg  
Ulmenallee 30  
1000 Berlin 19  
WEST GERMANY

Dr. J. Sketelj  
Institut za Patolosko Fiziologijo  
Medicinska Fakulteta  
Zaloska 4, p.p. 11  
61105 Ljubljana  
JUGOSLAVIJA

Dr. Sugriva Nath Tiwari  
Dept. of Physics  
University of Gorakhpur  
Gorakhpur - 273009  
INDIA

Dr. Jean-Pierre Toutant  
Laboratoire de Physiologie Animale  
I. N. R. A.  
9, Place Viala  
34060 Montpellier cedex  
FRANCE

Karl W.K. Tsim  
MRC Molecular Neurobiology Unit  
University of Cambridge Medical School  
Hills Road  
Cambridge CB2 2QH  
ENGLAND

Dr. Martine Verdiere-Sahuque  
Unite de Recherches Biologie et Pathologie Neuromusculaires  
INSERM U. 153  
17, Rue du Fer-a-Moulin  
75005 Paris  
FRANCE

ISRAELI PARTICIPANTS

Orna Asher  
Dept. of Chemical Immunology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Arnon Assaf  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Eyal Banin  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Hadassa Brik  
Dept. of Life Sciences  
Bar-Ilan University  
Ramat Gan 52100  
ISRAEL

Dr. Joab Chapman  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Jerry Eichler  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Sharon Einav  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Irit Eisner  
School of Chemistry  
Tel-Aviv University  
Ramat Aviv  
Tel-Aviv 69978  
ISRAEL

Michal Ginzburg  
School of Chemistry  
Tel-Aviv University  
Ramat Aviv  
Tel-Aviv 69978  
ISRAEL

Averell Ghatt  
Dept. of Biological Chemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Dr.Y. Grunwald  
Israel Institute for Biological Research  
P.O. Box 19  
Nes-Ziona  
ISRAEL

Elan Hevron  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Michael Krause  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Volker Kruff  
Dept. of Biological Chemistry  
Life Science Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Roxana Licht  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Judith Lieman-Hurwitz  
Dept. of Biochemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL



Cornel Lustig  
Dept. of Applied Mathematics  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Shira Luz-Chapman  
Israel Institute for Biological Research  
P.O. Box 19  
Nes-Ziona  
ISRAEL

Noam Meiri  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Drorit Neumann  
Dept. of Chemical Immunology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Dr. Itzhak Nussinovitch  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Dr. Lea Oron  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Dr. Catherine Prody  
Dept. of Biochemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Alan Robinson  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Dr. Michal Roll  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Noa Rosenberg  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Riva Rosenblum  
Dept. of Biochemistry  
Tel-Aviv University  
Ramat-Aviv  
Tel-Aviv 69978  
ISRAEL

Esther Roth  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Anat Safran  
Dept. of Chemical Immunology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Michal Silverberg  
Dept. of Life Sciences  
Bar-Ilan University  
Ramat Gan 52100  
ISRAEL

Dr. N. Steinberg  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

M. Su  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Dr. R. Tarrab-Hazdal  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Lili Toker  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Larry Varon  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovot  
ISRAEL

Nilly Yakir  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL

Prof. Haim Zakut  
Dept. of Obstetrics and Gynecology  
The Edith Wolfson Medical Center  
P.O. Box 5  
Holon 58100  
ISRAEL

Ronit Zamir  
Dept. of Biochemistry  
Life Sciences Institute  
The Hebrew University of Jerusalem  
Jerusalem 91904  
ISRAEL

Rivka Zisling  
Dept. of Neurobiology  
Weizmann Institute of Science  
Rehovoth 76100  
ISRAEL

Ayelet Zuckerman  
Dept. of Physiology  
Hebrew University-Hadassah Medical School  
P.O. Box 1172  
Jerusalem  
ISRAEL